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BAEP Brainstem auditory evoked potential
C Cytosine
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IF Incidental finding
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PCQ Productivity cost questionnaire
PSG Polysomnography
PSWQ Penn State Worry Questionnaire
xQALY Quality-adjusted life year
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TGP Targeted gene panel
VAS Visual analogue scale
VEP Visual evoked potential
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4 CHAPTER 1
This thesis focuses on the early health technology assessment (HTA) of next-generation se-
quencing (NGS) in clinical practice. In an HTA all relevant consequences – medical, societal, 
economic, and ethical – of a health care technology are evaluated. HTA aims to aid deci-
sion-makers in deciding how scarce resources should be optimally allocated towards those 
medical interventions that provide most value for money. Early evaluation of the potential 
value of medical interventions is gaining importance as a result of globally increasing health 
care expenditures over the last years, which are for a large part due to the swift evolution of 
innovative medical technologies[1]. 
A field that is rapidly evolving is the field of medical genetics, representing the branch of 
medicine that involves the diagnosis and management of hereditary disorders. A promising 
new technology is NGS, which allows for massive and quick DNA sequencing, facilitating the 
discovery of these DNA errors. NGS has proven to be a valuable research tool for studying 
the genetics underlying rare Mendelian disorders[2]. Additionally, it is increasingly used as 
a diagnostic tool in clinical practice in diverse disease areas, especially for clinically and ge-
netically heterogeneous disorders. 
The aim of this thesis is to explore the value and the challenges of early HTA of diagnos-
tic NGS technologies. This is illustrated by the case of whole exome sequencing (WES) in 
complex paediatric neurology (CPN). In this first chapter, HTA and economic evaluation are 
introduced, followed by an explanation of basic elements of genetics and related NGS tech-
nologies. Subsequently, the context of paediatric neurology is described. The final part of 
this general introduction provides an outline of the thesis.
Health technology assessment
HTA is the multidisciplinary field of policy analysis that studies all relevant short- and long-
term consequences – medical, societal, economic, and ethical – of the development, diffu-
sion, and use of health technologies[3, 4]. Health technologies include all drugs, devices, 
and medical and surgical procedures that are used in health care and the organisational 
systems within which health care is provided[5]. HTA has been positioned as the bridge 
between scientific evidence and decision-making[6], thereby aiming to inform and advise 
policy-makers on whether or not to implement and reimburse innovative health care tech-
nologies in health care[7]. 
HTA is an iterative process: the evaluation of a technology should start before it is developed 
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and continue throughout the technology’s life[8]. First, the burden of illness is determined 
as a baseline for assessing the potential of a new technology to improve health care. Then 
evidence is gathered on the technology’s efficacy, target population, and clinical effective-
ness. Subsequently, a trade-off between the costs and consequences of the technology is 
made. Finally, all evidence is integrated in decision-making on the further development or 
clinical implementation of the technology. After a positive development or implementation 
decision, the technology should be monitored and reassessed at relevant points in its life-cy-
cle, taking into account new evidence to ensure value for money in clinical practice[9].
HTA has rapidly gained importance over the last years. This is the result of globally increas-
ing health care expenditures, which are for a large part due to the swift development of 
innovative health care technologies[1]. As health care budgets are finite, it is becoming ever 
more important to optimally allocate the scarce health care resources towards those medi-
cal interventions that provide most value for money[10]. 
A challenge in the HTA process is the timing of evaluation. Ideally, evaluation should start as 
early as possible to select those technologies that are most likely to provide value for money 
from a larger pool of ideas. However, in the pre-development stage no, or only limited evi-
dence on the costs and effectiveness of a technology is available. Therefore, HTA is generally 
performed when a technology has already been developed and brought to market, when 
evidence on costs and effectiveness is becoming available. However, here Buxton’s law, “It 
is always too early, until suddenly it’s too late”, applies[11]. If a technology is only assessed 
when fully developed, it has usually already been diffused into clinical practice, and a tech-
nology that is already in use is difficult to dismiss, regardless the HTA results. The latter may 
ultimately result in a suboptimal allocation of the health care resources and consequently in 
suboptimal health care. With the rapid development of innovative health technologies and 
constraint health care budgets, the need for early HTA increases. 
Health economic evaluation
One of the main tools in HTA is the economic evaluation. An economic evaluation is a com-
parative analysis of alternative courses of action in terms of both their costs and conse-
quences[12]. In the field of health care there are four types of economic evaluation, varying 
in the way that the consequences of an intervention are measured and valued. These four 
types of evaluation are cost analysis; cost-benefit analysis (CBA); cost-effectiveness analy-
sis (CEA); and cost-utility analysis (CUA)[12]. In a cost-analysis only the costs of alternative 
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interventions are compared. Therefore, this type of economic evaluation can only be used 
if the consequences of the alternatives are equivalent. However, this is only seldom the 
case[13]. In a CBA, a monetary value is placed on both the costs and the effectiveness of 
an intervention. This allows for an easy evaluation on whether an intervention’s benefits 
exceed its costs. When the benefits are larger than the costs (positive net benefit), an inter-
vention is deemed worthwhile. In practice, however, assigning monetary values to health 
outcomes such as human lives is difficult and controversial[12]. Therefore, CBA is not much 
used in health care settings. A CEA is a health economic evaluation in which the incremental 
costs and incremental effectiveness of an intervention as compared to standard practice 
are determined. The cost-effectiveness of an intervention is expressed as an incremental 
cost-effectiveness ratio (ICER) (equation 1), which divides the incremental costs of an in-
tervention by the incremental effects, and informs on an intervention’s value for money. 
Effectiveness can be measured in diverse outcomes, such as life years gained or number of 
diagnoses reached. A CUA is a variant of the CEA, in which the effectiveness is measured in 
quality-adjusted life years (QALYs). QALYs are a combined measure of health-related quality 
of life (HRQoL) and life years gained from an intervention. HRQoL is expressed as a utility 
score, representing preferences for various health states on a scale from zero to one, where 
zero represents dead and one represents perfect health. The main advantage of using such 
a generic outcome measure as HRQoL is that it allows for a direct comparison between dif-
ferent interventions and disease areas. 
Cost-effectiveness and -utility outcomes can be divided into four categories (figure 1). De-
cision-making based on cost-effectiveness or cost-utility is obvious in the case of an inter-
vention that is both more effective and less expensive than current practice (figure 1, Q4). 
The same goes for an intervention that is less effective but more expensive (figure 1, Q1). 
However, in most cases new medical interventions are both more effective and more ex-
pensive (figure 1, Q2). In these cases, a decision has to be made on whether the ICER rep-
resents “good value for money”[14]. Whether an intervention is deemed cost-effective then 
depends on the maximum amount of money decision-makers are willing to pay for an ad-
ditional unit of effectiveness. Unlike the natural or physical effectiveness outcomes in CEAs, 
for QALYs a formal threshold of £20,000 to £30,000 per QALY gained has been established in 
the United Kingdom. Although in the Netherlands, no formal QALY threshold exists, €80,000 
per QALY is used as a threshold for the most burdensome diseases[15]. In theory, the same 
goes for interventions that are less effective, but also less expensive than current clinical 
ICER Cost  - Cost 
Effect
new medical intervention comparator
=
 - Effect new medical intervention comparator
1( )
7GENERAL INTRODUCTION
1
practice (figure 1, Q3). However, in practice, some issues around Q3 exist. First, it is known 
that people, in general, elicit higher willingness-to-accept, i.e. the required compensation 
for the loss of a desirable good, values for a QALY than they are willing to pay per QALY[16, 
17]. Additionally, there are ethical problems surrounding the implementation of such in-
terventions, as patients currently using the old intervention are now required to move to 
a less-effective one, thereby losing quality of life[18, 19]. Therefore, new medical interven-
tions in this lower left quadrant are difficult to value, and in practice such technologies are 
seldom implemented.
Genetics
A field that is rapidly evolving due to con-
stant technological innovation is the field 
of medical genetics, which involves the 
application of genetics to medical care, in-
cluding the diagnosis and management of 
hereditary disorders. Recently, NGS tech-
nologies have allowed for rapid Deoxyri-
bonucleic acid (DNA) sequencing, there-
by anticipating to improve current clinical 
practice in various disease areas. Howev-
er, NGS technologies might also impact 
health care expenditures. To understand 
NGS in more detail, it is of essence to gain 
insight into the basics of medical genetics.
DNA
DNA contains the genetic information required for the synthesis of all proteins defining 
an organisms’ structure and physiological processes. It acts as a blueprint and determines 
heritable traits such as blood type and hair colour. A DNA molecule consists of two poly-
nucleotides, twisted into a double helix structure, joined by hydrogen bonds between the 
complementary nucleotides  ‘A’  (adenine), ‘T’  (thymine), ‘G’ (guanine) and ‘C’ (cytosine) 
(figure 2). In human cells, these double helices are stored in the cell nuclei in the form of 46 
chromosomes. Approximately 1% - 2% of the nucleotide sequence encodes the structure of 
Figure 1. Cost-effectiveness plane
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a protein, referred to as the protein-coding regions, or genes (figure 2). 
In every cell division, DNA is replicated by unwinding the two strands of the double helix 
and building up a complementary strand 
on each of the original DNA strands, us-
ing free nucleotides. Despite tight control 
and regulation of this process by the cells’ 
DNA repair systems, errors in replication 
can occur, resulting in a mutation which is 
not only present in this cell but also in all 
its succeeding cells. 
DNA mutations can be classified accord-
ing to their size and type. Mutations that 
change the total number of chromosomes 
are referred to as numerical changes (an-
euploidies), of which Down syndrome is 
the one most commonly known (caused 
by an additional copy of chromosome 
21). Other variations affecting chromo-
some composition are referred to as 
structural variation, which can either be 
balanced, or unbalanced. Balanced rearrangements include sequence inversions, in which 
a part of the DNA sequence has been flipped, and chromosomal translocations, in which 
stretches of DNA sequence have been exchanged between two chromosomes[20]. Unbal-
anced rearrangements are generally termed copy number variations (CNVs), a term to col-
lectively describe deletions and duplications sized approximately 1 kilobase (kb) and larger. 
Point mutations represent the smallest mutations present in the human genome. They can 
be divided into single-nucleotide variants (SNVs) affecting only a single base pair and small 
insertion or deletion events (indels), in which one or more base pairs are inserted in, or 
deleted from, the DNA sequence. Mutations can either occur in the protein-coding genes, 
thereby potentially affecting protein function, or in the non-coding intervening sequence. 
If a genetic variation affects, or occurs in, the coding region and causes a change in protein 
structure or function, it might cause disease[21]. 
Many genetic disorders are monogenic, or Mendelian[22]. In Mendelian disorders, the dis-
Figure 2. From DNA to protein
DNA is the blueprint of an organisms’ proteins. One 
of the DNA helices is copied into an mRNA molecule 
(transcription), This mRNA molecule is then translat-
ed into amino acids, which are the building blocks of 
the proteins. Note that this figure provides a simplified 
overview of the transcription and translation process.
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ease-causing mutation, which can be located on an autosome, X-chromsome, or the mito-
chondrial DNA, can either be inherited from one (dominant disease) or both parents (reces-
sive disorder), or alternatively newly arise in the patient (i.e. de novo mutation) as a result 
of a mistake in the cell division process of the germ cells (e.g. a female egg or male sperm 
cell) of one of the parents[23]. 
Finding the genetic cause of disease
For patients with (rare) genetic disorders, finding the exact disease-causing mutation may 
be beneficial in diagnosis, prognosis, treatment and family planning. Nowadays, multiple 
techniques can be used to trace the various types of genetic variations. For example, classic 
cytogenetic techniques, used since the late fifties, are used to visualize large chromosomal 
abnormalities and aneuploidies. For instance, in a karyotype analysis, chromosomes of an 
individual are stained, visualizing various recognizable banding patterns, which can be made 
visible under a microscope[24]. CNVs on the other hand, are best detected using genomic 
microarrays which were only introduced in the early 2000s[25]. This technique allows for 
the detection of relative gains or losses of DNA by fluorescently labelling and hybridizing a 
patients’ DNA onto probed spots of the microarray. The probed spots represent the genom-
ic regions, such as genes, of interest. The more copies of a DNA fragment are present in the 
patients’ genome, the stronger the fluorescent signal of the corresponding microarray spot 
is. Hence, comparing the patients’ fluorescent signals with a control identifies whether CNVs 
are present[26]. In contrast to these cytogenetic technologies, molecular technologies, such 
as DNA sequencing, are used to determine the order of the nucleotide sequence and the 
mutations therein. The latter was first described by Fred Sanger in 1977, and was originally 
based on a dideoxynucleotide chain-termination reaction after which the DNA fragments 
of varying length are separated by gel electrophoresis. Later, this gel-based analysis was 
replaced by capillary sequencing, allowing for a single sequencing reaction, and automated 
computerised reading of the DNA sequence (Fig 3)[27].
For over 30 years Sanger sequencing has been the gold standard for DNA sequencing for the 
generation of DNA sequences. Although the technology has advanced considerably over 
time, it is limited by its throughput, and relative high ‘per nucleotide’  sequencing costs. 
It can only sequence one DNA fragment of up to around 1,000 bases within a predefined 
region or gene of interest at a time[28]. This makes sequencing of multi-gene panels rather 
time-consuming and expensive. For example, sequencing the first human genome was per-
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formed with Sanger sequencing and took 13 years with a cost of $2.7 billion[29]. 
Yet, the identification of mutations causing disease is limited by the knowledge of the (num-
ber of) genes involved in the disease (re-
ferred to as genetic heterogeneity), and 
whether or not the disease is clinically 
recognizable (referred to as clinical het-
erogeneity). That is, finding the cause of 
disease for a disorder that is caused by 
the same mutation, and always leads to 
the same clinical entity, is relatively easy 
(e.g. Down syndrome), whereas finding 
the genetic aetiology of clinically and 
genetically heterogeneous disorders is 
highly challenging. Especially the latter 
type of disorders benefited from the in-
troduction of NGS technologies, as it no 
longer requires the a priori knowledge of 
the genomic locus involved, nor the type 
of mutation it would entail.
Next-generation sequencing
Technological breakthroughs in the early 2000’s led to the development of a number of 
NGS technologies[30], with the major 
advantage being the massively parallel 
sequencing of numerous DNA fragments 
at the same time. This high-throughput 
state-of-the art technology makes NGS a 
considerably faster alternative to Sanger 
sequencing[31]. Besides technological 
advancements, the costs of sequenc-
ing have dropped considerably over the 
years. This decrease in costs even exceeds 
predictions from ‘Moore’s law’ for com-
Figure 3. Sanger sequencing
a. fluorescent sequencing peaks patterns; b. se-
quence ladder obtained by radioactive or fluorescent 
sequencing; c. gel electrophoresis sequence ladder
Figure 4. The development of sequencing costs (per raw 
megabase of DNA sequence) over time. 
Source: https://www.genome.gov/sequencingcosts/. 
Accessed on 10-01-2017.
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puter power, which is anticipated to double every two years at the same cost [32] (figure 4). 
Moreover, NGS allows for detecting all types of genomic variation in one single experiment.
Although the various sequencing platforms differ in their specific technical details, they all 
share general processing steps (figure 5). The first step is the preparation of a “DNA library”, 
consisting of small DNA fragments of up to several hundred base pairs. The fragments are 
than end-repaired and hybridized to oligonucleotides that are complementary to the DNA 
sequences of interest (e.g. the exome, or a panel of a number of specific genes) with technol-
ogy-specific adaptor sequences attached to them. These hybridised DNA with attached oli-
gonucleotide adapter fragments are captured, while the remaining DNA is washed away[2, 
33, 34]. Library preparation is mostly followed by a DNA amplification step where the library 
fragments are clonally amplified by for instance water-in-oil bead-based emulsion PCR or 
solid surface bridge amplification[34]. Once the DNA has been amplified, it is ready to be 
sequenced. Different sequencing platforms use different sequencing chemistries, includ-
ing pyrosequencing, sequencing by 
reversible dye terminators, and se-
quencing by sequential ligation of 
oligonucleotide probes[35]. Next, 
the sequencing reads are computa-
tionally aligned to the reference hu-
man genome. Finally, an algorithm, 
such as GATK, identifies all variants, 
i.e. the positions in the sequenced 
DNA that differ from the reference 
genome (a process known as vari-
ant calling). All called variants are 
filtered to remove the low quality 
variants and annotated with addi-
tional information such as the effect 
of a variant within a gene[36]. The 
last step is the interpretation of the 
data to identify the disease-causing 
mutation. In combination with the 
patients’ phenotype, variants are 
prioritized according to the impact 
and effect on protein function, and Figure 5. DNA sequencing process
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biological knowledge of normal gene function.
Three types of NGS are increasingly being used: targeted gene panels (TGP), whole exome 
sequencing (WES) and whole genome sequencing (WGS). TGP is usually performed in dis-
ease areas in which much is already known about the genetics underlying disease, and ge-
netic and phenotypic heterogeneity play a minor role. For these disorders, a gene panel 
consisting of a range of specified disease genes, can be constructed, leading to a targeted 
selective capture and sequencing of this limited set of genes.
For disease areas in which clinical and genetic heterogeneity play a larger role, WES or WGS 
are more suitable diagnostic tools. In the process of WES all protein-coding regions - the 
genes - are captured and sequenced. For diagnostic purposes, this is a more efficient man-
ner of sequencing, as it is believed that 85% of all disease-causing mutations are located in 
these protein-coding regions[37]. However, WES knows some technical limitations, e.g. dif-
ficulties in detecting triplet repeat changes, small indels, and mutations in CG-rich regions of 
the DNA[38]. WGS, in which the entire human genome, including the non-coding regions, is 
sequenced may serve an alternative diagnostic strategy as it better captures the numerical 
and structural variation when compared to WES, and in addition, is able to provide position-
al information of duplicated genomic regions. However, today WGS is used as a research 
tool rather than in diagnostics as WGS is also considerably more expensive than WES[39].
Next-generation sequencing in clinical practice
NGS technologies have improved clinical practice in various disease areas. In more details, 
WES has already proven to be al valuable tool in a research setting, studying the genetics 
underlying rare Mendelian disorders[2, 40-42]. Additionally, it has shown to be valuable 
in diagnosis genetic disorders[38, 43-45]. This thesis focuses on the application of WES in 
paediatric neurology.
Paediatric neurology
Paediatric neurological disorders represent a broad spectrum of disorders, including thou-
sands of often rare disorders of the brain, spinal cord, nerves and/or muscles. The estimat-
ed prevalence of neurodevelopmental conditions is approximately 3 - 4% for children in 
high-income countries[46, 47]. A considerable percentage of paediatric neurology patients 
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seen in university hospitals in the Netherlands are referred for complex neurological disor-
ders. These include clinically and/or genetically heterogeneous disorders, such as develop-
mental delay, movement disorders, neuromuscular disorders, and epilepsy. 
Typically, these disorders are suspected to be of genetic origin, and patients present at the 
paediatric neurologist with non-specific neurological symptoms, already at young age. Be-
cause these non-specific symptoms make it difficult to provide a straightforward clinical di-
agnosis that can be confirmed by a molecular diagnosis, the diagnostic trajectory in complex 
paediatric neurological disorders (CPND) usually involves various time-consuming and costly 
tests, such as magnetic resonance imaging (MRI), electroencephalography (EEG), muscle 
biopsies, and multiple blood, urine and genetic tests[48, 49]. Since the diagnostic yield of 
each individual diagnostic test is low in this patient population, many tests, some of which 
burdensome to the patients, are performed, often one after the other. Despite this intensive 
diagnostic trajectory, a diagnosis is only established in a minority of patients with CPND.
Even though treatment options for these patients are often limited, establishing a diagnosis 
might be important for other reasons, such as being of great value to patients and their 
families[50, 51]. First, a high frequency of hospital appointments and (invasive) diagnostic 
testing are known to cause both child and parental distress[52]. Establishing a quick diagno-
sis ends the diagnostic trajectory. This might prevent additional diagnostic tests from being 
performed and additional hospital appointments from being made, and therefore also re-
duce or prevent patient and parent distress. Second, the more accurate the diagnosis, the 
more can be said about the aetiology and prognosis of the disorder[53]. Moreover, it might 
enable parents to tap into established support networks. This might result in more effective 
coping and adaptation[52, 54]. Last, a genetic diagnosis might be important in family plan-
ning of the patients’ parents, siblings, and other family members[51, 55].
As the majority of CPN patients have disorders of a suspected genetic origin, it is expected 
that the clinical implementation of WES will improve the diagnostic trajectory of CPND by 
establishing a molecular diagnosis in a substantial number of patients. 
Outline of the thesis
This thesis is divided into two parts. In the first part of this thesis, we provide a detailed 
overview of current practice of CPND and address the problems in this diagnostic trajectory 
in order to determine whether there is room for improvement in this trajectory. To this end, 
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in order to determine whether there is room for improvement in this trajectory. To this end, 
chapter 2 provides a retrospective analysis of the health care resource use, duration and 
diagnostic yield of the conventional diagnostic trajectory. Subsequently, the health-related 
quality of life (HRQoL) of CPN patients and their parents is researched, as well as the factors 
that influence parental HRQoL (chapter 3).
The second part of this thesis comprises the health technological evaluation of WES for 
CPND. First, the feasibility and usefulness of a method for early health economic evaluation 
- the headroom method - is explored (chapter 4). Additionally, this method is applied to the 
diagnostic trajectory of CPND to determine the room for improvement in current clinical 
practice. Then, in order to gain insight in the (development of the) costs of NGS, chapter 5 
describes a cost-analysis of the various clinical applications of NGS. Chapter 6 describes the 
clinical utility in terms of diagnostic yield and costs of WES in CPN as compared to current 
clinical practice. Finally, the results of two cost-effectiveness analyses of WES in CPN are pre-
sented in chapter 7. In addition to a prospective trial-based CEA of WES in clinical practice, a 
model-based analysis was performed to explore the cost-effectiveness of WES as a first-tier 
diagnostic test. 
The thesis concludes with a general discussion and some directions for future research 
(chapter 8).
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Abstract
Background: The diagnostic trajectory of complex paediatric neurology may be long, bur-
densome, and expensive while its diagnostic yield is frequently modest. Improvement in 
this trajectory is desirable and might be achieved by innovations such as whole exome se-
quencing. In order to explore the consequences of implementing them, it is important to 
map the current pathway. To that end, this study assessed the healthcare resource use and 
associated costs in this diagnostic trajectory in the Netherlands.  
 Methods: Fifty patients presenting with complex paediatric neurological disorders of a sus-
pected genetic origin were included between September 2011 and March 2012. Data on 
their healthcare resource utilisation were collected from the hospital medical charts. Unit 
prices were obtained from the Dutch Healthcare Authority, the Dutch Healthcare Insurance 
Board, and the financial administration of the hospital. Bootstrap simulations were per-
formed to determine mean quantities and costs. 
Results: The mean duration of the diagnostic trajectory was 40 months. A diagnosis was 
established in 6% of the patients. On average, patients made 16 physician visits, under-
went four imaging and two neurophysiologic tests, and had eight genetic and 16 other tests. 
Mean bootstrapped costs per patient amounted to €12,475, of which 43% was for genetic 
tests (€5,321) and 25% for hospital visits (€3,112). 
Conclusion: Currently, the diagnostic trajectories of paediatric patients who have complex 
neurological disease with a strong suspected genetic component are lengthy, resource-in-
tensive, and low-yield. The data from this study provide a backdrop against which the intro-
duction of novel techniques such as whole exome sequencing should be evaluated.
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Background
The estimated prevalence of neurodevelopmental conditions is approximately 3-4% for chil-
dren in high-income countries[1, 2]. A considerable percentage of all paediatric neurological 
patients seen in university hospitals in the Netherlands are referred for a suspected complex 
neurological disorder of genetic origin. These disorders are heterogeneous, both clinically 
and genetically, and the symptoms are often nonspecific[3]. The diagnostic trajectory is gen-
erally long and expensive, as it depends on time-consuming and costly tests such as magnet-
ic resonance imaging (MRI), electromyography (EMG), muscle biopsy, and multiple genetic 
tests[4]. This pathway is burdensome for the patients and their families. Since the diagnostic 
yield of any individual test is low in this patient population, many tests are performed, often 
one after the other. Earlier research has shown that complex chronic conditions account for 
a large share of healthcare resource utilisation[5]. Moreover, it is known that neurological 
disorders are very costly and that children with a neurological impairment account for a sub-
stantial proportion of the inpatient resources utilised in the United States[6, 7]. Although 
the economic burden of disease is increasingly addressed by health and research policies, 
reliable cost estimates are often missing[6]. Likewise, estimates of healthcare resource use 
in the diagnostic trajectory of complex paediatric neurology (CPN) are inadequate[5, 8, 9]. 
To set the stage for exploring if and where there is room for improvement, we report here 
on the utilisation of healthcare resources and the associated costs as well as the duration 
and diagnostic yield of this diagnostic trajectory. Additionally, we explore whether the costs 
in this diagnostic trajectory could hypothetically be reduced by implementing whole exome 
sequencing (WES), an innovative genetic diagnostic technology, into clinical practice.
Methods
Study design and population
The study was conducted at the Department of Paediatric Neurology at the Radboud uni-
versity medical center in the Netherlands. Two experienced paediatric neurologists enrolled 
52 consecutive patients between September 2011 and March 2012. These were children (≤ 
18 years) with complex neurological problems that were suspected to have a genetic origin. 
The members of our study population presented with clinically and genetically heteroge-
neous disorders. Individuals with easily recognizable, straightforward genetic disorders such 
as neurofibromatosis type 1 were excluded from this study. All patients underwent the con-
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ventional diagnostic trajectory and were followed until October 31, 2013. To participate, 
both parents had to sign an informed consent form, which was approved by the medical 
ethics committee of the Radboud university medical center. Patient characteristics were ob-
tained from the hospital’s medical records and included gender, age at first physician visit in 
the Radboud university medical center, and diagnosis, if any had been established. 
Outcome measures
The outcome measures were healthcare resource use, the associated direct medical costs, 
and the duration and yield of the diagnostic trajectory. Healthcare resource use was defined 
as the number of hospital visits, inpatient stays, outpatient stays and emergency room visits 
related to a diagnostic test (i.e., visits to the university hospital), and diagnostic tests. There 
were four categories of diagnostics: imaging tests; neurophysiologic tests; genetic tests; and 
other tests. A complete overview of the tests included in these categories, is provided in 
appendix 1. The medical records were used to extract the number of hospital visits and 
the types and number of diagnostic tests performed in the university medical center. Data 
were collected retrospectively, starting with the first physician contact in the university hos-
pital. If a patient was referred by a general hospital, the diagnostic tests performed there 
were retrieved from the referral letters. The number of physician visits in general hospitals 
could not be retrieved, since these visits are generally not reported in referral letters. Unit 
costs were obtained from the Dutch Healthcare Authority, the Dutch Healthcare Insurance 
Board[10], and the financial administration of the university hospital. Such costs cover the 
test, the interpretation of its results, and the physician fee. All unit costs were converted to 
2012 prices in Euros, using price indices from Statistics Netherlands[11]. For some diagnos-
tic tests, several subtypes are priced differently, so a weighted mean of the costs of these 
separate tests was calculated. The duration of the diagnostic trajectory was measured from 
the first physician visit in the university hospital until a diagnosis was established. If none 
had been determined, censored cost data were included up to October 31, 2013.
Statistical analysis
Statistical analyses were performed in Microsoft Excel and were descriptive. For the patient 
characteristic variables age and duration of the diagnostic trajectory the mean, median, 
minimum, maximum, and quartile values were reported. Since the cost data were highly 
skewed, we performed bootstrap simulations with 1000 replications to estimate the mean 
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costs and 95% confidence interval[12, 13]. This was also done for the data on healthcare 
resource use. The uncertainty interval was represented by the 2.5 and 97.5 percentiles. 
For healthcare resource use and the corresponding costs, the bootstrapped mean and 95% 
confidence interval were reported. To examine the relation between the total costs and the 
duration of the diagnostic trajectory, a linear regression analysis of cost and duration data 
was performed in IBM SPSS Statistics version 20. 
Subgroup analysis
It is known that some paediatric neurology patients have siblings with comparable symp-
toms. If they too are being examined, they might undergo a different diagnostic trajectory, 
because not all diagnostic tests will be performed on each sibling. In order to identify po-
tential differences in healthcare resource use between index patients and their siblings, an 
exploratory subgroup analysis was performed.
Scenario analyses
In order to explore whether the costs in this diagnostic trajectory could be reduced by 
implementing WES, scenario analyses were performed. These included two hypothetical 
scenario’s based on how WES may be used in clinical practice, according to a paediatric 
neurologist at the Radboud university medical center. The first scenario assumes that WES 
replaces all genetic tests currently used and the second assumes that also the repeated and 
burdensome tests as well as a 50% of the physician visits will be substituted by WES. Repeat-
ed tests are tests that are on average performed more than once per patient. Burdensome 
tests include lumbar punctures and several types of biopsies. The costs of WES are estimat-
ed on €3,600 for a patient-parent trio. 
Results
Demographics
A total of 52 patients were included, namely 50 probands, and two siblings who were stud-
ied separately. Those two underwent fewer diagnostic tests than they would have if the pro-
bands had not been examined too, so the data on the siblings were not representative. The 
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demographic characteristics are shown in table 1. In the study sample, 58% of the patients 
were female and the mean age at the first physician visit in the university hospital was 4.5 
years (range: 0.3 to 16.2 years).
Healthcare resource utilisation 
The number of physician visits and the number of telephone or email consultations are 
shown in table 2. The bootstrapped mean numbers of such visits and consultations were 
15.55 and 14.21, respectively. Overall healthcare resource utilisation and corresponding 
costs are presented in table 3. The majority of patients (94%) were referred by a general 
hospital. All patients visited a physician at least twice. In addition to seeing the paediatric 
neurologist who enrolled the patients for this study, many patients also saw a clinical genet-
icist (48%), a paediatrician (46%), an ophthalmologist (40%), or another physician (50%). 
Each patient underwent genetic testing, on average eight tests. All but one had at least one 
Table 1. Demographics
n %
Gender
Female 29 58
Male 21 42
Age (years)
0-1 10 20
1-2 7 14
2-3 8 16
3-4 5 10
4-5 3 6
5-10 11 22
>10 6 12
Mean (range) 4.5 (0.3 – 16.2)
Median (Q1; Q3) 3.0 (1.1; 9.6)
Definitive diagnosis established?
Yes 3 6
No 47 94
Definitive diagnosis
Fragile X syndrome 1a 2
Sotos syndrome 1 2
7q21.11q22.3 deletion 1 2
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imaging test, usually an MRI under anaesthesia (94%), combined with an outpatient admis-
sion (92%). The majority of patients underwent neurophysiologic testing (72%), mostly an 
EEG (62%). They all underwent other diagnostic tests too, 16 on average. Most had a basic 
blood test (94%), metabolic blood test (88%), or urine (84%) test.
Total costs and relationship with duration
The costs of this diagnostic trajectory was mainly driven by the genetic testing, which ac-
counts for 43% of the total costs (€5,321). This large share reflects the high unit prices as 
well as the large number of genetic tests performed. Hospital visits are another major cost 
driver, accounting for 25% of the total costs (€3,112), largely due to the average number of 
physician visits (15.55). The bootstrapped mean total costs per patient were €12,475 (95% 
CI: €10,774 - €14,404). 
The duration of the diagnostic trajectory is shown in table 4. The mean duration was 40 
months, ranging from 6 to 145. During this trajectory, a definitive diagnosis could be estab-
lished for three patients after six months (Sotos Syndrome), 10 months (Fragile X Syndrome),
Table 2. Number of hospital contacts
Number of patients (n) % Telephone or email 
consultations
n %
Number of physician visits
1-5 17 34 0 2 4
6-10 12 24 1-5 14 28
11-15 5 10 6-10 15 30
16-20 7 14 11-15 8 16
21-30 3 6 16-20 3 6
31-40 2 4 >20 8 16
> 40 4 8
Bootstrapped mean 15.55 14.21
(2.5 – 97.5 percentile)  (11.67 - 20.05) (10.46 - 18.60)
Type of physicians visited
Paediatric neurologist 50 100
Clinical geneticist 24 48
Paediatrician 23 46
Ophthalmologist 20 40
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and 27 months (7q21.11q22.3 deletion), respectively. Other patients only received descrip-
tive, unspecific diagnoses such as psychomotor retardation, developmental delay, epilepsy, 
and neuromuscular disorder of unknown origin; a definitive diagnosis is only given when the 
precise cause of disease is found. One patient died after being in the diagnostic trajectory 
for 12 months. A linear regression revealed a coefficient of determination between total 
costs and duration of the trajectory of 0.064, indicating that there is no relation between the 
costs and duration of the diagnostic trajectory.
Subgroup analysis
Initially, we included 52 patients, of whom 50 were probands and the other two siblings. 
We decided to exclude the latter two because they did not have a representative health-
care resource use. Of course, probands with an affected sibling will visit the neurologist 
now and then. To identify potential differences in healthcare resource use between index 
patients and their siblings, an exploratory subgroup analysis was performed. If we take the 
two siblings into account in our analyses, we find an average cost of €12,038 per patient. 
On average, the diagnostic trajectory for probands (€12,475) was six times as expensive as 
for their siblings (€1,988). This is mainly because the siblings are tested more directly than 
the index patients; siblings undergo the same types of tests, but less often. As in the initial 
patient population, the major cost drivers for the siblings were the genetic tests, accounting 
for 40% of their total costs, followed by hospital contacts, accounting for 35%. Due to the 
small number of siblings, taking their use of healthcare resources into account did not affect 
the final outcome. 
Table 4. Duration of the diagnostic trajectory*
Number of 
patients (n)
%
Duration of the diagnostic trajectory
0 – 12 months 4 8
12 – 24 months 11 22
24 – 36 months 19 36
36 – 48 months 3 8
> 48 months 13 26
Mean (range) 40 (6 – 145)
Median (Q1; Q3) 29 (23 – 50)
*The duration was measured between the first physician contact in the university 
hospital and the moment a diagnosis was established (n=3) or the end of the 
study (October 31, 2013).
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Scenario analysis
The first scenario analysis performed, assumes that WES will replace all genetic tests cur-
rently used in the diagnostic trajectory of CPND, which currently add up to a cost of €5,321 
per patient (table 3). Since the costs of WES are estimated to be €3,600, replacing all genetic 
tests might reduce the total costs per patient with €1,721. The second scenario assumes 
that WES replaces all genetic tests, as well as all repeated and burdensome tests and 50% of 
the physician visits, which leads to a cost reduction of  €3,175 per patient (table 3). 
Discussion
Our study confirmed and quantified the relatively low yield, long duration, and resource-in-
tensive nature of the diagnostic pathway taken by children with complex neurological dis-
orders of suspected genetic origin in the Netherlands. After an extensive diagnostic trajec-
tory, a definitive diagnosis was established in only 6% of the patients. Receiving a definitive 
diagnosis is important for the parents of the patients, even if no treatment is possible, as 
it might provide psychological benefit by giving emotional relief and promoting acceptance 
of the child’s disease[14, 15]. Furthermore, a diagnosis opens up opportunities to inform 
the parents about reproductive choices, financial planning, and the availability of special 
services[16]. 
The high costs found for diagnostic testing are not surprising, since genetic tests for paedi-
atric neurological disorders are increasingly available[8]. Because complex paediatric neu-
rological disorders (CPND) are clinically and genetically heterogeneous, it is difficult to pri-
oritize candidate genes[17]. This leads to long diagnostic trajectories with extensive genetic 
testing, generally without any result. Earlier studies have demonstrated that patients with 
complex chronic conditions generally have a high utilisation of healthcare resources[5-9]. 
Berry et al. revealed that children with neurological impairment account for a substantial 
proportion of hospitalisations in the United States[7]. In our study we found an average of 
2.5 hospitalisations per patient, only including hospitalisations for diagnostic reasons such 
as an MRI. The overall estimates of annual costs for mental and neurological disorders in 
Europe as given by Olesen et al. show that these are in general very expensive[6]. However, 
the total costs of the diagnostic trajectory in CPN patients had not been researched yet. At 
a mean cost of €12,475 per patient, we have now confirmed the high level of healthcare 
resource use and costs that had been expected for these patients. This study is the first to 
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assess the diagnostic pathway and its associated costs in children presenting with complex 
neurological conditions of an expected genetic origin. By enrolling the patients consecu-
tively, we ensured that the outcomes represent the overall patient population. Data on the 
healthcare resource utilisation of these patients were collected retrospectively. Since the 
diagnostic tests performed in the general hospital were directly reported in the referral let-
ters, this study provides a full and detailed overview of diagnostic testing in CPN patients.
Despite these strengths, this study also has some limitations. First, with just 50 patients, 
the sample was relatively small. Due to the diversity in complex neurological disorders, the 
population was also heterogeneous, leading to a wide spread in the costs. We included our 
patients consecutively, however, to ensure that the study population would be representa-
tive of the overall CPN patient population. To provide reliable measures of the mean costs 
and the spread in costs, we bootstrapped our data using 1,000 replications, showing the 
mean and 95% confidence intervals of healthcare use and associated costs. The exploratory 
subgroup analysis was performed on a group of two patients, which is too small for informa-
tive analyses, so no conclusions can be drawn from this subgroup analysis.
Second, we performed a retrospective study, which has several consequences. For instance, 
only the direct medical costs could be taken into account. Direct and indirect non-medical 
costs such as travel expenses and productivity losses were not incorporated. Nor were phy-
sician visits in the general hospitals included. Leaving those visits out may cause a consid-
erable underestimation of the total costs because the majority of the patients (94%) were 
referred from general hospitals. Also, there was not one predefined diagnostic pathway 
which all patients followed. This means we induced much inter-patient variability in terms 
of diagnostic tests. Although one could ask oneself whether this affects the generalisability 
of these results, it clearly reflects the difficulties paediatric neurologists experience with 
diagnosing these patients in daily clinical practice. Additionally, it may result in an under-
estimation of the reported duration of the diagnostic trajectory. We measured the time 
that lapsed between the first physician contact in the university hospital and the moment a 
diagnosis was established or the end of the study (October 31, 2013). However, the actual 
start of the trajectory will lie before the date used in this study. Moreover, for patients who 
have not yet received a definitive diagnosis, the trajectory continues.
Third, this study included only one university hospital. This could induce a certain bias in our 
data, since these reflect only the local ways of diagnosing CPN patients. On the other hand, 
it might be expected that comparable health care resource utilisation will be found in other 
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hospitals. Due to the heterogeneity in disorders and the non-specificity of the symptoms pa-
tients present with, no standard diagnostic pathway or guidelines exist, and the diagnostic 
yield of individual diagnostic tests is low. As a consequence, the diagnostic work-up of these 
patients typically includes many diagnostic tests, often one after the other, in an attempt to 
find or exclude possible causes of disease. 
Finally, unit prices, but also clinical practice, are known to differ between countries[18]. 
Therefore, the results may not be generalizable to other settings. Interested readers can 
enter the resource use or unit prices they expect to be relevant in their country in an online 
spreadsheet (online supplementary materials 1). This spreadsheet will show the impact of 
these alterations on the results.  
Despite the considerable healthcare resource use and associated costs found in this study, 
the diagnostic yield is low. After a mean duration of 40 months, a definitive diagnosis could 
only be established for three patients (6%). In part, this lengthy trajectory can be explained 
by the long waiting times for an MRI or EEG, for example. However, the main reason for this 
long duration is the low diagnostic yield of the individual tests, prompting many diagnostic 
tests, often one after the other.
The diagnostic trajectory includes tests that are burdensome for the patients and their fam-
ilies. Some room for improvement in this trajectory might be found in the genetic diagnostic 
tests. Recent innovations in genetic testing technology make massively parallel next-gener-
ation DNA sequencing of the entire human exome possible[9, 19]. Whole exome sequenc-
ing (WES) allows for the detection of genetic variation in all genes and has proven to be a 
valuable tool in diagnosing genetically heterogeneous disorders[20-24]. Since the majority 
of CPND have a genetic origin, they are expected to be amenable to WES[3]. Its implemen-
tation might provide a higher diagnostic yield in a single experiment, and was also found 
to reduce healthcare expenditure when substituting other genetic tests. In the current di-
agnostic trajectory, patients undergo 7.6 genetic tests on average, adding up to €5,321 per 
patient. Healthcare expenditure could be reduced even more by substitution of repeated 
and burdensome tests as well as 50% of the physician visits. Whether the implementation 
of next-generation DNA sequencing could really improve the diagnostic trajectory of CPN is 
a topic for further research.
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Conclusion
In spite of extensive diagnostic investigations that may be burdensome to the patient and 
the family and that incur considerable costs, the yield in terms of a conclusive diagnosis is 
low in children with complex neurological disorders of suspected genetic origin. It is against 
this backdrop that novel diagnostic strategies, including next-generation sequencing tech-
niques, should be evaluated.
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Abstract
Background: Complex paediatric neurology (CPN) patients generally present with non-spe-
cific symptoms, such as developmental delay, impaired movement and epilepsy. The di-
agnostic trajectory in these disorders is usually complicated and long-lasting, and may be 
burdensome to the patients and their parents. Additionally, as caring for a chronically ill 
child can be stressful and demanding, parents of these patients may experience impaired 
health-related quality of life (HRQoL). This study aims to assess parental HRQoL and factors 
related to it in CPN.
Methods: Physical and mental HRQoL of 120 parents was measured and compared to the 
general population using the SF-12 questionnaire. Parents also completed this question-
naire for the measurement of patient HRQoL. Additional questionnaires were used to mea-
sure parental uncertainty (Visual Analogue Scale) and worry phenomena (Penn State Worry 
Questionnaire), and to obtain socio-demographic data. A linear mixed model with random 
effect was used to investigate which of these variables were associated with parental HRQoL. 
Results: As compared to the general population, HRQoL of these parents appeared dimin-
ished. Fathers showed both lowered physical (51.76, p<0.05) and mental (49.41, p<0.01) 
HRQoL, whereas mothers only showed diminished mental (46.46, p<0.01) HRQoL. Patient 
HRQoL and parental worry phenomena were significantly correlated with overall and men-
tal parental HRQoL. 
Conclusions: The reduction in parental mental HRQoL is alarming, also because children 
strongly rely on their parents and parental mental health is known to influence children’s 
health. Awareness of these problems among clinicians, and supportive care if needed are 
important to prevent exacerbation of the problems. 
39PARENTAL QUALITY OF LIFE IN COMPLEX PAEDIATRIC NEUROLOGY
3
Background
Complex paediatric neurological disorders (CPND) for which patients are referred to aca-
demic paediatric neurology departments are a heterogeneous group of chronic disorders. 
Often, these have a genetic origin and patients present at young age with non-specific 
symptoms, ranging from developmental delay to epileptic seizures and motor symptoms. 
Because of the non-specificity of the symptoms, the diagnostic trajectory in complex pae-
diatric neurology (CPN) is usually long, and conclusive diagnoses are established in a only 
minority of patients[1].
CPND, such as epilepsy, cerebral palsy and pervasive developmental disorders, are known to 
affect the health-related quality of life (HRQoL) of both patients and caregivers, which are in 
these disorders usually the parents[2-4]. Previous studies show that parents of children with 
developmental disabilities experience increased stress[5, 6], impaired mental health[7], a 
sense of devaluation and self-blame[8], impaired physical functioning, and fatigue or ex-
haustion[4, 9, 10]. Moreover, parents of children with cerebral palsy indicate that caring 
for a child with a neurological disorder has an impact on physical health, involves disrupted 
sleep and limited time, and puts pressure on both marital and other social relationships[11]. 
In CPN, many children remain currently undiagnosed despite intensive diagnostic trajec-
tories[1]. The high frequency of hospital appointments (on average, 15.6 in this patient 
population) and (invasive) diagnostic testing (on average 30.0 imaging, neurophysiologic, 
genetic and other diagnostic tests) is known to cause both child and parental distress[1, 12]. 
Moreover, diagnostic uncertainty may result in less effective coping and poorer adaptation, 
as parents have no information on prognosis and no ability to tap into established support 
networks. Therefore, CPDN are expected to affect parental HRQoL[12, 13]. 
As chronically ill children demand parental participation and adaptation, and rely on their 
parents for health care decisions, careful evaluation of parental HRQoL is important[14]. 
Furthermore, determining factors associated with parental HRQoL might allow for early de-
tection of parental health problems and provision of supportive care when needed. 
Parental HRQoL might be affected by patient-related factors. For example, more severely 
affected patients who need more care, causing a higher burden for parents, are expected 
to impact their parents’ HRQoL more than less severely affected patients. The HRQoL of the 
patient is therefore expected to be positively correlated with parental HRQoL. Patient age 
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on the other hand, is expected to be negatively correlated with parental HRQoL. As patients 
usually present with symptoms at very young age, patient age is assumed to be a proxy 
measure for the duration of the diagnostic trajectory of the patient. A long-lasting diagnos-
tic trajectory is expected to reduce parental HRQoL. Not only is this diagnostic trajectory 
expected to result in more stress over time due to the numerous trips to the hospital and 
many (invasive) diagnostic procedures, care giving requirements for children with neurolog-
ical symptoms might also increase over time, as pointed out by Carmichael et al. and Macias 
et al.[12, 15]. 
In addition to patient factors, parental characteristics may also be associated with their 
HRQoL[16-18]. Lower education and less hours of employment are known predictors for 
parental stress[19]. Therefore, higher education and employment are expected to be pos-
itively correlated with parental HRQoL[18]. Moreover, Macias et al. showed that older 
mothers of children with spina bifida report greater stresses related to medical and legal 
concerns than younger mothers[15]. Additionally, HRQoL is known to generally decrease 
with aging[20, 21]. Hence, parent age is expected to be positively correlated with parental 
stress and therefore negatively correlated with parental HRQoL. Also, Lenhard et al. state 
that uncertainty around the aetiology of disease constitutes a determinant of long-lasting 
emotional burden for parents[22]. Therefore, the uncertainty parents experience regarding 
the aetiology of disease is expected to reduce parental HRQoL. Finally, since parental worry 
is known to be related to parental anxiety and stress, we expect parents with high levels of 
trait worry to have a lowered HRQoL[16, 17, 23]. 
The aim of this study is twofold, namely to assess parental HRQoL in CPN and to gain insight 
in the relation between parental HRQoL and several patient and parental variables.
Methods
Study population and design
This cross-sectional study was conducted at the Department of Paediatric Neurology at the 
Radboud university medical center in Nijmegen, the Netherlands. Two experienced paedi-
atric neurologists consecutively enrolled 100 eligible patients and their parents between 
August 2013 and January 2015. Patients were children ≤ 18 years, presenting with com-
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plex neurological problems of unknown aetiology, of suspected genetic origin, who were 
referred for diagnostic reasons. Patients presented with clinically heterogeneous disorders 
and displayed non-specific symptoms varying from developmental delay to epileptic sei-
zures and neuromuscular symptoms. In 65 out of 98 patients (66%) the clinical phenotype 
was dominated by one feature, namely psychomotor retardation (n=42); a movement dis-
order (n=13); a neuromuscular disorder (n=5); or epilepsy (n=5). In the other 33 patients 
(34%) at least two important features were present, namely psychomotor retardation plus 
epilepsy (n=19), psychomotor retardation plus a movement disorder (n=4), psychomotor re-
tardation plus a neuromuscular disorder (n=4), or other combinations (n=6).To participate, 
both parents signed an informed consent form, which was approved by the medical ethics 
committee of the Radboud university medical center. After returning the informed consent 
forms, parents received the following questionnaires: The SF-12 questionnaire to measure 
parental and patient HRQoL, the Penn State Worry Questionnaire (PSWQ) for measuring 
parental trait of worry; a visual analogue scale (VAS) to determine parental uncertainty; and 
a socio-economic questionnaire to obtain parental level of education, employment status, 
hours of employment and age. All questionnaires were completed separately by each pa-
tient’s mother and father. Parents who did not return the questionnaires within two months 
were reminded by telephone or email. 
Conceptual model
A conceptual model (figure. 1) was constructed to examine the relation between parental 
HRQoL and several patient and parental variables. Patient variables included patient HRQoL 
(measured by parent-proxy) and patient age. Parental variables included education level, 
hours of employment, uncertainty and parental trait of worry. 
Measures
Parental HRQoL
Parental HRQoL was measured and compared to the general Dutch population using the 
SF-12. This is a generic HRQoL instrument, in which respondents evaluate their health state 
“over the past four weeks”. It contains 12 multi-level items derived from the SF-36[9]. The 
SF-12 generates two summary scores: The Physical Component Score (PCS), measuring the 
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physical dimension of HRQoL and the Mental Component Score (MCS), measuring the men-
tal dimension of HRQoL. SF-12 summary scores were calculated using Dutch item weights, 
according to Mols et al.[21]. We chose the SF-12 specifically for its ability to separately 
determine the physical and mental component of HRQoL, in combination with a low respon-
dent burden[24]. 
The SF-6D algorithm of the University of Sheffield was used to convert SF-12 data to SF-6D 
utility scores. Utility scores express HRQoL on a scale from zero to one, where zero rep-
resents dead, and one represents perfect health[25]. The use of utility scores allows for 
both Quality-Adjusted Life Year (QALY) calculation for cost-utility analysis and comparability 
with other disease areas. The SF-6D is a six-dimensional multilevel health instrument with 
18,000 unique health states defined, for describing and valuing individuals’ health. Prefer-
ence-weighted values, which are required to calculate utilities, are obtained for each of the 
possible health states via a standard gamble experiment in which a sample of the general 
population valued a subset of the possible health states. The SF-6D uses seven of the SF-12 
items (or 11 items of the related SF-36) to calculate the utility value, which can range be-
tween 0.345 and 1. Since Dutch normative SF-6D utility values are not available, UK weights 
were used, and SF-6D utility scores were compared to the UK general population[20]. 
Figure 1. Conceptual model
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Patient-by-proxy HRQoL
Patients were not asked to complete a questionnaire themselves, as the majority of patients 
had limited ability to understand their disease, limited linguistic skills and time perspective 
due to their young age and disorders[26]. Neurologists indicated that scoring the severity 
of disease of all patients on a single scale was not possible due to the heterogeneity and in-
comparability of the patients’ symptoms. Therefore, we asked parents to complete a proxy 
measure of HRQoL for their child. Currently, no generic HRQoL questionnaires using child 
preference weights have been validated for proxy-use in measuring child HRQoL[27]. To as-
sure consistency between the results for parent and patient HRQoL, the SF-12 was used for 
the proxy measurement of patient HRQoL. 
The Pearson correlation coefficient was calculated to assess the correlation between pa-
tient-by-mother-proxy and patient-by-father-proxy utility scores. 
Patient and parent age
Patient and parent age were obtained from the medical charts of the university hospital. 
Parental uncertainty 
A VAS ranging from zero to ten was used to determine the extent of feelings of uncertainty 
of parents regarding their child’s disease. The item of this VAS scale was: “Not knowing the 
diagnosis of my child, makes me feel [not at all uncertain – very uncertain]”. 
Parental trait of worry
In order to investigate the relation between the trait of worry of the parents and their 
HRQoL, parents completed the PSWQ. This is a 16-item questionnaire that assesses general-
ity, excessiveness and uncontrollability aspects of the trait of worry[28]. Items are rated on a 
Likert-type scale from one (“not at all typical of me”) to five (“very typical of me”). The total 
score of the PSWQ ranges from 16 to 80, with higher scores indicating higher trait of worry. 
Average Dutch scores are 39 and 44 for men and women below the age of 45, respectively, 
and scores ≥59 indicate pathological worry[29]. 
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Education and employment
The education level and hours of employment of the parents were assessed with a socio-eco-
nomic questionnaire, which was based on the Productivity Cost Questionnaire (PCQ)[30]. 
Statistical analyses
Descriptive statistics were used to analyse parental HRQoL values. In order to compare pa-
rental MCS, PCS and SF-6D utility scores to those of the general population, one-sample 
t-tests were performed. As all variable values were obtained from both the fathers and 
mothers of the patients, a linear mixed model with random effect (patient) was used to 
investigate potential relations between parental SF-6D utility scores (dependent variable) 
and the factors presented in figure 1 (independent variables). For the variable education, 
dummy variables were used, while all other variables were continuous. All variables were 
tested for normality and collinearity. First, all disease-related and parental variables were 
implemented in a mixed model. A backward selection was applied to eliminate non-signifi-
cant parameters, with a removal criterion of p ≥ 0.10. 
Since we expect the mental component of HRQoL to be most affected, we did the same 
analysis with parental MCS scores as the dependent variable. All statistical analyses were 
performed using IBM SPSS, version 20. 
Results
Demographics
In total, 100 patients were included. Two patients were excluded because they died during 
the study. Therefore, 196 parents of 98 patients were asked to complete the questionnaires. 
With a total of 129 completed questionnaires, the response rate was 66%. Nine parents 
(3 mothers, 6 fathers) completed too few questions to calculate HRQoL scores, and were 
excluded. This resulted in a total of 120 useful questionnaires with data on (parents of) 65 
different patients, with a mean age of 6.9 years old. For 55 patients data was received from 
both parents, for 10 patients data was available from only one parent (supplemental figure 
1). Relevant patient and parent demographics are shown in table 1. In this study sample, 
one third of the parents had a high education level (35%), and 40% of the parents were 
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Table 1. Demographics
Total 
(n=120)
Dutch 
norms 
(%)
Mothers 
(n=63)
Dutch 
norms 
(%)
Fathers 
(n=57)
Dutch 
norms 
(%)
Age, mean (SD) 40.2 (6.2) 39.3 (6.0) 41.2 (6.3)
Parental level of education, 
n (%)*
Low 30 (25.0) 23.7 15 (23.8) 23.5 15 (26.3) 23.9
Intermediate 47 (39.2) 46.2 23 (36.5) 48.2 24 (42.1) 44.2
High 42 (35.0) 29.4 25 (39.7) 27.7 17 (29.8) 31.0
Missing 1 (0.8) 0.8 0 0.6 1 (1.8) 0.9
Employment status, n (%)**
Unemployed 12 (10.0) 6.5 10 (15.9) 6.7 2 (3.5) 6.3
Part-time employed 54 (45.0) 38.2 45 (71.4) 53.6 9 (15.8) 23.4
Fulltime employed 48 (40.0) 37.2 6 (9.5) 16.1 42 (73.7) 57.7
Missing 6 (5.0) 18.1 2 (3.2) 23.6 4 (7.0) 12.6
Hours of employment, mean 
(SD)***
29.5 (11.0) 30.1 22.2 (9.46) 24.5 36.7 (6.79) 34.9
* 2007 Dutch population norms (age 15 – 65). Source: Statistics Netherlands[31]. 
** 2014 Dutch population norms (age 20-65 for employment numbers, age 25-75 for unemployment numbers). 
Source: Eurostat[32]. The high missing rate indicates people who are not employed but also not part of the labour 
force.
*** Mean number of employment per week was calculated over all employed parents[32]. Dutch population norms 
(2014) were obtained from Eurostat. 
Table 2: HRQoL, PSWQ and uncertainty scores
Total (n=120) Mothers (n=63) Fathers (n=57)
n Mean (95%-CI) n Mean (95%-CI) n Mean (95%-CI)
Parental SF-12 
PCS scores
120 51.63 
(50.23 – 53.03)
* 63 51.50 
(49.65 – 53.36)
57 51.76 
(49.59 – 53.94)
*
Parental SF-12 
MCS scores
120 47.86 
(46.44 – 49.29)
** 63 46.46 
(44.52 – 48.39)
** 57 49.41 
(47.33 – 51.50)
**
Parental SF-6D 
utility score
120 0.798 
(0.78 – 0.82)
63 0.79 
(0.76 – 0.82)
57 0.81 
(0.78 – 0.84)
Patient-by-
proxy SF-6D 
utility score
106 0.70 
(0.68 – 0.73)
56 0.69 
(0.66 – 0.73)
50 0.72 
(0.68 – 0.75)
PSWQ score 113 42.24 
(40.21 – 44.27)
57 44.51 
(41.46 – 47.57)
56 39.93 
(37.29 – 42.56)
Range 19 – 72 19 – 72 19 – 65
VAS Uncer-
tainty score 
117 5.14 
(4.62 – 5.66)
61 5.45 
(4.69 – 6.21)
56 4.80 
(4.08 – 5.52)
Range 0-10 0-10 0-10
*Significantly lower than general Dutch population at p < 0.05.
**Significantly lower than general Dutch population at p < 0.01.
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Table 3: Predicting variables for parental HRQoL (SF-6D utility scores)
Full model β-Coefficient p-value 95% confidence interval
Intercept 0.936 0.000 0.733 – 1.139
Patient age 0.005 0.063 -0.0003 – 0.011
Parent age -0.002 0.404 -0.006 – 0.002
Educationa
     Middle -0.028 0.256 -0.077 – 0.021
     High -0.004 0.863 -0.055 – 0.046
Hours of employment 0.0001 0.885 -0.001 – 0.001
PSWQ score -0.007 0.000 ** -0.009 – -0.005
VAS uncertainty score -0.0007 0.847 -0.009 – 0.007
Patient-by-proxy 
SF-6D utility score 0.263 0.003 ** 0.094 – 0.432
Final model β-Coefficient p-value 95% confidence interval
Intercept 0.878 0.000 0.728 – 1.027
Patient age 0.005 0.033 * 0.0004 – 0.009
PSWQ score -0.007 0.000 ** -0.008 – -0.005
Patient-by-proxy 
SF-6D utility score 0.237 0.003 ** 0.081 – 0.393
Table 4: Predicting variables for parental mental HRQoL (MCS scores)
Full model β-Coefficient p-value 95% confidence interval
Intercept 56.40 0.000 44.540 – 68.262
Patient age 0.127 0.443 -0.202 – 0.457
Parent age -0.049 0.678 -0.280 – 0.183
Educationa
     Middle -0.232 0.873 -3.103 – 2.638
     High 0.322 0.219 -2.607 – 3.250
Hours of employment 0.053 0.150 -0.020 – 0.125
PSWQ score -0.451 0.000 ** -0.563 – -0.339
VAS score -0.154 0.503 -0.611 – 0.302
Patient-by-proxy 
SF-6D utility score 15.428 0.003 ** 5.707 – 25.149
Final model β-Coefficient p-value 95% confidence interval
Intercept 55.02 0.000 46.902 – 63.144
Hours of employment 0.062 0.072 0.006 – 0.130
PSWQ score -0.466 0.000 ** -0.566 – -0.367
Patient-by-proxy 
SF-6D utility score 15.289 0.001 ** 6.273 – 24.304
a. Low education was used as the reference value.
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fulltime employed. 
Health-related quality of life
Parents of children with CPND, on average had MCS scores of 47.86 (table 2), which is sig-
nificantly lower than the Dutch norm value of 51.07 (p < 0.01)[21]. Additionally, fathers had 
decreased PCS scores (51.76) (p < 0.05), whereas mothers did not (51.50), when compared 
to the general Dutch population (54.55 and 52.76, respectively).
SF-6D utility scores were normal for both fathers (0.81) and mothers (0.79), compared to UK 
norm values, which are 0.820 and 0.799 for males and females, respectively[20]. 
Overall patient-by-proxy SF-6D utility scores of 0.70 were found, with a substantial correla-
tion between patient-by-mother and patient-by-father proxy scores (r = 0.80, p < 0.01). 
Factors associated with parental HRQoL
Both mothers and fathers on average had normal PSWQ scores. However, 14% of the moth-
ers, and 7% of the fathers in this sample presented with pathological worry (PSWQ score 
≥59)[29]. Mothers were significantly more uncertain than fathers (p < 0.05) (table 2). A lin-
ear mixed model indicated that parental HRQoL (SF-6D utility scores) decreased with in-
creasing PSWQ scores and decreasing patient-by-proxy HRQoL (SF-6D utility scores by par-
ent-proxy) (P < 0.01) (table 3). Although both factors were strongly associated with mothers’ 
SF-6D utility scores (p < 0.01), patient-by-proxy SF-6D utility scores were not associated with 
fathers’ SF-6D utility scores (Appendix A). Additionally, patient age was found to be posi-
tively correlated with SF-6D utility scores. As patient age is assumed as proxy measure for 
the duration of the diagnostic trajectory, this suggests that the longer the patient is in the 
diagnostic trajectory, the higher the parental SF-6D utility scores. 
PSWQ scores and patient-by-proxy SF-6D utility scores were found to also be predicting 
variables for overall parental mental HRQoL (SF-12 MCS scores) (p < 0.01) (table 4). PSWQ 
scores appeared to be associated with the MCS scores of both fathers and mothers (p < 
0.01). Additionally, mothers’ MCS scores were positively associated with patient-by-proxy 
SF-6D utility scores (p < 0.05), whereas fathers’ MCS scores were associated with their ed-
ucational level (p < 0.05) (Appendix A). Residuals were normally distributed and there were 
no problems of collinearity (variance inflation factor 1.9).
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Discussion
To our best knowledge, our study is the first to assess parental HRQoL related factors in 
CPND of unknown origin. We showed that the HRQoL of these parents is diminished com-
pared to the general population. Fathers showed both diminished PCS and MCS scores, 
whereas in mothers, only mental health was affected. SF-6D utility scores however, did not 
differ from the general population. Patient-by-proxy SF-6D scores, patient age, and parental 
PSWQ scores were predicting variables for parental HRQoL.
The main strength of this study is the fact that we collected self-assessed and patient-by-
proxy HRQoL data from both fathers and mothers. This enabled us to identify variables that 
are correlated to parental HRQoL, for fathers and mothers separately, improving our under-
standing of how the quality of the life of parents of children with CPND is affected. 
Our study has a number of limitations that need to be taken into account. First, since no 
Dutch norm scores for the SF-6D are available, UK scores were used, while for the SF-12 PCS 
and MCS scores Dutch norms were used. As norm scores might differ across countries, this 
potentially biases our results. Second, in the current study the SF-12 was used for measuring 
parental as well as patient-by-proxy HRQoL. The use of the SF-12 in children however, has 
not been validated. QualityMetric did develop and validate the SF-10 for use in children over 
5 years old. Nonetheless, almost half of our patient population was under five years of age. 
The advantage of the SF-12 over the SF-10, is that these scores can be converted into SF-6D 
utility scores. Today, no validated HRQoL questionnaires using child preference weights, that 
are suitable for proxy-measurement are available[27]. Lastly, we did not include a patient 
self-assessment of HRQoL. Therefore, it should be borne in mind that a proxy bias might be 
present, as caregivers are known to incorporate part of their own HRQoL into the proxy-as-
sessment of the patients’ HRQoL[33-35]. To what extent they do this is unclear, especially 
when caregivers experience a diminished HRQoL themselves. This might cause biased re-
sults on the patients’ HRQoL, as well as the relation between parental and patient HRQoL. 
Note that a substantial correlation between patient-by-mother-proxy and patient-by-father-
proxy scores was found.
According to Pickard and Knight, three perspectives to assess HRQoL can be used: Patient 
self-assessment, proxy assessment from the proxy’s view, and proxy assessment in which 
you ask the proxy to complete the questionnaire from the patient’s view[36]. Asking the 
parents to rate the HRQoL of the patients as they think the patient would rate his or herself 
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might be informative. However the usefulness of this perspective in studies of children is 
currently unknown[36]. Another possibility to overcome, or at least estimate, this potential 
proxy bias is including another measure of the severity of disease from a new perspective, 
such as a VAS scale completed by the neurologist for each patient. However, this is challeng-
ing in this population as the symptoms and complaints of these patients are very diverse 
and cannot easily be mapped onto one severity scale. 
The diminished parental HRQoL we found in both physical and mental domains, is in accor-
dance with earlier studies on HRQoL in parents of chronically ill children[8, 37-39]. Howev-
er, literature on other neurodevelopmental disorders reports that mothers have a greater 
reduction in both physical and mental HRQoL when compared to fathers, whereas accord-
ing to our results, fathers’ PCS scores are more affected than mothers’ PCS scores[28, 38]. 
Although the reductions in MCS scores (-3.2 points) were significant, it is uncertain if these 
reductions are also clinically relevant. The reductions in MCS scores in this study are higher 
than reductions in MCS scores found in traumatic injury (-2.8 points) and insomnia patients 
(-2.0 points)[40, 41]. However, Ware et al. state that guidelines for the sizes of differences 
that should be considered not only statistically, but also clinically relevant, are currently not 
available and must await the results of future studies. For the PSWQ scores on the other 
hand, clinically relevant cut-off scores are available[29]. In this sample, 11% of the parents 
showed pathological PSWQ scores. This shows that a considerable proportion of the parents 
of CPN patients presents with worry problems. As our regression model shows, this affects 
their HRQoL substantially.
Although parental HRQoL was expected to be negatively correlated with patient age, a pos-
itive correlation was found. As generally patients present with symptoms at very young age, 
these results suggest that when the duration of the diagnostic trajectory increases, the as-
sociated negative impact on the parents’ quality of life diminishes. This might be explained 
by the fact that over time, parents start accepting their child’s disease and learn to cope 
with it despite the absence of an aetiological diagnosis[42]. It might also be explained by 
the fact that parents tend to worry less about older children. This process of coping also 
seems to become apparent in the patient-by-proxy SF-6D utility scores. With a range be-
tween 0.45 and 1.00, there is a considerable variability in patient-by-proxy HRQoL values, 
which might be due to the large heterogeneity of our patient population. Despite this wide 
range of patient-by-proxy SF-6D utility scores, with an average of 0.70 (25 percentile 0.62), 
these scores are considerably higher than the patient-by-proxy utility values in childhood 
epilepsy (0.334), asthma (0.554), skin disorders (0.610), learning disabilities (0.420) and au-
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tism spectrum disorders (0.433) as measured with the Health Utilities Index Mark III[43]. 
Besides coping, these high SF-6D utility scores might result from bias. It is not clear how the 
parents interpreted the SF-12 questions on their child’s health. These questions should be 
interpreted as compared to a healthy child, but might as well be interpreted as compared to 
the expectations of the parents regarding their own child. In the latter case, parents might 
rate their child’s health relatively highly despite the impairments of the child. 
The fact that patient-by-proxy HRQoL appeared to be positively related to parental HRQoL is 
understandable, as parents of children with chronic illnesses are known to have substantial 
levels of social, financial and emotional burden and are completely responsible for the care 
of their children[44-47]. Our model gives no information, however, about the causal direc-
tion of the relationship between parental and patient-by-proxy HRQoL. Besides the fact that 
caring for a chronically ill child is stressful for the parents, and therefore might decrease 
their HRQoL depending on the severity of disease, it is known that parental mental health 
also influences their children’s health[39]. Since chronically ill children strongly depend on 
their parents, early detection of diminished parental mental HRQoL and provision of sup-
portive care if needed is therefore important in order to prevent additional HRQoL prob-
lems in these children and their parents. Paediatricians should be alert for parental HRQoL 
problems, as parents do not always bring forward their own problems, needs and concerns. 
HRQoL problems might be prevented or reduced, for example, by an open communicative 
exchange on needs and concerns related to daily life with the physician or a multidisci-
plinary health care team.
Conclusion
HRQoL of parents of a child with a complex neurological disorder is diminished compared 
to the general population. This study demonstrates that 11% of the parents in this sample 
present with pathological worry, and that this affects their mental and overall HRQoL sub-
stantially. Also, parents that rate the HRQoL of their children lower are more vulnerable for 
reductions in (mental) HRQoL. Paediatricians should be aware of this, as parental mental 
health is known to influence children’s health. In order to prevent additional HRQoL prob-
lems in these children and their parents, it is important that parental health problems are 
detected timely and that supportive care is provided at an early stage.  
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Supplemental figure 1. Questionnaire flowchart
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Abstract
Background: The headroom method was introduced for the very early evaluation of the 
potential value of new technologies. It allows for establishing a ceiling price for technologies 
to still be cost-effective by combining the maximum effect a technology might yield, the 
maximum willingness-to-pay (WTP) for this effect, and potential downstream expenses and 
savings. Although the headroom method is QALY-based, not all innovations are expected 
to result in QALY gain. This paper explores the feasibility and usefulness of the headroom 
method in the evaluation of technologies that are unlikely to result in QALY gain. This will be 
illustrated with the diagnostic trajectory of complex paediatric neurology (CPN).  
Results: Our headroom analysis showed a large room for improvement in the current diag-
nostic trajectory of CPN in terms of diagnostic yield. Combining this with a maximum WTP 
value for an additional diagnosis and the potential downstream expenses and savings, re-
sulted in a total headroom of €15,028. This indicates that a new technology in this particular 
diagnostic trajectory, might be cost-effective as long as its costs do not exceed €15,028.
Conclusions: The headroom method seems a useful tool in the very early evaluation of 
medical technologies, also in cases when immediate QALY gain is unlikely. It allows for al-
locating health care resources to those technologies that are most promising. It should be 
kept in mind however, that the headroom assumes an optimistic scenario, and for that rea-
son cannot guarantee future cost-effectiveness. It might be most useful for ruling out those 
technologies that are unlikely to be cost-effective. 
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Background
Technological innovations are known to be a major cost driver in healthcare[1]. Since health-
care expenditures are rapidly increasing and economic pressure is also expanding, there is 
growing need for early evaluation of the potential value of such innovations. 
The health economic evaluation process alongside the development of new technologies 
can roughly be divided into three phases[2, 3]. In the very early phase, a technology is still 
in concept, and not yet under development. Generally, decisions on product development 
have to be made with no, or only limited evidence on costs and effectiveness being available. 
Once a positive development decision has been made, a technology enters the develop-
ment stage. Some clinical evidence on costs and effectiveness becomes available, allowing 
for early stage evaluation such as iterative decision modelling and one-way sensitivity anal-
yses for determining the key parameters influencing the technology’s cost-effectiveness[4]. 
Health economic evaluations including cost-effectiveness, cost-utility, and value-of-infor-
mation analyses are mostly performed at a late stage of development. At this post mar-
ket stage, a technology has already been developed and brought to market, and additional 
costs and effectiveness data are becoming available from clinical studies. If, at this stage, a 
technology appears not to be cost-effective, it might not be reimbursed. In this case, con-
siderable investments in research and development have been made that cannot be recov-
ered.  To predict these wasted resources, there is interest in making reliable estimates of the 
cost-effectiveness of innovations at an early stage of development.
As a tool to select those technologies that are most likely to provide value for money from 
a large pool of ideas, Cosh et al. introduced the headroom method[5]. This method exam-
ines the potential of a new technology under optimistic assumptions. It aims to quantify 
the room for improvement in current clinical practice by combining the maximum effect 
an innovation might have, the maximum willingness to pay (WTP) for this effect, and the 
potential downstream expenses and savings. Thus, the headroom method is an assessment 
of the maximum potential value of an innovation, informing on the upper ceiling price of a 
technology, to still be cost-effective[5]. If it is realistic to assume that the headroom is large 
enough to cover the costs of the new technology, further development and economic anal-
yses are worth undertaking. If the headroom is too low, on the other hand, one might rather 
focus on other innovations. 
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The headroom method was introduced and is currently used on a quality-adjusted life year 
(QALY) basis[5-7]. This implies that effectiveness is measured in terms of QALYs, which are 
a combined measure of health-related quality of life (HRQoL) and life years gained from an 
intervention[8]. However, not every innovation is expected to result in QALY gain. This is for 
example the case in technologies that are expected to increase diagnostic yield or expedite 
diagnosis in untreatable diseases. As these technologies are not expected to result in QALY 
gain, performing a headroom analysis on a QALY basis would result in direct rejection, even 
though such a technology might improve clinical practice in other ways and therefore be 
valuable. 
Such a scenario arises in the diagnostic trajectory of complex paediatric neurology (CPN). 
Complex paediatric neurological disorders (CPND) are a heterogeneous group of predomi-
nantly genetic disorders including epilepsy, movement disorders, neuromuscular disorders 
and metabolic disorders. The current diagnostic trajectory for these patients is lengthy, re-
source-intensive and has a low diagnostic yield[9]. Therefore, it is expected that there is 
ample room for improvement in this diagnostic trajectory, especially in terms of diagnostic 
yield and duration. As effective treatments for these disorders are currently often not avail-
able, no QALY gain as a result of improving this trajectory may be expected. 
This paper explores the feasibility and usefulness of the headroom method in the very early 
health economic evaluation of diagnostic technologies that are not expected to result in a 
QALY gain. The first part of the paper will describe the theory behind the headroom method. 
In the second part of the paper, the case of the diagnostic trajectory in CPN will be used as 
an illustration on the feasibility and usefulness of the headroom method for technologies 
that are not expected to result in an immediate QALY gain. 
The headroom method
The headroom method is based on the net-monetary-benefit equation as introduced by 
Hoch et al.[10]. It involves two main aspects, namely the establishment of what is called 
the ‘effectiveness gap’, and the actual calculation of the headroom, which is the maximum 
additional cost at which the implementation of a new technology could still be considered 
cost-effective[11]. As we are interested in an upper ceiling price for a new technology, this 
calculation assumes an optimistic scenario, taking into account the maximum effect a new 
technology might yield (effectiveness gap), society’s WTP for this incremental effect and any 
costs or savings associated with the use of the new technology. This results in equation 1, of 
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which each step will be further explained in the following paragraphs. 
           Headroom = effectiveness gap x WTP - net additional costs (1)
The effectiveness gap
New diagnostic technologies are being developed because they are expected to be more ef-
fective than current clinical practice. For an innovation to be more effective, there needs to 
be room for improvement in current practice. This room for improvement is the maximum 
increase in effectiveness a new technology could provide compared to the reference stan-
dard, also defined as the effectiveness gap[5]. This is represented by equation 2, in which 
max effectnt is the maximum effect the new technology could provide compared to current 
clinical practice (effect
cp
).
           Effectiveness gap = maxΔeffect = max effectnt - effectcp   (2)
There are several measures to express this effectiveness gap, such as life years gained, num-
ber of diagnoses, or unnecessary diagnostic tests prevented. However, the preferred out-
come measure is the QALY, which combines HRQoL and survival. 
For example, McAteer et al. assumed that the use of bowel tissue in substitution cystoplas-
ty, which is the reference standard, after resection for bladder cancer, resulted in a median 
utility score of 0.95. They compared this technique to tissue-engineered bladder substitute, 
which has a maximum increment in effect of 1 – 0.95 = 0.05. Assuming that bladder cancer 
patients live for 10 more years after resection, the effectiveness gap in this case would be 
(1– 0.95) x 10 = 0.5 QALY[12].
Headroom calculation
As in the net-monetary-benefit calculation, the effectiveness gap should be valued in mon-
etary terms. This is done by multiplying the effectiveness gap with a certain maximum WTP 
value for an additional unit of effect. For QALYs, such a WTP value is in the UK well estab-
lished between £20,000 and £30,000 for every additional QALY gained[13]. This means that, 
according to equation 1, in the example of McAteer et al., the headroom for tissue-engi-
neered bladder substitute equals 0.5 x 30,000 = 15,000[12]. 
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Additionally, the introduction of a new technology might be accompanied with potential 
downstream expenses or savings, indirect costs such as productivity losses, or wider in-
frastructural costs such as staff training, which should also be taken into account in a to-
tal headroom calculation[14]. For example, McAteer et al. considered a potential saving 
in hospital bed days as a consequence of tissue engineering compared to current clinical 
practice[12]. They found a mean saving of four hospital days with an average cost of £317 
per day. Hence, in their case, an additional saving of £1,268 could be added to the total 
headroom.
Headroom of the diagnostic trajectory in complex paediatric neurology
In this part of the paper we will illustrate the feasibility and the usefulness of the headroom 
method in the diagnostic trajectory of CPN. First we will define the effectiveness gap of the 
current diagnostic trajectory. Second we will calculate the headroom, given a certain WTP 
value and taking into account additional savings and expenses.
Assessing the effectiveness gap of the current diagnostic trajectory
CPND are a heterogeneous group of predominantly genetic disorders and patients present 
at the neurologist with non-specific symptoms. Although these patients clearly have a neu-
rological disorder, their diagnostic trajectories are generally lengthy and a clinical diagnosis 
is established in only a small minority of patients. Despite CPND being generally untreatable, 
a definitive diagnosis might end the diagnostic Odyssey and provide useful information on 
disease aetiology, prognosis, and / or family planning. 
Currently, the diagnostic trajectories of these patients on average take at least 40 months, 
include extensive imaging, neurophysiologic, and genetic testing, and result in a definitive 
diagnosis for only 6% of the patients[9]. These numbers suggest ample room for improve-
ment in this diagnostic trajectory. In the most optimistic scenario, only two physician visits 
and one diagnostic test are required to provide a definitive diagnosis for every patient. This 
could reduce the length of the diagnostic trajectory considerably, while increasing diagnos-
tic yield from 6% to 100%. This results in an effectiveness gap of 94% or 0.94. Note that we 
are not assuming that in reality a new technology will close all of the effectiveness gap. The 
effectiveness gap here is the maximum effect that could be achieved hypothetically, inform-
ing on an upper ceiling price for a new technology to be still cost-effective. In this way, we 
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assume the most optimistic scenario, with the new technology being a perfect test, provid-
ing a diagnosis for all patients without false positive or false negative results. 
Monetising the effectiveness gap
To monetise the effectiveness gap we need to know the monetary value for an addition-
al unit of benefit. Although for QALYs the WTP is well established between £20,000 and 
£30,000, for intermediate outcomes WTP values are less clear. In 2009, Regier et al. studied 
families of children with idiopathic developmental disability, in which the exact cause of 
the disability was unknown[15]. Using a discrete choice experiment, they simultaneously 
obtained monetary values for increasing the diagnostic yield, and for reducing the interval 
between presentation and diagnosis. They presented test scenarios with varying levels of 
diagnostic yield (10, 14, 20, and 25 out of 100 children tested); time waiting for results (1, 3, 
6, and 12 weeks); and cost to the family (CND$750, CND$1100, CND$1750, and CND$2500). 
They found that families of patients were willing to pay approximately €85 (CND$131) for 
one additional child receiving a diagnosis in every 100 patients tested. Converting this 2009 
WTP value to the 2015 price level, using price indices, implies a WTP of €95 per percentage 
point additional diagnostic yield[16]. As mentioned before, in the most optimistic scenario, 
the diagnostic yield in CPN will increase from 6% to 100%, resulting in an effectiveness gap 
of 94%. Assuming that the WTP value of €95 found by Regier et al. is a representative value 
for the societal WTP for one extra diagnosis in every 100 patients in paediatric neurology, 
the monetised effectiveness gap in current practice would be 94 x €95 = €8,930.
Net additional costs 
Implementing new technologies into clinical practice might result in additional expenses 
or savings. As the majority of CPND have a genetic origin, it is likely that innovations in this 
diagnostic pathway are in the field of next-generation sequencing (NGS). Applying these 
technologies in clinical practice may lead to so-called incidental findings, which are clini-
cally relevant mutations that are not related to the disease under investigation[17]. These 
might lead to follow-on testing and treatment initiation - potentially with complications - 
and thereby cause downstream expenses. Although these incidental findings are very rare, 
their downstream costs can be considerable[14]. In contrast, the application of NGS early 
in the diagnostic trajectory might partly substitute current diagnostic testing, especially ge-
netic tests. 
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For this headroom analysis we assume an optimistic scenario, consistent with its underlying 
philosophy, which is to determine an upper ceiling price to be still cost-effective in such a 
scenario. To this end, we assume that there are no downstream costs, as incidental findings 
are very rare. Moreover, NGS is assumed to substitute all genetic tests of the current diag-
nostic trajectory, as well as 25% of all physician contacts. These substitutions would result in 
savings equalling €6,098 per patient[9].
Interpreting the headroom
When ignoring additional costs or savings, the headroom in the current diagnostic trajec-
tory of CPN equals €8,930. This means that if a new technology would be introduced as an 
add-on test, the maximal marginal cost would be €8,930. 
Taking into account the expected savings of €6,098 by substituting all genetic tests and 25% 
of the physician visits, the total headroom equals €8,930 + €6,098 = €15,028. Of course, 
there is uncertainty around the number of current diagnostics that will be replaced by a 
new technology. To address this uncertainty, additional scenario analyses regarding these 
substitution savings can be performed to reduce the chance of investing in a technology that 
at a later stage turns out not to be cost-effective. Figure 1 shows the total headroom in the 
Figure 1. Total headroom in the diagnostic trajectory of complex paediatric neurology
ΔE = effectiveness gap; WTP = willingness to pay; WES = whole exome sequencing
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diagnostic trajectory of CPN in the case of an add-on test and in a scenario in which the new 
technology partly substitutes current diagnostics. 
Discussion
This paper shows that headroom analysis is a feasible and useful tool in the early health eco-
nomic evaluation of diagnostic technologies, also when no immediate QALY gain is expect-
ed. An effectiveness gap calculation is informative on the room for improvement in current 
clinical practice. It indicates whether there is a problem, and allows for quantification of this 
problem. Additionally, combining a monetary valuation of the effectiveness gap with the 
foreseeable downstream costs and savings due to a new technology provides an estimation 
of the potential societal value of this technology. In the case of CPN, headroom analysis 
indicated a large room for improvement, as in the current trajectory only 6% of all patients 
receive a diagnosis. In addition, it is realistic to assume that savings will materialize since 
new technologies can substitute a considerable part of the current diagnostic trajectory. A 
total headroom of €15,028 was found, indicating that a new technology in this diagnostic 
trajectory could be cost-effective if its costs do not exceed €15,028. 
Although definitely informative, it should be noted that the headroom method has certain 
limitations. Most notably, the headroom method assumes an optimistic scenario, with the 
effectiveness gap considering the maximum effect a new technology might theoretically 
gain. However, in clinical practice, new technologies are unlikely to be perfect and will there-
fore not close the entire effectiveness gap. Therefore, the established ceiling price is likely 
to be an overestimation, and it cannot be guaranteed that a technology that is brought to 
the market for less than this ceiling price will actually be cost-effective. On the other hand, 
Chapman et al. show that with a specificity of 92%, the headroom method is a very valuable 
tool in no-go decisions, to avoid investment in technologies that could never be cost-ef-
fective, as its expected costs exceed the calculated headroom[18]. Clearly, one could also 
calculate the effectiveness gap with a range of more realistic estimates of effectiveness in a 
scenario analysis on the effectiveness. Finally, updating the initial headroom analysis when 
more evidence becomes available, gives more accurate estimations on the potential value 
of a technology and thereby reduces chances on investing in technologies that are unlikely 
to meet societal criteria of cost-effectiveness[19]. 
The same goes for downstream costs and additional expenses and savings. In early stages, 
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these are highly uncertain. It is hard to decide to what extent and over what time horizon 
these costs and savings should be taken into account, and to what extent these will vary 
within and between countries. Here too, scenario analyses can provide insight in the expect-
ed value of a new technology.
Finally, the main issue is the fact that intermediate outcomes are difficult to value in mone-
tary terms, complicating headroom analyses of technologies that do not result in QALY gain. 
Although for QALYs a clear WTP threshold has been established, this is often not the case for 
intermediate outcomes. Determining the WTP for intermediate outcomes can be done by 
using, for example, contingent valuation or discrete choice experiments[20, 21]. However, 
these data are seldom readily available, and such experiments are relatively time-consum-
ing and expensive to conduct, requiring large numbers of respondents (depending on e.g. 
design, number of choice sets, attributes and levels)[22]. As intermediate outcomes may 
be valued differently in varying disease areas or over time, such experiments should be 
performed for every specific context separately[23]. Another issue with the elicitation of 
WTP values is the choice on whose preferences to incorporate; the patients’ or the general 
public’s. The study of Regier et al, on which the WTP values in this study were based, used 
the preferences of family members of the patients to elicit WTP. Hence, these WTP values 
are useful for diagnostics that have to be paid out-of-pocket. However, in many countries, 
such diagnostics will be covered by health insurance. In these cases, WTP values should be 
based on the preferences of the general public[24]. Taking these factors into account makes 
the transferability of the WTP values of Regier et al. to our case study questionable.
Despite these limitations, the headroom method seems a useful tool. For the supply side, 
it does not only inform on the commercial opportunity of a technology by establishing a 
maximum ceiling price for which it could be cost-effectively brought to market. It is also a 
quick method for rapid decision-making in both selecting the most promising concepts from 
a larger pool of options, and in investment and development decisions[3]. Especially when 
combined with some additional scenario analyses on both cost and effectiveness parame-
ters, it could be helpful in channelling research and development resources towards those 
technologies that are most promising. 
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Conclusion
The headroom seems a valuable tool in the very early evaluation of medical technologies, 
even when no immediate gain in QALYs is expected. It is informative on the room for im-
provement in a certain disease area and allows for selecting the most promising concepts 
from a larger pool of options, for decision-making regarding investments in research and 
further development, and for calculating a maximum ceiling price to still be-cost effective. 
As an optimistic scenario is assumed, it indicates the potential for, but does not guarantee 
future cost-effectiveness and / or reimbursement. Hence, the headroom method might be 
most valuable as a rule-out tool to avoid investment in technologies that are very unlikely to 
be able to meet even the most generous criteria for cost-effectiveness.
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Abstract
Background: The substantial technological advancements in next-generation sequencing 
(NGS), combined with dropping costs, have allowed for a swift diffusion of NGS applications 
in clinical settings. Although several commercial parties report to have broken the $1,000 
barrier for sequencing an entire human genome, a valid cost overview for NGS is currently 
lacking. This study provides a complete, transparent and up-to-date overview of the total 
costs of different NGS applications. 
Methods: Cost calculations for targeted gene panels (TGP), whole exome sequencing (WES) 
and whole genome sequencing (WGS) were based on the Illumina NextSeq500, HiSeq4000, 
and HiSeqX5 platforms, respectively. To anticipate future developments, sensitivity analyses 
are performed.
Results: Per-sample costs were €1,669 for WGS, €792 for WES and €333 for TGP. To reach 
the coveted $1,000 genome, not only is the long-term and efficient use of the sequencing 
equipment needed, but also large reductions in capital costs and especially consumable 
costs are required. 
Conclusion: WES and TGP are considerably lower-cost alternatives to WGS. However, this 
does not imply that these NGS approaches should be preferred in clinical practice, since 
this should be based on the trade-off between costs and the expected clinical utility of the 
approach chosen. The results of the present study contribute to evaluating such trade-offs. 
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Background
Over the last years, substantial technological advancements in next-generation sequencing 
(NGS) have been made in terms of sequencing speed, read length, and throughput [1]. At 
the same time, sequencing costs have rapidly decreased, contributing to a rapid diffusion 
of NGS applications into clinical settings [2-4]. Whereas only ten years ago the sequencing 
costs of a million base pairs were approximately $1,000, the costs are now below $0.10 [2, 
5-8]. Several commercial parties claim to have broken the barrier of the $1,000 genome [9, 
10], which would allow for large-scale clinical application, furthering our understanding of 
genetic diseases and ultimately contributing to personalized medicine in a major way [11].  
In clinical applications, three NGS approaches are predominantly applied in postnatal set-
tings: targeted gene panels (TGP), whole exome sequencing (WES), and whole genome se-
quencing (WGS). These techniques have not only proven to be promising tools in studying 
the genetics underlying rare Mendelian disorders [12-14], but have also shown to be valu-
able diagnostic tools in genetic diseases [3, 8, 15-19]. A recent review showed that although 
several studies on the cost-effectiveness of NGS applications have been performed, a com-
plete and valid cost overview is currently lacking [20]. Moreover, the costs for the sequenc-
ing process itself might only be a small part of the total costs. Apart from sequencing, ex-
pensive equipment needs to be acquired and maintained, personnel is needed for sample 
preparation, data interpretation and report, and large amounts of data must be managed 
and properly stored. As these costs are often not taken into account, the real costs of NGS 
applications are often considerably underestimated. It is therefore questionable whether 
the $1,000 genome has indeed been achieved or is within reach in the near future.
This study aimed to answer this question by providing a complete and transparent overview 
of the total per-sample costs of the clinical application of TGP, WES and WGS, which could 
serve as a resource for future cost-effectiveness analyses and inform clinical decision makers 
on which NGS approach to use. 
Methods
Availability of data
All data used for the study are available in the online Supplement accompanying this article.
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Framework for cost calculation
Relevant cost items and associated prices were determined in the Radboud university med-
ical center. Our calculations were based on platforms that are currently used in clinical prac-
tice: the NextSeq500 (TGP), HiSeq4000 (WES), and HiSeqX5 (WGS). All three are platforms 
were from Illumina. We assumed that the genetic material was obtained from whole blood 
via venipuncture. Base case assumptions on sequencing platforms, technical details and 
personnel, are shown in table 1. 
Since per-sample costs of NGS could be influenced by the selected sequencing platform, 
consumables, and instrument/platform utilisation, a costing model was developed in Micro-
soft Excel, in which all cost components were incorporated and could be adapted to labora-
tory-specific conditions (Online Supplemental Materials file that accompanies this article).
Sequencing depth was arbitrarily chosen to resemble current clinical practice at the Rad-
boud university medical center and other diagnostic laboratories [21-24]. Sequencing 
depths of 100x, 70x, and 30x were assumed for TGP, WES, and WGS, respectively.
Utilisation of the platforms of 75% was assumed for WES and WGS since 100% utilisation 
is unlikely due to contributors such as maintenance. For TGP a utilisation of only 10% was 
assumed since the capacity of the machine substantially exceeded demand and realistic 
clinical throughput. 
Personnel time required for sample preparation, sequencing, and data analysis and inter-
pretation were based on in-house experience for TGP and WES, and extrapolated for WGS. 
Breakdown of costs
Costs were divided into three categories: capital costs, maintenance costs, and operational 
costs. Capital costs were defined as the non-recurring costs for equipment, consisting of the 
platform itself and, in the case of WES and WGS, the Hamilton Microlab STARlet, which was 
required for sample preparation. Yearly capital costs were calculated by dividing the initial 
costs for equipment acquisition by an annuity factor, taking into account the lifetime of the 
equipment (5 years), and an interest rate of 4.5%, as advised in the Dutch Manual for costing 
research [25]. 
Maintenance costs were defined as the yearly costs for maintaining the equipment, and 
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were fixed in agreement with the manufacturer. During the first year, no maintenance costs 
were calculated since these costs are generally included in the initial acquisition costs. Plat-
form-related unit prices, such as acquisition, maintenance and consumables were based on 
list prices of the supplier to enhance transparency and transferability of the results between 
hospitals and countries. Other costs, such as personnel, were derived from the hospital’s 
financial administration. 
Operational costs were defined as the costs for running the sample, and included consum-
ables, personnel, data handling, processing, interpretation and storage. The operational 
per-sample costs were added to the per-sample capital and maintenance costs, resulting in 
a total per-sample cost.
Only direct costs associated with NGS were taken into account. Indirect costs, such as clin-
ical geneticist consultations, downstream costs for additional testing and treatment, and 
overhead costs, were not taken into account. All costs are expressed in 2015 Euros. A de-
tailed overview of the assumptions underlying our calculations is provided in the Online 
Supplemental Materials file that accompanies this article.
Analyses
In the base case analysis, we calculated the per-sample capital, maintenance and operation-
al costs for all three approaches using the assumptions as described in table 1. 
Considerable technical advances in NGS applications have been made in recent years. Si-
multaneously, the costs have rapidly decreased and have deviated from Moore’s law [6]. 
Although it is difficult to predict whether costs will continue to drop, scenario and sensitivity 
analyses provide insight into which cost components might contribute to future cost reduc-
tions, and to what extent these costs reductions might be expected. Sensitivity analyses are 
analyses that show how the per-sample costs are influenced by the changes in the various 
input parameters, e.g. coverage, utilisation and life cycle of the equipment and capital or 
consumables costs [26]. To this end, we varied the main parameters of the base case analy-
sis. 
To determine the influence of the investment costs for equipment on the per-sample costs, 
a sensitivity analysis was performed in which the capital costs for the sequencing platform 
were reduced with 50%. This was also done for the consumable costs. 
76 CHAPTER 5
Because technical developments are expected to continue, the lifecycle of five years used in 
the base-case calculations might be an overestimation. Therefore, the life cycle of the NGS 
platforms was varied between three and five years. 
Additionally, since there is currently no gold standard for sequencing depth in clinical ap-
plications, coverage was varied between 30x and 100x. Utilisation was varied between 1% 
and 15% for TGP, and between 55% and 95% for WES and WGS. Finally, to indicate to what 
extent future cost reductions might be expected, a best case and worst case scenario were 
constructed, providing a lower and upper bound of the expected costs of NGS in the near 
future.
Results
Table 1. Base case assumptions for cost calculations of NGS applications
TGP WES WGS
Sequencing platform NextSeq500 HiSeq4000 HiSeqX5
Life cycle of the platform (years) 5 5 5
Average coverage 100x 70x 30x
Capacity (samples/year)* 248,927 7,800 9,801
Utilisation 10% 75% 75%
Actual annual throughput 24,892 5,850 7,350
Data processing (CPU hours/sam-
ple)
5 100 1,000
Data storage (Gb/sample) 1 150 600
Data storage time 5 years 5 years 5 years
Personnel sample preparation** 10,000 samples 
/ FTE
1,280 samples / 
FTE
1,280 samples / 
FTE
Personnel first data analysis** 10,000 samples 
/ FTE
1,280 samples / 
FTE
1,280 samples / 
FTE
Personnel for data interpretation 
and report***
30 minutes per 
sample
60 minutes per 
sample
90 minutes per 
sample
Software for read mapping, vari-
ant calling, and annotation
Freeware**** Freeware**** Freeware****
* For TGP a gene panel consisting of 90 genes, with 23 amplicons per gene on average, is assumed
** 1 FTE represents a gross annual salary of €32,268, which is the average gross salary of a laboratory technician 
in the Netherlands.
*** Data interpretation is done by a clinical molecular geneticist with a gross annual salary of €69,408
**** For example BWA, GATK, and VEP, respectively
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Cost analysis
Annual capital costs for WGS (€1.3 million) were 6 and 27 times as high as the capital costs 
for WES (€205,847) and TGP (€47,074), respectively (table 2). Given the assumed platform 
utilisation and coverage, per-sample capital costs were €175 (WGS), €35 (WES), and €2 
(TGP). Per-sample maintenance costs of WGS were €72, which was 6 and 79 times higher 
than for WES (€12) and TGP (€1), respectively. The operational costs accounted for the larg-
est part of the per-sample costs of NGS applications, adding up to €330 for TGP, €744 for 
WES, and €1,422 for WGS, with the major cost driver being the consumables required for 
sample preparation and sequencing.
Under the assumptions as shown in table 1, total per-sample costs of TGP, WES, and WGS, 
were €333, €792, and €1,669, respectively. Table 2 displays an overview of the costs of the 
NGS applications, with a detailed outlining available in the Online Supplemental Materials 
file that accompanies this article . 
Table 2: Costs of the NGS applications, based on the base-case assumptions
TGP WES WGS
Sequencing platform NextSeq500 HiSeq4000 HiSeqX5
Annual throughput (utilisation) 24,892 (10%) 5,850 (75%) 7,350 (75%)
Capital costs (€)
Platform initial costs 206,654.00 853,738.00 5,607,475.00
Hamilton Microlab STARlet 0.00 90,000.00 90,000.00
Capital costs / year* 47,073.80 205,847.04 1,288,702.85
Capital costs / sample 1.89 35.19 175.33
Maintenance costs (€)
Annual maintenance contract with 
Illumina**
28,300.00 83,000.00 655,000.00
Annual maintenance contract 
Hamilton Microlab STARlet
0.00 5,509.00 5,509.00
Maintenance costs / year 22,640.00 71,909.00 529,509.00
Maintenance costs / sample 0.91 12.29 72.04
Operational costs (per sample) (€)
Blood withdrawal 10.64 10.64 10.64
DNA Extraction 31.53 31.53 31.53
Sample preparation consumables 242.62 296.68 27.61
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Sensitivity analyses
Capital costs accounted for only a small percentage of the per-sample costs (0.6%, 4.4%, and 
10.5% for TGP, WES and WGS, respectively). Future reductions of 50% in these capital costs 
therefore would have only a modest impact on the per-sample costs, reducing the per-sam-
ple costs of TGP, WES and WGS by 0.3%, 2.1%, and 5.2%, respectively (table 3). Reducing the 
consumable costs for enrichment and sequencing by 50%, on the other hand, decreased the 
per-sample costs of TGP, WES, and WGS by 37.1%, 35.2%, and 32.5%, respectively. 
Decreasing the life cycles of the platforms from 5 years to 3 years had a modest impact, 
increasing the per-sample costs of TGP, WES and WGS by 0.3%, 2.3%, and 5.5% respectively. 
Varying sequencing depth between 30x and 100x coverage had a modest impact on the 
per-sample costs of TGP, while it influenced per-sample costs of WGS considerably. Costs 
varied between €328 - €333 (TGP), €615 - €929 (WES), and €1,669 - €5,430 (WGS). Varying 
the platform utilisation rate resulted in per-sample costs between €332 - €358 (TGP), €782 - 
€809 (WES), and €1,617 - €1,759 (WGS). An overview of the sensitivity analyses is displayed 
in table 3.
Table 2 (continued)
TGP WES WGS
Sequencing consumables 4.56 262.24 1,057.81
Lab personnel 8.97 70.08 70.08
Data processing*** 0.50 10.00 100.00
Data storage*** 0.05 0.75 30.00
Data interpretation and report 31.23 62.65 93.97
Operational costs / sample 330.10 744.27 1,421.64
Total costs per sample (€) 332.90 791.75 1,669.02
* To calculate the annual capital costs, the platform initial costs were divided by 4.39, and the costs for the Hamil-
ton Microlab STARlet were divided by 7.913. These annuity factors take into account a life cycle of 5 and 10 years, 
respectively, and an interest rate of 4.5% [25].
** During the first year of the life cycle no maintenance costs occur since these are included in the initial price of 
the equipment.
*** Costs for data processing and data storage are estimated on €0.10 per CPU hours and €0.01 per Gb, based on 
the commercial pricing of Amazon for cloud computing and data storage. It is assumed that data is stored for five 
years [35]. 
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Best case and worst case scenario analyses
To gain insight into the extent to which future cost reductions might realistically be expect-
ed, a best-case and worst-case scenario were constructed (table 4).  
In the most optimistic scenario, per-sample costs could be reduced by 38.3%, 49.3%, and 
39.8%, to €205 (TGP), €401 (WES), and €1,006 (WGS), respectively. This scenario required 
very efficient and long-term application of the sequencing equipment, cost reductions of 
50% in both capital and consumable costs, and technological advances allowing for 30x 
coverage. On the other hand, short-term and inefficient use of the sequencing equipment, 
in combination with a sequencing depth of 100x, might increase the per-sample costs by 
10.5%, 24.9%, and 268.9% for TGP, WES, and WGS, respectively. 
Table 4: Best case and worst case scenario analyses
Best case Worst case
TGP WES WGS TGP WES WGS
Capital costs -50% -50% -50% Current Current Current
Consumable costs -50% -50% -50% Current Current Current
Life cycle (years) 5 5 5 3 3 3
Utilisation 15% 95% 95% 1% 55% 55%
Required coverage 30x 30x 30x 100x 100x 100x
Per-sample costs (€) 205 401 1,006 368 989 6,157
Table 3: Sensitivity analyses
Per-sample costs (€) TGP WES WGS
Base case 333 792 1,669
Capital costs -50% 332 775 1,582
Consumable costs -50% 209 513 1,126
Life cycles of 3 years 334 810 1,761
30x coverage 328 615 1,669
100x coverage 333 929 5,430
Lower utilisation (1%, 55%, 55%) 358 809 1,759
Higher utilisation (15%, 95%, 95%) 332 782 1,617
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Discussion
In this study we attempted to provide a transparent, complete and up-to-date overview of 
the costs of diagnostic NGS applications, including not only the sequencing process but also 
equipment acquisition, maintenance, data analysis and storage. With estimated per-sample 
costs of €1,669 for WGS, the desirable $1,000 dollar genome has not yet been achieved. 
In the best-case scenario anticipating future cost developments, however, the per-sample 
costs of WGS approach €1,000, which is nowadays approximately $1,100 [27]. 
Per-sample costs for TGP (€333) and WES (€792) were considerably lower. The large differ-
ences in per-sample costs are mainly caused by the consumables for sample preparation 
and sequencing, which are the major cost driver. For TGP these costs add up to €247, for 
WES to €559, and for WGS these are €1,085. These differences are caused by the large dif-
ferences in the number of bases sequenced, affecting both consumable price and annual 
throughput of the NGS systems. Whereas with WGS the entire genome is sequenced, WES 
only sequences the protein coding parts (exons), which constitute approximately 1-2% of 
the genome [8, 20, 28]. The sensitivity analyses showed that future cost reductions are 
most likely to occur if consumable costs decrease considerably. Currently, a few large players 
dominate the sequencing market. Therefore it is questionable whether the costs for con-
sumables and equipment will decrease further, or might even increase as a result of these 
monopoly positions. 
However, with the increased application of NGS in clinical settings it is likely that new parties 
in sequencing technology will arise. As a result of competition and economies of scale, this 
might result in cost reductions for both equipment and consumables. 
Recently, another micro-costing paper reported considerably higher per-sample costs for 
TGP (€589-€1949) and WES (€1,499 – 3,388) [29]. These costs are not directly comparable 
to our cost calculations since they provide mean costs based on the cost-analyses of nine 
different laboratories involving various sequencing platforms and consumables, applied in 
both germline and somatic mutations. Life cycles and sequencing depth were not specified 
and might even differ between laboratories. Moreover, their calculations included confirma-
tive testing, development and validation of the bioinformatics pipeline and protocols, and 
overhead costs, which we did not include. 
The main strength of our study is the transparency and transferability of our cost calcu-
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lations. Although the per-sample costs found in this study are not directly generalizable, 
by specifically stating which costs are included, which are not, and how we valued every 
cost category, we ensured transparent results. The use of universal list prices and current 
Amazon prices for cloud computing and storage allows for direct transferability of the capi-
tal, maintenance, and consumable costs, and data processing and storage costs within and 
between countries. Choosing for other methods of data processing and storage will bring 
along additional costs for hardware and software. Other costs that will differ between lab-
oratories and should be adapted in the provided Excel sheet are costs for personnel and 
costs if other platforms or consumables are used. Additionally, costs will vary with sequenc-
ing depth and chosen software for read mapping, variant calling and annotation. Note that 
overhead costs are not incorporated in our cost calculations, and will also differ consider-
ably between laboratories. 
The provision of a calculation sheet (Online Supplemental Materials file that accompanies 
this article) allows for easy adjustment of the costs to specific situations. Therefore, our 
results could be very useful, both in clinical decision-making and as input for future cost-ef-
fectiveness analyses. One should keep in mind that we calculated the direct costs for diag-
nostic applications of NGS from a hospital perspective. For a full health economic analysis, a 
societal perspective should be adopted that also considers patient costs. 
Despite these strengths, this study has a number of limitations. First, per-sample costs of 
these technologies depend on the sequencing platform used. In our study we calculated 
the per-sample costs based on three Illumina platforms since they currently are the market 
leader in sequencing technology. However, a large diversity of suppliers and platforms is 
available. 
Second, several platforms allow for multiple applications. The Illumina HiSeq4000, for ex-
ample, can be used both for WES and WGS. One could argue that for smaller sequencing 
centres, it might be more efficient to offer one or two sequencing technologies, and buy 
only one platform on which all analyses can be performed. For sequencing centres with a 
large annual throughput it might be more cost-effective to offer all technologies and buy 
three different platforms with a capacity as high as possible. However, the aim of this study 
was to provide a complete and transparent overview of the per-sample costs of the clinical 
application of TGP, WES, and WGS. Deciding which (combination of) sequencing platforms 
a specific sequencing centre should use given its expected annual throughput is beyond the 
scope of this article. Nonetheless, the calculation sheet in the Online Supplemental Mate-
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rials file that accompanies this article allows for easy adjustment of all costs to laboratory 
specific situations, and can therefore be used as a useful tool for (clinical) decision making 
of sequencing equipment and respective running costs.
Third, per-sample costs as calculated in this study are still a slight underestimation of the 
real per-sample costs. As Buchanan et al. stress, costs for the clinical geneticist consult for 
reporting the results to the patient should for example also be included[30]. These were 
not taken into account in our calculations since we aimed to provide per-sample costs for 
the diagnostic test only. Importantly, there is little to no experience in the large-scale use of 
genome sequencing in clinical practice, making it hard to estimate personnel costs for inter-
pretation. Interpretation is much easier in the coding region than in the non-coding region, 
and diagnostic interpretation of genomes may initially remain limited to variants affecting 
the coding region. For this reason we have not increased interpretation time extensively 
in our cost calculations. Also, the overhead costs were not taken into account since these 
were expected to vary considerably between, and even within countries. Other costs that 
contribute to the per-sample costs of NGS applications are downstream costs such as addi-
tional testing, medication, or genetic counselling resulting from NGS. Notably, whereas the 
expense of WGS may initially be more expensive, it may result in a refrain from future ge-
netic diagnostic testing, thereby possibly reducing costs in the long term. These costs and/
or savings were not taken into account because they were expected to vary considerably 
between patient populations. For a full health economic evaluation however, they should 
be incorporated. 
Finally, in current clinical practice, no gold standard for sequencing depth exists. Commercial 
parties have recommended 30x coverage for WGS for the detection of germline mutations. 
Although this is not yet evaluated for clinical applications, a recent study has shown that, 
for germline mutation detection, a lower coverage is required for WGS than is for WES since 
WGS does not involve an enrichment step and therefore minimizes coverage variation over 
the sequencing targets [21]. However, other studies have shown that, in clinical settings, a 
higher coverage may be required for accurate mutation calling, especially when considering 
the detection of low-level somatic mutations that are increasingly being recognized as a 
prominent cause of genetic disease [31-33]. A higher coverage, and thereby higher quality, 
however, inevitably goes with higher per-sample costs since every base is sequenced more 
times. Although our cost calculations assumed germline mutations, the provided calculation 
sheet allows for cost calculation for adjusted coverage in somatic, infectious disease, or mi-
crobiological applications.
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WES and TGP are considerably less costly alternatives compared to WGS for genetic diagnos-
tics in clinical practice. However, this does not imply that these should be preferred in clini-
cal practice since the choice of NGS approach depends not only on the per-sample costs but 
also on its diagnostic yield, which defines its effectiveness. It also depends on for how many 
patients additional diagnostic testing is required. Moreover, a genetic diagnosis might alter 
treatment, and thereby improve health-related quality of life. Whether the diagnostic yield 
of WGS will be considerably higher than the yield of TGP depends on the patient population. 
Also, comparing WGS to WES might result in (small) differences in diagnostic yield since 
WES already takes into account all protein-coding regions, in which 85% of all mutations 
are believed to occur [34]. On the other hand, WGS is able to better detect copy-number 
changes, triplet repeat changes, and small deletions than WES, and might therefore have a 
higher diagnostic yield in certain patient populations in whom such genetic alterations play 
an important role [8]. For each patient population, the decision on which NGS approach and 
what sequencing depth to use should be based on a careful trade-off between the per-sam-
ple costs, sequencing quality, and consequences for the patient. The results of the present 
study contribute to making these trade-offs. 
Conclusion
With per-sample costs for WGS of €1,669, the acclaimed $1,000 genome has not been 
achieved. To achieve this coveted $1,000 genome, not only are long-term and efficient use 
of the sequencing equipment needed, but also large reductions in capital, and especially 
consumable costs. Today, WES and TGP are considerably lower-cost alternatives to WGS. 
Decision-makers should be aware of this, and carefully weigh the extra costs with the added 
benefits before implementing WGS as a standard diagnostic test in clinical practice. 
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Abstract
Background: Implementation of novel genetic diagnostic tests is generally driven by tech-
nological advances, as they promise shorter turn-around-times and/or higher diagnostic 
yields. Other aspects, including impact on clinical management or cost-effectiveness, are 
often not assessed in detail prior to implementation. 
Methods: We study the clinical utility of whole exome sequencing (WES) in complex paedi-
atric neurology in terms of diagnostic yield and costs. We analyzed 150 patients (and their 
parents) presenting with complex neurological disorders of suspected genetic origin. In a 
parallel study all patients received both the standard diagnostic work-up (including e.g. ce-
rebral imaging, muscle biopsies or lumbar punctures, and sequential gene-by-gene-based 
testing) and WES simultaneously.
Results: Our unique study design allowed for direct comparison of diagnostic yield of both 
trajectories and provided insight into the economic implications of implementing WES in 
this diagnostic trajectory. We show that WES identified significantly more conclusive diag-
noses (29.3%) than the standard care pathway (7.3%) without incurring higher costs. Explor-
atory analysis of WES as first tier diagnostic test indicates that WES may even be cost saving, 
depending on the extent of other tests being omitted. 
Conclusion: Our data support such a use of WES in paediatric neurology for disorders of 
presumed genetic origin.
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Background
Paediatric neurologists aim to provide a swift and precise diagnosis as well as appropriate 
therapeutic and supportive management for children with neurological disorders, and their 
families. Many different, often rare and severe, acquired as well as genetic disorders of the 
brain, spinal cord, and neuromuscular system, are encountered in everyday practice[1]. A 
diagnosis may lead to rational therapeutic choices and, even if no medical treatment is avail-
able, offers insights into the prognosis and recurrence risk of the disorder within the family.
Finding a diagnosis is in many cases a complex, expensive, and lengthy process, involving 
burdensome procedures. This is especially the case in patients presenting with developmen-
tal delay, movement disorders, neuromuscular disorders, severe epilepsy, and/or combina-
tions thereof, that are expected to be of genetic origin[2]. The armamentarium to reach a 
diagnosis includes multiple tests including magnetic resonance imaging (MRI), electro-en-
cephalography (EEG), biochemical and metabolic tests of blood, urine, and cerebrospinal 
fluid, muscle biopsy, genomic microarrays, Sanger sequencing of one or more genes, as well 
as multiple consultations from various medical specialists.2 However, the diagnostic yield of 
each individual test is low[3,4]. Despite all efforts of doctors and patients, a definitive diag-
nosis is reached in only a minority of all children with a neurological disorder of presumed 
genetic origin[3], leaving ample room to improve the diagnostic process. 
Whole exome sequencing (WES) has recently proven to be of great potential value as a 
diagnostic tool in clinical practice. Successful applications of WES in paediatric neurology 
have mostly been confined to single case reports and retrospective studies in which WES 
was used as a last resource genetic test[5-11]. However, prospective clinical utility studies 
in larger groups of patients have not yet been performed. Here we present such data, using 
a cohort of 150 patients who received both the standard diagnostic assessment as well as 
WES, allowing for a direct comparison of the performance of both trajectories.
Materials and Methods
Patient recruitment, selection and counseling
The department of paediatric neurology of the Radboudumc is a tertiary referral center for 
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paediatric neurology. The majority of patients are referred by paediatricians, neurologists, 
and psychiatrists, for further diagnostics or second opinions. 
Here, 150 consecutive patients with (non-acute) neurological symptoms of suspected genet-
ic origin were included. This group consisted of patients who were newly referred by either 
a general practitioner (n=11) or medical specialist (n=55), and patients who had been re-
ferred to our center previously, but still visited the outpatient clinic for diagnostic purposes 
as no conclusive diagnosis had been reached yet (n=84). As such, the group is representative 
of paediatric patients presenting with complex neurological symptoms of suspected genetic 
origin seen in a tertiary referral center. 
Family history was negative for 143 cases. For 7 patients a recessive disorder was expected 
based on affected siblings and/or parental consanguinity. Patients with well-known, clinical-
ly easily recognizable genetic disorders such as neurofibromatosis type 1 were not included 
in this study. A clinical geneticist counseled all 150 patients and their parents for the WES 
procedure, and all participants or their legal representatives gave written informed consent. 
This study was approved by the Medical Review Ethics Committee Arnhem-Nijmegen under 
the realm of clinical diagnostic genetic testing (2011/188).
Study design and classification of outcome of diagnostic workup 
After inclusion, all patients 
received two diagnostic 
pathways in parallel, i.e. 
the standard diagnostic 
pathway and the WES 
pathway (figure 1). Data 
on diagnostic tests and 
outcomes were not ex-
changed between the two 
pathways prior to reach-
ing a conclusion in each 
of them separately. All 
patients were followed up 
for minimally 6 months after starting WES (median 17 months, range 6 - 42 months). The 
primary endpoint for this study was the diagnostic yield of both diagnostic pathways.
Figure 1: Schematic representation of the parallel study design
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For the standard diagnostic pathway, diagnostic workup was left to the discretion of the 
paediatric neurologists, which they based on the clinical presentation of the patient. The 
outcome of this pathway was classified as follows: 
1. There is no conclusive diagnosis. A clinical, descriptive, diagnosis can however be 
reached, but genetic testing does not confirm this clinical descriptive diagnosis.
2. A conclusive diagnosis is reached. The clinical diagnosis is confirmed by the presence 
of a causative genetic variant (class 4 or 5)[12] in a disease-gene associated with the 
patient’s phenotype.
In the WES pathway, DNA of 150 patients and their parents (in 143 of 150 patients) was 
isolated from whole blood. Exome sequencing was performed according to our diagnostic 
procedures under ISO15189 certification (online online table S1; figure S1). Sequencing was 
performed to an approximate read depth of 70-100 fold. Variant calling and interpretation 
was essentially performed as described previously (online online table S1)[13.14]. First, 
an in silico gene panel analysis was performed on the WES data, referring to the situation 
where variants (both single nucleotide variants (SNV) as well as copy number variations 
(CNV)) in known genes for the patients’ phenotype are evaluated for pathogenicity (online 
online table S1; figure S1). In a second step, variants outside the gene panel are evaluated 
for pathogenicity and relevance for disease (both SNV and CNV). Patients who were se-
quenced as singletons received SNV analysis of the respective disease gene panel(s) as well 
as CNV analysis limited to genes within the relevant disease gene panels (online online table 
S1 and figure S1).
The results of the WES procedure were classified in accordance with American College of 
Medical Genetics and Genomics (ACMG) guidelines[12,13]: 
1. There is no conclusive diagnosis: no obvious pathogenic variant was detected that 
could potentially explain disease.
2. A possible diagnosis is obtained: a variant(s) of unknown significance (class 3) in a 
gene(s) is identified in a disease-gene that is associated with the patient’s phenotype. 
Or alternatively, a pathogenic variant(s) (class 4 or 5) in a candidate disease-gene(s) is 
identified with a potential relationship to the patient’s phenotype.
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3. A conclusive diagnosis is obtained: a causative genetic variant (class 4 or 5) in a dis-
ease-gene associated with the patient’s phenotype.
Diagnostic endpoints for each of the care pathways were compared and discussed after 
completion of the diagnostic quest in monthly meetings, and in the presence of molecular 
geneticists, clinical genetic laboratory specialists, clinical geneticists, and paediatric neurol-
ogists.
Diagnostic concordance between the standard care pathway and WES was measured by 
comparing diagnostic yield in the two pathways at individual patient level. 
Determining costs associated with the diagnostic pathways
To accurately estimate the costs associated with diagnostic tests in the standard diagnostic 
pathway, types and volumes of diagnostic tests used were determined for each patient in-
dividually. This included diagnostic tests that were performed after inclusion of the patient 
(until a diagnosis was established) and diagnostic tests that had been used prior to inclusion, 
in our hospital or elsewhere. For the latter, data were extracted from medical records and 
from referral letters.
For the costs of genetic testing in the WES pathway, we used €3,500 for a trio analysis, and 
€1,800 for a singleton, representing prices for diagnostic exome sequencing in our labora-
tory (Aug 2016)[15].
To obtain an estimate of the costs associated with WES as a first tier test in these patients, 
an exploratory analysis was conducted based on the following:
In children where WES resulted in a conclusive diagnosis, conventional tests (and associat-
ed costs) performed in the standard pathway could have been precluded. To estimate the 
magnitude of the substitutive effect of WES, the paediatric neurologists indicated for all 44 
patients receiving a conclusive diagnosis what conventional diagnostic tests would –in the 
context of clinical practice- still have been performed. Additionally, we assumed that these 
patients would still make two physician visits (pre- and post WES test counseling), and one 
telephone consult to inquiry on patients general wellbeing.
In children in whom WES did not result in a conclusive diagnosis (n=106), the costs of the 
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conventional diagnostic tests would have remained identical, with the exception of costs 
associated with genetic testing, which were replaced by those of diagnostic WES.
Unit cost prices were obtained from the Dutch Healthcare Authority (https://www.nza.nl/ 
organisatie/sitewide/english/). Such costs cover the test, the interpretation of its results, 
and the physician fee. All unit costs were converted to 2016 Euros. As cost and utilisation 
data are generally skewed, bootstrap simulations with 1,000 replications were performed to 
estimate the mean costs and utilisation and 95% confidence intervals[16].
Results
Demographics
A total of 150 paediatric patients with complex neurological disorders of suspected genetic 
origin were included between November 2011 and January 2015. Median age of our study 
cohort at the time of inclusion was 5 years and 7 months (range 5 months–18 year), and 
53.3% of the patients were males (online table S1; figure S2). The patients were diagnosed 
in the following major clinical subgroups: intellectual disability (ID; 78 patients), movement 
disorders (20 patients), neuromuscular disease (8 patients), epilepsy (5 patients), or a com-
bination thereof, such as ‘ID + epilepsy’ or ‘ID + movement disorder’ (39 patients; online 
table S1). This cohort thereby represents the broad phenotypic spectrum of disorders seen 
in daily routine paediatric neurology care at tertiary referral centers in the Netherlands.
Diagnostic yield in the standard diagnostic pathway
In the standard diagnostic pathway 11 (7.3%) of 150 patients obtained a conclusive diagno-
sis confirmed by genetic testing (table 1, online table S2). These diagnoses included both 
well-known syndromes, such as Sotos syndrome (NSD1 point mutation) and Fragile X syn-
drome ((CGG)n repeat expansion), as well as CNVs of various sizes, ranging from a 2.2Mb 
duplication to a mosaic whole chromosome 8 trisomy. On average, conclusive diagnoses in 
the standard pathway were reached after 4.6 genetic tests (range 2-7 tests; online table S3). 
As it may be expected that patients receiving a conclusive diagnosis either obtained less 
(‘easy to diagnose’) or more testing  (‘perseverance of continued diagnostic testing’), we 
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compared whether patients receiving a conclusive diagnosis had less or more genetic tests 
than those without a diagnosis. There was however no difference in the number of genetic 
tests in the standard pathway performed between patients who received a diagnosis and 
patients without one (p=0.58, two-tailed T-test).
Diagnostic yield using whole exome sequencing
In the WES pathway, 44 patients (29.3%) received a conclusive diagnosis, including 26 clin-
ically well-known syndromes (e.g. MECP2 syndrome, KBG syndrome; table 1, online table 
S2). In 13 patients, a de novo point mutation was identified in a recently reported disease 
gene (table 1). In addition, 5 pathogenic CNVs were identified, ranging in size from 342 kb 
to a whole chromosome 8 trisomy. Of note, the 44 patients who obtained a diagnosis using 
WES had received an average of 4.7 genetic tests in the standard diagnostic pathway (range 
1-12), which was no different from those patients who had tested negative by WES (p=0.23, 
two-tailed T-test).
In addition to 44 conclusive diagnoses, WES identified a possible diagnosis in 41 further 
patients (27.3%), reporting on presumably disease-causing mutations in candidate disease 
genes (online table S4).
Diagnostic concordance between the standard care pathway and WES 
Next, we compared the diagnoses obtained at individual patient level to determine the 
concordance between both pathways. In total, 47 patients (31.3%) obtained a diagnosis 
through either the standard or WES pathway (table 2; online table S2). For eight patients 
(17.0%) the same 
conclusive diagno-
sis was obtained 
by both pathways. 
Three further pa-
tients (6.4%) only 
received their ge-
netic diagnosis 
through the stan-
dard genetic care 
Table 2. Diagnostic concordance between standard genetic care 
pathway and WES
WES pathway
St
an
da
rd
 
pa
th
w
ay Conclusive Possible No Total
Conclusive 8 0 3 11
No 36 41 62 139
Total 44 41 65 150
Details on the conclusive diagnosis obtained are listed in table 1 whereas tables S2 
and S4 show concordance between diagnostic pathways and an overview of the 41 
possible diagnosis, respectively.
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pathway, whereas 36 patients (76.6%) only received their genetic diagnosis through WES 
(table 2; online table S2). Statistical analysis comparing the overall diagnostic yields be-
tween both pathways indicates that the use of WES resulted in significantly more conclusive 
diagnoses than the standard care pathway (n=11 vs n=44, p=9.7×10-7, 2-tailed Fisher’s exact 
test). The three genetic diagnoses that were not identified using WES included a 9-bp dupli-
cation event (patient 114), a repeat (CGG)n expansion in FMR1 (patient 43) and a mosaic 27 
Mb duplication of chromosome 7 (patient 49) (table 2; online table S2).
Health care resource use
To gain insight into the cost-to-diagnosis, we collected the healthcare resource use during 
the diagnostic process, both retrospectively (prior to inclusion to our study) as well as pro-
spectively (after inclusion to our study). On average, patients had 23.3 physician-patient 
contacts, and an extensive diagnostic work-up, including i) various forms of imaging tech-
nology (n=4.1 tests), ii) neurophysiology exams (n=2.2 tests), iii) genetic diagnostic testing 
(n=5.4 tests; online table S3), iv) metabolic assays (n=0.5 assays), v) basic clinical chemistry 
tests on blood, urine and spinal fluid (n=54.7 tests), and vi) other diagnostic laboratory tests 
(n=2.2; table 3). 
Table 3. Health care resource use in the standard diagnostic trajectory
Bootstrapped mean 
quantity per patient 
Bootstrapped mean 
costs € per patient
Physician contacts Mean 95% CI Mean 95% CI
Consultations 11.80 9.43 - 14.55 1,922 1,535 - 2,372
Telephone 11.31 9.15 - 13.55 192 156 - 230
Sub Total Contacts 23.27 19.13 - 28.18 2,121 1,729 - 2,594
Imaging technology     
Magnetic resonance imaging MRI 1.72 1.48 - 2.03 426 363 - 505
Radiography X-ray 0.78 0.53 - 1.03 54 37 - 72
Ultrasonography echo 1.17 0.83 - 1.57 106 75 - 144
Computed tomography CT 0.19 0.09 - 0.31 27 13 - 44
Other 0.24 0.09 - 0.44 98 40 - 167
Sub Total Imaging 4.10 3.36 - 4.87 709 593 - 833
Neurophysiology exams Mean 95% CI Mean 95% CI
Electroencephalogram EEG 1.52 1.14 - 1.93 497 374 - 636
Electrophysiology EP 0.15 0.08 - 0.24 28 12 - 48
Other 0.53 0.35 - 0.73 78 52 - 108
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Total costs for the standard diagnostic pathway, on average, amounted to €10,685 per pa-
tient (95% confidence interval: €9,544–€11,909), of which genetic testing was the major 
driver of diagnostic costs (€4,164). In more detail on the latter, 150 patients received 806 
genetic tests with an average of 5.4 per patient (range 0-28 tests; table 3, online figure S3-
Table 3 (continued)
Bootstrapped mean 
quantity per patient 
Bootstrapped mean 
costs € per patient
Sub Total Neurophysiology 2.19 1.72 - 2.74 603 466 - 754
Genetic
Genomic microarray 1.05 0.93 - 1.19 814 721 - 918
Karyotypering 0.28 0.2 - 0.37 215 1545 - 283
Fluorescent in situ hybridization FISH 0.07 0.03 - 0.12 56 26 - 93
Multiplex dependent probe amplication MLPA 0.25 0.17 - 0.34 196 135 - 264
Chromosome X-inactivation studies 0.01 0 - 0.03 10 0 - 26
Cytogenetic screening n.o.s. 0.04 0 - 0.10 32 0 - 75
Mitochondrial DNA diagnostics 0.40 0.26 - 0.56 313 201 - 433
Sanger sequencing 3.27 2.67 - 3.91 2,525 2,066 - 3,024
Sub Total Genetics 5.39 4.73 - 6.12 4,164 3,654 - 4,726
Metabolic testing
Mitochondrial enzymes diagnostics 0.19 0.11 - 0.29 191 108 - 287
Lysosomal enzymes 0.27 0.18 - 0.35 263 179 - 351
Mitochondrial biochemical diagnostics 0.05 0.01 - 0.10 48 7 - 106
Complex 1 deficiency testing 0.01 0 - 0.02 6 0 - 20
Mitochondrial analysis n.o.s. 0.03 0 - 0.05 21 0 - 345
Sub Total Metabolics 0.54 0.41 - 0.70 533 398 - 689
Routine biochemical assays
Blood 36.77 30.09 - 44.7 1,450 1,235 - 1,688
Urine 11.75 8.58 - 15.55 138 106 - 182
Cerebrospinal fluid 6.12 4.56 - 7.89 205 145 - 271
Sub Total Routine labs 54.67 44.94 - 65.76 1,780 1,567 - 2,046
Other diagnostics
Biopsy LP 0.35 0.26 - 0.44 59 44 - 73
Biopsy, histology 0.34 0.25 - 0.44 20 14 - 25
Biopsy, metabolic 0.41 0.29 - 0.54 405 287 - 530
Other 1.07 0.74 - 1.43 304 220 - 395
Sub Total Others 2.17 1.67 - 2.73 787 594 - 988
Total 91.90 77.8 - 108.14 10,685 9,544 - 11,909
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S4, online table S3). Of note, patients who were already in a diagnostic trajectory in our 
university hospital before inclusion, on average underwent a significantly a greater amount 
of genetic tests (n=6.6) than patients that were either referred from a general practitioner 
(n=2.9; p<0.01), or referred from a peripheral hospital (n=4.1; p<0.01).
In comparison, the average costs for WES-based genetic testing in this cohort were €3,420. 
Consequently, substitution of conventional genetic testing by WES in this cohort resulted in 
an average cost saving of €744 per patient. Notably, 17 patients (11.3%) received additional 
diagnostic testing as a consequence of the WES diagnostic report to support or decline the 
WES diagnosis (figure S5; online table S5).
Our exploratory analysis of the costs of diagnosis if WES were used as a first-tier test indicat-
ed that in 36 of 44 patients in whom WES led to a conclusive diagnosis, no additional tests 
would have been performed. The remaining eight patients would still have received addi-
tional (confirmatory) diagnostic tests, ranging from a single cerebral imaging test or meta-
bolic investigation to all diagnostic work-up as performed before (figure S6; online table S6). 
Taking this into account, the mean costs of diagnostic tests in our patient cohort would have 
amounted €8,356 (95% CI: €7,591- €9,247) per patient. In patients with a conclusive WES 
diagnosis, those costs could be further reduced to €4,349 (95% CI: €3,994–4,777) as only 
limited other diagnostic testing would be required, whereas in patients with a negative WES 
diagnosis, those costs would be €10,035 (95% CI: €9,312-€10,797) as the remainder of the 
diagnostic pathway would remain the same (figure S6; online table S6).
Discussion
Over the last few years, WES has been implemented in routine diagnostic genetic testing 
for clinically and genetically heterogeneous disorders[13,17-20]. This implementation was 
technology-driven and was largely based on the added diagnostic value obtained in patients 
who had reached the end stage in the standard diagnostic pathway. Here, we have per-
formed a clinical utility study using a design in which 150 consecutive patients with complex 
paediatric neurological disorders received both the standard diagnostic pathway as well as 
WES in parallel, to determine the value of WES in paediatric neurology care. Using this study 
design, we were able to show that WES provides significantly more conclusive genetic diag-
noses than the standard genetic care, without incurring higher costs.
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WES was able to provide a conclusive diagnosis in 44 (29.3%) of 150 patients, whereas the 
standard diagnostic pathway was only able to diagnose 11 patients (7.3%). The overall diag-
nostic yield for the different clinical entities as seen in paediatric neurology, is in agreement 
with previous studies reporting on the diagnostic yield of WES for each of these entities 
(table S7). Despite the relatively high number of conclusive diagnoses by WES, three dis-
ease-causing mutations were only identified by standard genetic analysis. The three dis-
ease-causing mutations not identified by WES are directly related to technical pitfalls of 
WES. Two of three were not detected using the SNV detection tool, including a (CGG)n 
repeat expansion which cannot be mapped due to the high repeat content of the expan-
sion and a 9-bp duplication which was not mapped due to relative long duplication in an 
homopolymer (G) stretch in relation to the length of the sequence read. The third was not 
detected by the CNV detection tool, being a mosaic 27Mb duplication. In retrospect, the 
latter mosaic duplication could be detected upon visual inspection of the data. Optimization 
of both the sequencing technology as well as the bioinformatic algorithms dedicated to the 
detection of such variants (both at SNV and CNV level) would eventually overcome these 
current technological pitfalls. In this respect, much progress is to be expected from genome 
(long-read) sequencing technologies, as these will also capture (non-)coding variants and 
structural variation that currently remain undetected by WES[7,21,22].
The standard care pathway did not identify 36 conclusive genetic diagnoses, including those 
of 21 known syndromes. This lack of conclusive diagnoses for known syndromes may be ex-
plained by three main factors. Firstly, the median age of our patient cohort is low and young 
patients may not (yet) display all characteristic clinical features of the syndrome. Secondly, 
previous genetic testing may not have uncovered the causal variant. For two patients, we 
identified a CNV explaining the patient’s phenotype, despite the fact that those patients 
received genomic microarray-based testing in their standard genetic pathway. Retrospective 
analysis of these original array data indicates that these two regions are poorly covered on 
the array, explaining why these escaped detection (figure S7). Thirdly, the clinical and genet-
ic heterogeneity of the disorders encountered in paediatric neurology clinic is enormous. 
Over the last few years, the use of next generation sequencing technologies has led to the 
discovery of many novel disease-causing genes, especially for such clinically and genetically 
heterogeneous disorders[23]. This makes it virtually impossible to keep up to date on all 
genes involved in the respective diseases, limiting the possibility to request the right gene 
for targeted mutation analysis. Patient 37, who was clinically diagnosed with Kabuki syn-
drome, exemplifies this situation. KMT2D, causing Kabuki syndrome when mutated, was 
tested but no mutations were identified. Then WES identified a disruptive mutation in KD-
102 CHAPTER 6
M6A. Mutations in the KDM6A gene also cause Kabuki syndrome, but this was published[24] 
only weeks after the patient was last seen by the medical specialist. This difficulty is further 
underlined by the fact that 13 of 44 (30%) of the conclusive WES diagnoses affected a gene 
that has only been implicated in disease in the last few years. 
WES provided a possible genetic diagnosis in another 41 patients (27%). Whereas further 
clinical and genetic follow-up in larger cohorts of patients with similar phenotypic char-
acteristics is required to establish the true nature of these diagnoses, our experience has 
shown that up to two-third of these possible diagnoses will be revised to conclusive diag-
noses once additional patients with mutations in the same gene are identified and charac-
terized[13,25,26]. Moreover, with increasing knowledge over time and more genes being 
implicated in disease, WES data can be revisited and re-interpreted, and more conclusive 
diagnoses can be made. For instance, already three of 106 WES-negative patients have ob-
tained a conclusive genetic diagnosis since our data-freeze (July 2015), based on the avail-
ability of new clinical information and targeted re-analysis of existing WES data. Although 
speculative, it can be anticipated that the conclusive diagnostic yield of WES in this cohort 
may be as high as 50%, but this would require regular re-analysis of the available WES data. 
In this study, we gathered data on healthcare resource use to gain insight into the cost-to-di-
agnosis in both the standard pathway as well as the WES genetic diagnostic tract. The stan-
dard care pathway results in a mean cost of €10,685 per patient, with €4,164 for genetic 
testing. Replacing all diagnostic efforts in this cohort by WES increased the diagnostic yield, 
while reducing the expenses for genetic testing by €744. Our study as such determined the 
potential savings resulting from clinical implementation of WES, albeit for the Dutch health-
care system. In this system, all patients (and parents) received complete insurance coverage 
for their diagnostic pathway, including the genetic tests. Patients who were already in a 
diagnostic trajectory in our hospital prior to study inclusion had received more genetic tests 
than patients that were newly referred. This suggests that the cost-to-diagnosis could be 
reduced if clinicians perform WES instead of the conventional genetic tests in an earlier 
stage of the diagnostic trajectory. Moreover, it may be suggested to refrain patients from ex-
tensive (genetic) diagnostic work-up after a negative WES result to reduce cost-to-diagnosis 
even more as our data show that only 2% of patients with a negative WES report obtained 
a conclusive diagnosis using the standard diagnostic work-up while costs associated with 
these additional diagnoses are immense. In the light of cost-effectiveness, it is also note-
worthy that a reduction in cost-to-diagnosis in a WES-first approach may only be obtained 
in certain paediatric patients with complex phenotypes, as patients with less complex phe-
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notypes may be easier to diagnose with cheaper targeted testing such as gene panel strat-
egies. Additionally, given the worldwide differences in prices for diagnostic WES[11] and 
other (genetic) diagnostic tests analyzed in our study, the extensibility and translation of our 
cost-analyses to other health care systems and countries requires further studies. 
A more precise (genetic) diagnosis may have a major impact on clinical management and 
facilitates personalized medicine. For instance, in patient 146, diagnosed with an SCN8A 
mutation, the anti-epileptic drug was changed to oxcarbazepine, which exerts its action at 
by blocking voltage-sensitive sodium channels. In our study, we revisited the diagnostic care 
pathways of our patients and evaluated what changes could have been made if WES would 
have been the first tier diagnostic test. Importantly, for 36/150 patients (24%) the diagnostic 
process would have been limited to WES, and patients would have been refrained from ad-
ditional (invasive) medical procedures. We have previously reported on the time-to-diagno-
sis for 50 of the 150 patients for the conventional pathway[3], which showed that the mean 
duration is at least 40 months. Routine turn-around times of WES are however worldwide 
4-6 months, which can likely be reduced to weeks[27,28] by further automation and stream-
lining of the laboratory and interpretation process.
One aspect of responsible healthcare innovation and changes of diagnostic pathways is 
the perception, expectations and needs of the end users of the novel product. We have 
previously explored the parents’ information and communication needs in the counseling 
strategies for diagnostic WES using in-depth semi-structured interviews with 15 families of 
our cohort[29]. Additionally, we investigated the psychosocial effects of WES diagnoses[30]. 
Whereas our interviews did not identify any major hurdles for wide spread implementation 
of WES as (first tier) diagnostic test, which is in line with other studies[31], the interviews did 
emphasize that a diagnosis has a broader impact than just a medical one[29,30]. The latter 
was highlighted by novel (psycho-social) uncertainties that parents face when their child is 
diagnosed with a rare genetic disease of which little is known, and only few patients have 
been diagnosed with worldwide. Also, parents reported the need for more post-counseling 
advise, which can be fulfilled by a genetic counselor who, after the diagnosis, maintains 
long term contact with the family and helps with everyday problems associated with having 
a child with a (rare) genetic disease. Another important aspect of patient empowerment is 
the disclosure of incidental findings and consent procedure related hereto[32-35]. Several 
groups have reported incidental findings to vary between 1.2% and 4.6% of patients under-
going WES[36,37]. Our study did however not reveal any. Nonetheless, the detailed inter-
views with parents did point out that a tailor-made disclosure policy for incidental findings 
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is warranted, which is in accordance with previous studies[38,39]. 
In conclusion, we performed a study on the diagnostic yield and costs of whole exome se-
quencing in paediatric neurology, as compared to the conventional diagnostic trajectory. 
Our data show that WES provides more conclusive genetic diagnoses than standard (genet-
ic) care without incurring higher costs. Moreover, in this patient population a reduction of 
costs associated with obtaining a molecular diagnosis may be achieved if WES were used as 
first tier test, thereby partially substituting imaging studies, biopsies and lumbar punctures 
and replacing conventional genetic diagnostics. Our data support a change in clinical paedi-
atric neurology practice towards WES as first tier test in the diagnostic trajectory of patients 
presenting with complex neurological disorders of presumed genetic origin. 
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Abstract
Background: The current diagnostic trajectory in complex paediatric neurology is 
lengthy, resource-intensive, and has a low yield. As complex paediatric neurolog-
ic disorders (CPND) often have a genetic origin, implementing whole exome sequenc-
ing (WES) might improve this trajectory. However, this might also increase costs. 
Objective: To empirically examine the cost-effectiveness of WES in clinical paediatric neu-
rology practice. 
Methods: 100 consecutive children with CPND of suspected genetic origin were included 
and underwent both the conventional diagnostic trajectory and WES. The primary effective-
ness outcome was diagnostic yield. A trial-based cost-effectiveness analysis (CEA) of WES 
was performed with prospectively collected cost data. Uncertainty was addressed using 
bootstrapping. In addition, to explore the cost-effectiveness of WES as a first-tier test, a 
model-based CEA was performed based on retrospectively collected cost data.
Results: WES increased diagnostic yield from 8% to 30%. The average costs of the conven-
tional diagnostic trajectory were €1,885; when retrospectively collected costs were includ-
ed, these amounted to €9,353. The costs of the WES trajectory were €3,809. This resulted 
in an incremental cost-effectiveness ratio (ICER) of €8,950 per additional diagnosis. Our de-
cision model indicated that WES as a first-tier test could result in cost savings if at least 30% 
of a paediatric neurology patient population consists of patients with CPND. 
Discussion: We showed that WES can provide value for money if not used as a last-resort 
test, and could even be cost-saving when applied as a first-tier test. Physicians should take 
this into account in deciding whether and when to use WES.
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Background
Complex paediatric neurologic disorders are clinically and genetically heterogeneous disor-
ders, including movement disorders, neurodegenerative diseases and developmental de-
lay. Patients often present with non-specific symptoms, already at young age[1]. The con-
ventional diagnostic trajectory of patients with complex paediatric neurological disorders 
(CPND) is often lengthy and resource-intensive, and at the same time the diagnostic yield is 
relatively low[2]. 
Improvement in this diagnostic trajectory is expected with the implementation of whole 
exome sequencing (WES)[3]. WES provides an analysis of all human protein-coding genes 
in a single experiment, allowing the detection of disease-causing variants without a priori 
knowledge on the patients’ phenotype. The latter is of particular interest for disease with 
a large degree of phenotypic and genetic heterogeneity. Consequently, WES is expected to 
result in a higher diagnostic yield than current practice. Indeed, WES has been shown to 
identify conclusive genetic diagnoses in patients with complex diseases who had reached 
the end stage of standard diagnostic trajectories[4, 5]. However, WES is also perceived as 
an expensive technology which might increase health care expenditure in complex paedi-
atric neurology (CPN)[6]. Therefore, not only the possible benefits of increasing diagnostic 
yield by WES, but also its costs should be assessed prior to (large scale) implementation 
into clinical practice. In a so-called cost-effectiveness analysis (CEA), the costs and effects 
of a medical intervention are compared with current practice to consider which technology 
provides most value for money[7].
Previously, we showed that WES significantly improves the diagnostic yield in CPN. More-
over, we suggested that implementing WES into clinical practice would not increase health 
care expenditures, especially when performed as a first-tier test[8]. Here, the cost-effective-
ness of WES in clinical practice is empirically examined, by prospectively measuring health 
care resource use (HRU) of CPN patients. In addition, a model-based analysis is performed 
to explore the cost-effectiveness of WES as a first-tier test.
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Methods
Study design and population
This study was conducted at the Departments of Paediatric Neurology and Human Genetics 
of the Radboud university medical center in the Netherlands. 100 consecutive patients with 
CPND, defined as patients with neurologic disorders of suspected genetic origin in whom 
diagnosis may be complicated by extensive genetic and clinical heterogeneity, ≤18 years 
were enrolled between August 2013 and January 2015 (patients 51-151 from Vissers et al. 
GiM). Individuals presenting with easily recognizable genetic disorders (spot diagnosis) such 
as neurofibromatosis type 1, and patients with disorders of (suspected) acquired or multi-
factorial origin, were not included.
A parallel study design was used, in which all patients received both the traditional diagnos-
tic pathway and WES, allowing for a direct comparison of the performance of both trajec-
tories. 
To participate, both parents of the patients signed informed consent. This study was ap-
proved under the realm of clinical diagnostic genetic testing by the medical ethics commit-
tee of the Radboud university medical center (2011/188). 
Costs
HRU for diagnostic purposes was collected from the patients’ medical charts. A health care 
perspective was used, in which only direct medical costs were taken into account. To de-
termine total costs, HRU was multiplied with the associated unit costs, obtained from the 
Dutch Health care Authority[9] and the Dutch Health care Institute[10].
Cost data were collected prospectively and retrospectively. Data collection started at inclu-
sion (prospectively) or with the first hospital visit at our university hospital (retrospectively) 
and ended when a conclusive diagnosis was established, or if no diagnosis was reached, one 
year after inclusion.
For a WES-first approach, the diagnostic pathway was assumed to consist of two phy-
sician visits (pre- and post test counselling) and trio-based WES (patient and both 
parents), or in the case of a suspected recessive disorder, two physician visits and 
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WES for the proband. The costs for WES were estimated at €3,500 for a trio anal-
ysis, and €1,800 for a singleton, representative for the diagnostic exome sequenc-
ing prices in our laboratory (October 2016)[11]. All costs are calculated in 2016 Euros. 
Diagnostic yield
The primary effectiveness outcome was the diagnostic yield of both trajectories, expressed 
as the percentage of patients receiving a conclusive diagnosis. The measurement and cate-
gorisation of diagnostic yield is described in detail elsewhere[8]. 
To assure comparability of both trajectories, patients with a possible WES diagnosis were 
assigned to the “no conclusive diagnosis” trajectory. 
Analyses
As cost data are usually highly skewed due to a minority of patients utilising large amounts 
of resources, bootstrap simulations with 1,000 replications were performed to estimate the 
mean costs and 2.5 - 97.5 percentile interval[12, 13]. Likewise, diagnostic yield was boot-
strapped. 
A trial-based CEA of WES in clinical practice was performed on the costs that were prospec-
tively measured after inclusion in the study. Additionally, a model-based analysis on the 
retrospective costs was performed.
WES in clinical practice
An incremental cost-effectiveness ratio (ICER) informing on the costs for achieving an addi-
tional diagnosis was calculated by dividing the difference in prospective costs between both 
trajectories by the difference in diagnostic yield. The ICER was calculated per patient and 
represents the extra costs that need to be made to gain one additional diagnosis. Whether 
WES is deemed cost-effective, depends on how much society is willing to pay for an addi-
tional diagnosis. Only when the ICER is lower than this willingness-to-pay (WTP) threshold, 
WES is deemed cost-effective. Results of this CEA will be presented in a cost-effectiveness 
plane[14]. 
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Sensitivity analyses
To address the uncertainty around the costs and effects, the cost-effectiveness plane was 
based on the bootstrapped costs and effects (in this case diagnostic yield). Additionally, 
two one-way sensitivity analyses were performed, anticipating future improvement of WES 
regarding costs and diagnostic yield. 
In the base case analysis, the costs for WES were representative for the diagnostic exome 
sequencing prices in our laboratory (October 2016). In a previous study, we calculated 
the costs for several diagnostic next-generation sequencing (NGS) applications, including 
WES[6], resulting in per-sample costs of €792 per WES test. To determine the influence of 
the costs of WES on the ICER, we ranged the costs for WES between these lower per-sample 
costs and our current laboratory prices. 
Second, the end results of the WES procedure were assigned to one of three diagnostic 
classes: 1) “no conclusive diagnosis”; 2) “a possible diagnosis”; 3) “a conclusive diagnosis”. 
For the base case analysis, all patients with a possible diagnosis were assigned to the “no 
conclusive diagnosis” category. For a majority of these patients, this diagnosis will however 
be revised into a conclusive diagnosis[8]. Based on in-house experience, we varied the di-
agnostic yield between the observed diagnostic yield (%) based on “conclusive diagnoses” 
only, and a scenario assuming that a conclusive diagnosis will be established for 60% of the 
patients in the “possible diagnosis” category. 
WES as a first-tier test
To explore the cost-effectiveness of WES as a first-tier test in CPN, a simple decision model 
was developed (Figure 1), using the average retrospective costs and diagnostic yield of both 
diagnostic pathways as input values. Patients with CPND who received no conclusive diag-
nosis after first-tier WES, were assumed to undergo the entire conventional diagnostic path-
way excluding further genetic testing. For other paediatric neurology patients, the conven-
tional diagnostic trajectory was assumed to include two physicians contacts, one MRI scan, 
one genetic test, and a basic metabolic investigation (adding up to €1,820).  As part of our 
study, we established that 84% of all paediatric neurology patients were patients with CPND. 
In addition, a threshold analysis was performed. CPN patients are part of the total popula-
tion of patients with paediatric neurologic disorders of suspected genetic origin. Performing 
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Figure 1. Health economic decision model on the retrospective costs of WES and the standard trajectory
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WES as a first-tier diagnostic test for all these patients results in sequencing patients who 
would have received a diagnosis after a minimum of diagnostic tests in the conventional 
pathway. Hence, in these patients WES is likely to be more expensive than conventional 
care. Therefore, we calculated the minimal percentage of complex patients in a cohort to 
justify WES as a first-tier test. 
Results
Demographics
Two patients died before WES was performed. Hence, no prospective comparison of the 
performance of and health care resource use in both trajectories could be made. Therefore, 
these patients were excluded. All patients (n=98) presented with heterogeneous disorders 
and displayed non-specific symptoms, varying from developmental delay to epileptic sei-
zures and neuromuscular symptoms. More specifically, in 65 out of 98 patients (66%) the 
clinical phenotype was dominated by one feature, such as developmental delay (n=42); a 
movement disorder (n=13); a neuromuscular disorder (n=5); or epilepsy (n=5). The other 33 
patients displayed at least two important features, namely psychomotor retardation plus 
epilepsy (n=19); psychomotor retardation plus a movement disorder (n=4); psychomotor 
retardation plus a neuromuscular disorder (n=4); or other combinations (n=6). Median age 
at inclusion was 5.7 years, and 59.2% of the patients were male. 
Costs
Table 1 shows the HRU in both diagnostic trajectories. Note that because all patients un-
derwent both trajectories, for WES a hypothetical trajectory was assumed, including two 
physician visits and (trio-based) WES.
The bootstrapped mean costs in the conventional diagnostic trajectory were €9,353, of 
which €1,885 incurred after study inclusion. Genetic tests were the major cost driver, ac-
coutning for 44% of the costs after inclusion (prospective collection), and 35% of the total 
trajectory (retrospective collection). In the WES trajectory, mean costs were €3,809.
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Table 1. Health care resource use and costs of the current diagnostic trajectory and 
WES
Number of 
patients (%)
Unit 
price (€)*
Mean 
quan-
tity
Mean 
costs 
(€)
Bootstrapped mean 
costs (€) (2.5 – 97.5 
percentile)
Current diagnostic trajectory, 
prospective resource use
Non-genetic tests
Physician consults 62 (63.27) 163.00 1.73 283 282 (206 – 368)
Telephone consults 88 (89.80) 17.00 6.38 108 109 (84 – 137)
Imaging tests 33 (33.67) 186.19 0.58 108 109 (69 – 158)
Neurophysiologic tests 16 (16.33) 279.18 0.32 88 89 (36 – 155)
Laboratory** 44 (43.90) 64.76 6.61 428 430 (290 – 588)
Other diagnostics 6 (6.12) 293.70 0.13 39 38 (6 – 81)
Total non-genetic 15.76 1,055 958 (739 – 1,196)
Genetic tests 47 (47.96) 772.76 1.07 828 833 (591 – 1,096)
Total 16.83 1,883 1,885 (1,515 – 2,258)
Current diagnostic trajectory, 
retrospective resource use
Non-genetic tests
Physician consults 98 (100.00) 163.00 10.34 1,685 1,693 (1,326 – 2,137)
Telephone consults 93 (94.9) 17.00 10.14 172 172 (135 – 212)
Imaging tests 92 (93.9) 159,77 3.85 615 615 (496 – 763)
Neurophysiologic tests 58 (59.2) 256.71 2.00 513 513 (352 – 697)
Laboratory* 96 (98.0) 66.04 42.38 2,798 2,454 (2,101 – 2,830)
Other diagnostics 37 (37.8) 314.49 0.95 298 302 (189 – 422)
Total non-genetic 69.65 6,082 6,069 (5,275 – 6,894)
Genetic tests 94 (95.9) 772.76 4.27 3,296 3,972 (3,386 – 4,578)
Total 73.92 9,378 9,353 (8,324 – 10,561)
WES trajectory
Physician contacts 98 (100.00) 163.00 2.00 326 326 (326 – 326)
WES*** 98 (1.00) 3,483 1.00 3,483 3,483 (3,449 – 3,500)
Total 98 (100) 3.00 3,809 3,809 (3,775 – 3,826)
* Weighted average
** Blood, urine, liquor and biochemistry. Every fluid measure is counted separately
*** For 97 patients a patient-parent WES trio was performed. For 1 patient, a single WES was performed, as a 
recessive disorder was suspected.
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Diagnostic yield
Eight of 98 patients (8.0%, bootstrapped 
mean) received a conclusive diagnosis with 
the current diagnostic trajectory. For seven 
of them, the same diagnosis was identified 
using WES, whereas one a 9-bp duplication in 
NKX2.1., remained undetected. WES, on the 
other hand, identified a conclusive diagnosis 
for 29 patients (30%, bootstrapped mean) 
(Figure 2), 22 of which were missed in the 
current diagnostic trajectory. The diagnoses 
of these patients  are described in more de-
tail elsewhere; patients 51-150 from Vissers 
et al. GiM)[8].
Cost-effectiveness of WES in clinical practice
The ICER for WES compared to current clinical practice is shown in the cost-effectiveness 
plane in figure 3. The incremental prospective costs of WES compared to the current diag-
nostic trajectory were €1,924 per patient. The increment in diagnostic yield was 0.215. This 
results in an ICER of €8,950 per additional diagnosis. 
Sensitivity analyses
Figure 3 shows the uncertainty surrounding the incremental costs and effects, based on 
the bootstrap analysis. In all bootstrap simulations, WES was more costly and yielded more 
diagnoses. 
In the sensitivity analysis assuming that a single WES can be performed for €792, the costs 
for the WES trajectory, including a trio-based WES and two physician visits, were reduced to 
€2,686. This reduced the ICER to €3,641 per additional diagnosis.
In our study, 25 patients received one or more possible diagnoses. Assuming that 60% of 
these patients will eventually receive a conclusive diagnosis increased diagnostic yield to 
45% and reduced the ICER to €5,214.
Figure 2. Diagnostic yields of the conventional diag-
nostic trajectory and WES. 
In the standard pathway a definitive diagnosis is es-
tablished for 8% of patients, whereas in the WES path-
ways 30% of patients receive a definitive diagnosis. For 
23% of all patients, a definitive diagnosis is established 
by both pathways, and 69% of patients do not receive 
a definitive diagnosis in either pathway.
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WES as a first-tier test
The total HRU in the conventional di-
agnostic trajectory without WES was, 
on average, €9,353. A simple decision 
model (figure 1) indicated that the 
application of WES as a first-tier diag-
nostic test for all paediatric neurolo-
gy patients with a suspected genetic 
disorder would result in cost savings 
when assuming that 84% of the pa-
tients are patients with complex neu-
rological phenotypes. The costs of the 
conventional pathway with WES as an 
add-on test were on average €11,091. 
Figure 3. Incremental cost-effectiveness ratio (ICER) of WES compared to the conventional diagnostic trajectory, 
measured as cost per additional diagnosis.
Figure 4. Threshold analysis
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In the WES-first pathway the average costs were €7,376. 
The threshold analysis indicated that using WES as a first-tier test would result in cost sav-
ings if at least 30% of all patients with a paediatric neurologic disorder of suspected genetic 
origin would be a complex patient (Figure 4). 
Discussion
To our knowledge, this is the first study assessing the cost-effectiveness of WES in CPN. Our 
parallel study design allowed for direct comparison of diagnostic yield of the convention-
al and WES trajectory. As costs were collected both prospectively and retrospectively, we 
could also indicate the most favourable application of WES in clinical practice.
WES resulted in a diagnostic yield of WES of 30%, which is in line with previous studies[15-19] 
and is considerably higher than in conventional practice without WES (8%).When measured 
prospectively,  WES was also more expensive (€3,809) than current practice (€1,885). How-
ever, many of the patients received (genetic) testing prior to inclusion in our study - retro-
spectively measured, the average cost of the conventional diagnostic trajectory was €9,353. 
Our decision model indicated that applying WES as a first-tier diagnostic test in all patients 
with a presumed genetic neurologic disorder might result in cost savings, if at least 30% 
would be complex patients. Based on our analysis that 84% of patients are in fact patients 
with such complex genetic phenotypes, WES is likely to be a cost-effective first-tier diagnos-
tic test. However, one should keep in mind that the patients that are seen in a university 
hospital often already received (extensive) diagnostic testing before referral. The more di-
agnostic tests they have received (i.e. higher incurred costs), the less cost-effective WES will 
be. Paediatricians should be aware that WES is more likely to be cost-effective when applied 
earlier in the diagnostic trajectory. Also in hospitals without NGS services, physicians should 
consider WES as an alternative to sequential genetic testing for patients without clinically 
recognizable disorders and patients with genetically heterogeneous disorders. They should 
keep in mind however, that for patients, in whom a diagnosis may be established with a 
minimum of conventional diagnostic testing, WES will be cost-increasing. Yet, determining 
beforehand whether or not a patient is going to need an extensive diagnostic trajectory is 
challenging[8]. 
Our study has some limitations. First, we focused on costs and diagnostic yield, but did not 
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regard the impact of a (conclusive) diagnosis on the patient and his/her family. Preferably, a 
final outcome, such as quality-adjusted life years (QALYs), which combine quality of life and 
survival due to an intervention, is used in cost-effectiveness analyses. Using the intermedi-
ate outcome “diagnostic yield” instead, complicates the interpretation of the CEA, as it is 
difficult to value an additional diagnosis in monetary terms. 
Second, a health care perspective was used. Other costs, such as out-of-pocket expenses 
(e.g. travel expenses) and productivity losses may also be relevant. Unfortunately, these 
data were not available for this patient cohort. This may result in an underestimation of the 
cost-effectiveness of WES, as for the conventional diagnostic trajectory more physician visits 
are made. On the other hand, the use of WES might incite follow-on testing (e.g. to verify 
the genetic diagnosis by MRI) and/or treatment initiation (e.g. in case of incidental findings) 
and thereby cause downstream expenses[20]. Although incidental findings are rare – pre-
vious studies indicate that these are seen in up to 5% of patients[21, 22], but none were 
encountered in this study – their downstream costs (e.g. additional diagnostics or medica-
tion) may be considerable. To what extend WES incited additional clinical tests could not 
be monitored in our study design, as these patients already underwent those tests in the 
conventional trajectory. So it is not clear what the actual resource use of these patients in a 
WES trajectory would have been. Nevertheless, the neurologists in our hospital estimated 
that a large majority of the patients with a positive WES diagnosis would not require any, or 
only minor additional testing[8]. Hence, minimal downstream costs after first-tier WES are 
expected. Additionally, our design could have resulted in an underestimation of the costs of 
the conventional diagnostic trajectory, and thereby an underestimation of the cost-effec-
tiveness of WES, since the application of WES might have resulted in refraining from con-
ventional genetic testing in patients. Yet, the use of this parallel design allowed us to directly 
compare the diagnostic yield of both trajectories. 
We found that WES is a valuable test in the diagnostic trajectory of CPN. It increases diag-
nostic yield and allows for substitution of conventional diagnostic testing. However, when 
applied as an add-on test, when a substantial number of conventional diagnostic testing has 
already been performed, WES is more expensive, resulting in an ICER of €8,950 per addition-
al diagnosis. Whether this is deemed cost-effective depends on the WTP for an additional 
diagnosis. Regier et al. estimated the WTP for a diagnosis by means of a discrete choice 
experiment in paediatric idiopathic developmental disability, and found a WTP value of €85 
for one additional diagnosis in every 100 patients[23]. However, it is questionable whether 
WTP values can be translated to other patient populations and whether these can directly 
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be used as payer ceiling thresholds.
In CPN patients, a conclusive diagnosis does generally not result in treatment alterations or 
health effects, and therefore patients are not expected to gain QALYs. Nevertheless, a con-
clusive diagnosis might have valuable non-health effects on both patients and family mem-
bers[20, 24]. For instance, genetic testing is particularly important in family planning [25]. 
In addition, a conclusive diagnosis provides insight into prognosis, allows for better coping 
with the disease, and better access to social services [26]. On the other hand, for parents, 
disclosure of a conclusive genetic diagnosis might result in loss of hope and other negative 
feelings associated with the realisation their child has a serious disorder[27]. Particular-
ly in genetic diagnostics, feelings of (self) blame for passing disease-causing mutations to 
the child play a role[27]. On the other hand, a genetic diagnosis may also take away these 
feelings of blame and demonstrate that the disease could not have been prevented and 
occurred by pure bad luck. This is in particular the case for de novo mutations (explaining 
the majority of complex early-onset disorders), which occur in all children but only result in 
disease when affecting a disease gene. Whether and how these non-health values should be 
taken into account in CEAs of genetics diagnostics is topic for further research.
Conclusion
WES is a valuable test in the diagnostic trajectory of CPN, as it increases the diagnostic yield 
substantially. We showed that WES provides more value for money if not used as a last-re-
sort test, and could even be cost-saving when applied early in the diagnostic trajectory. 
The cost-effectiveness of WES depends on the value of an additional diagnosis, how many 
diagnostic tests a patient already underwent, and how many patients with a suspected ge-
netic disorder are complex patients. These factors should be taken into account in deciding 
whether and when to adopt WES in clinical practice. 
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The aim of this thesis was to explore the value and challenges of early health technology 
assessment (HTA) of diagnostic next-generation sequencing (NGS) technologies in clinical 
practice. To this end, the case of whole exome sequencing (WES) in complex paediatric neu-
rology (CPN) was evaluated. In this final chapter, the main findings of this thesis are present-
ed, followed by discussion of the methodological considerations. Subsequently, implications 
for clinical practice and future research are given. 
Main findings
The first part of this thesis focused on the current diagnostic trajectory of complex paediat-
ric neurological disorders (CPND). We performed a retrospective analysis on the health care 
resource use, duration, and diagnostic yield of the current diagnostic trajectory of 50 CPN 
patients (chapter 2). This study showed that with a mean duration of at least 40 months, this 
trajectory is a protracted one. Patients made a substantial number of physician visits (15.55) 
and telephone or email consultations (14.21). Moreover, they underwent a considerable 
number of imaging (4.46), neurophysiologic (2.48), genetic (7.73), and other (15.08) diag-
nostic tests. Health care expenditure in this trajectory was high, with an average of €12,475 
per patient. This is in line with health care expenditure in similar patient populations[1-3]. 
The major cost drivers in CPN diagnostics were genetic testing (€5,321) and physician con-
tacts (€3,112). Despite these extensive and resource-intensive diagnostic investigations, 
which in addition may be burdensome to the patients and their families, the diagnostic 
yield of this trajectory is low (6%). 
Extensive diagnostic trajectories involving high frequencies of hospital appointments and 
(invasive) diagnostic testing are known to cause distress to both patients and their parents 
(or other caregivers) [4]. Chronic paediatric neurological conditions, such as epilepsy, cere-
bral palsy, and pervasive developmental disorders, are associated with diminished patient 
and parent HRQoL[5-7]. As chronically ill children rely on their parents for health care deci-
sions, careful evaluation of parental HRQoL is of utmost importance[8]. Chapter 3 showed 
that, although their SF-6D utility scores were normal, parents of patients with CPND showed 
diminished mental HRQoL (SF-12 MCS scores) as compared to the general Dutch popula-
tion. Parental mental HRQoL appeared to be positively correlated with patient HRQoL and 
negatively correlated with parental trait of worry. Patient HRQoL (SF-6D utility score), which 
was scored by the parents, seemed also diminished. However, as we did not include patient 
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self-assessment, these utility scores may suffer from a proxy-bias. Moreover, the use of the 
SF-12 questionnaire has not been validated for children. The low diagnostic yield and di-
minished HRQoL in CPN suggest there is ample room for improvement in the conventional 
diagnostic trajectory. 
The second part of this thesis comprised the health technological evaluation of WES for 
CPND. Chapter 4 showed that the headroom method, although introduced and currently 
used on a QALY basis, is also a feasible and useful tool in the early health economic evalu-
ation of diagnostic technologies that are not expected to result in QALY gain. Effectiveness 
gap calculation is informative on the room for improvement in current clinical practice. It 
indicates whether there is a problem in current care, and allows for quantification of this 
problem. Combining a monetary valuation of the effectiveness gap with the foreseeable 
downstream costs and savings due to a new technology provides an estimation of the tech-
nology’s potential value. In the case of CPND, we found a large effectiveness gap in terms of 
diagnostic yield, as in current clinical practice diagnostic yield was only 6%. Although mon-
etising the value of an additional diagnosis appeared challenging, adopting an optimistic 
scenario, we foresaw potential cost savings of €6,098 per patient as a result of implement-
ing WES in this diagnostic trajectory. As a complete and up-to-date overview of the costs of 
various NGS applications was still lacking, we calculated per sample costs of targeted gene 
panels (TGP) (€333), WES (€792), and WGS (€1,669), including not only the sequencing pro-
cess, but also equipment acquisition, maintenance, data analysis and storage (chapter 5). 
Thus, the costs of a WES trio are currently approximately €2,375, suggesting that WES might 
be cost-effective in CPN. 
We showed that the coveted $1,000 genome has not yet been achieved. In fact, only in 
our best-case scenario analysis, assuming very efficient and long-term application of the 
sequencing equipment, cost reductions of 50% in both capital and consumable costs, and 
technological advances allowing for 30x coverage, a €1,000 (approximately $1,100) genome 
would be approached.
Chapter 6 concerns a clinical utility study (n = 150) focusing on diagnostic yield and costs. 
This study combined the 50 patients from the retrospective study (chapter 2) and 100 pa-
tients from the prospective studies (chapter 3 and chapter 7) and showed that in total 44 
of 150 patients (29.3%) received a conclusive diagnosis with WES, versus 11 (7.3%) in the 
conventional diagnostic pathway. Eight patients received the same conclusive diagnosis by 
both pathways. For 36 patients, conclusive diagnoses were only reached through WES, de-
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spite the fact that 21 of them concerned known syndromes. Three disease-causing muta-
tions were only identified by the conventional diagnostic trajectory. These included a (CGC)
n repeat expansion, and a 9-bp duplication, which WES nowadays cannot detect due to 
technical pitfalls, and a mosaic 27 Mb duplication in 20-30% of cells which, in retrospect, 
could have been, but was not detected. With an average of 5.4 genetic tests (€4,164) in the 
conventional diagnostic trajectory, implementing WES (€3,420) as a first-tier genetic test 
is expected to result in cost-savings in this patient population, assuming that it substitutes 
all other genetic diagnostic testing. However, it should be noted that this study involved a 
selected group of complex patients, of whom a substantial number already underwent an 
extensive diagnostic workup in either a peripheral or the university hospital, which did not 
result in a conclusive diagnosis. Clearly, the afore-mentioned cost-savings will be achieved 
only if neurologists are able to identify complex patients timely, thereby preventing redun-
dant diagnostics. Yet, it is uncertain whether these complex patients can be reliably identi-
fied in an earlier phase. 
In chapter 7, two cost-effectiveness analyses are performed. First, we empirically examined 
the cost-effectiveness of WES in CPN clinical practice by prospectively measuring health 
care resource use and diagnostic yield of 100 CPN patients who underwent both the tradi-
tional diagnostic trajectory and WES. With incremental costs of €1,885 per patient, and an 
incremental diagnostic yield of 0.215, we found an ICER of €8,950. Whether this is deemed 
cost-effective depends on the willingness to pay (WTP) for an additional diagnosis. Whereas 
a well-defined WTP value for QALYs has been established, this is not the case for interme-
diate outcomes, such as diagnostic yield, [9]. Additionally, we performed a model-based 
analysis on the retrospective health care resource use of the current diagnostic trajectory. 
This allowed us to explore the cost-effectiveness of WES when performed as a first-tier diag-
nostic test. A subsequent threshold analysis enabled us to calculate the minimal percentage 
of complex patients among all paediatric neurology patients to justify WES as a first-tier test. 
Taken together, these analyses indicated that WES provides most value for money if not 
used as a last-resort test, and could even be cost-saving when applied early in the diagnostic 
trajectory. The use of WES as a first-tier test would result in cost savings if at least 30% of all 
patients with a paediatric neurological disorder of suspected genetic origin would be com-
plex patients (i.e. patients presenting with non-specific neurological symptoms who would 
not receive a diagnosis with a minimum of conventional diagnostic testing). Whether this 
threshold is achieved in practice should be the subject of further research. 
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Methodological considerations
Study design
The studies in this thesis involved two cohorts of complex paediatric neurology a (retrospec-
tive cohort, n = 50, and a prospective cohort, n = 100). All patients in these studies under-
went two diagnostic pathways, i.e. the standard CPN diagnostic pathway and WES, simulta-
neously. Ideally, in the interest of this research, these diagnostic pathways would have taken 
place completely independently of each other, with no communication of results between 
the paediatric neurologists (standard pathway) and clinical geneticists (WES), and without 
the withholding of any conventional diagnostic tests. However, in practice, the paediatric 
neurologists might have acted in the interest of the patient, refraining from burdensome 
diagnostic testing (e.g. biopsies). Moreover, the application of WES might have resulted in 
refraining from conventional (genetic) testing in some of these patients. Although acting 
in the interest of the patient is clinically the right thing to do, it may have complicated the 
outcomes of our research. That is, the use of this study design, in which all patients under-
go both diagnostic trajectories, may have caused an underestimation of the health care 
resource use of the conventional diagnostic trajectory, and thereby an underestimation of 
the cost-effectiveness of WES in CPND. Additionally, although this study design allowed for a 
direct comparison of the diagnostic yield of both trajectories, as the patients were their own 
controls, comparison of patient reported outcomes, such as HRQoL, between the different 
strategies could not be made. For this, a randomized controlled trial is needed. Yet, such 
study design is not ethically sound, as the equipoise status for WES disappeared soon given 
the enormous increase in diagnostic yield (in other genetically and clinically heterogeneous 
disorders).
As a result, the cost-effectiveness analysis was not QALY based, but based on the intermedi-
ate outcome diagnostic yield. Although useful, intermediate outcomes are difficult to value 
in monetary terms. While for QALYs a clear WTP threshold has been established (£20,000 
- £30,000 per QALY), this is not the case for intermediate outcomes. Determining the WTP 
for intermediate outcomes can be achieved by using, for example, contingent valuation or 
discrete choice experiments. However, these are relatively time-consuming and expensive 
methods to conduct[10]. Moreover, as intermediate outcomes may be valued differently in 
varying disease areas, WTP values should be determined for each specific disease area and 
patient population separately. 
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Study population
For the studies in this thesis, two CPN patient cohorts were included. The first cohort con-
sisted of 50 patients who were already known in the university hospital. These patients were 
included to estimate the value of WES in CPN patients who already received multiple diag-
nostic tests, without a conclusive diagnosis. This pilot cohort also allowed for a retrospective 
analysis of the health care resource use associated with the diagnostic pathway of CPN as is 
shown in chapter 2.
The second cohort was planned to consist of 100 patients new to the university hospital, 
who were referred either directly from the general practitioner or from a general hospital, 
with no or limited prior diagnostic testing. This would have allowed for a prospective cost-ef-
fectiveness analysis informing on the value of WES in newly referred patients. In practice 
however, it appeared difficult to include only new patients in a short time span, as a large 
percentage of all patients seen in a tertiary university hospital already underwent extensive 
diagnostic trajectories prior to inclusion to our study. Therefore, the second cohort consist-
ed of a mix of patients, including patients who were already known in the university hospital 
(n=36), patients who were referred from general or other university hospitals (n=53), and 
patients newly referred from the general practitioner (n=11). Although this cohort is a good 
representation of clinical practice, it distorted the prospective cost analysis, as most pa-
tients already underwent multiple diagnostic tests before inclusion in this study. This might 
have resulted in an underestimation of the cost-effectiveness of WES in CPN. Additionally, 
it makes it difficult to draw conclusions on the value of WES as a first tier test or early in the 
diagnostic trajectory of newly referred patients. Therefore, we performed a model-based 
cost-effectiveness analysis on the retrospective health care resource use of the current di-
agnostic trajectory. This analysis allowed us to explore the cost-effectiveness of WES when 
performed as a first-tier diagnostic test. Additionally, a threshold analysis was performed to 
determine the minimum percentage of paediatric neurology patients who have to be pa-
tients with CPND, in order to justify WES as a first-tier test (Chapter 7). Despite the potential 
shortcomings of the evaluations due to the study design and patient population, all analyses 
together indicate that WES is likely to be a valuable diagnostic test for patients with CPND.
 
Timing of health technology assessment
Regarding the timing of evaluation, this thesis once again shows that evaluation of new 
technologies is generally performed late, i.e. when a technology has already been devel-
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oped and brought to market. In the ideal situation, HTA is an iterative process that takes 
place alongside the development of new health care technologies, starting before a technol-
ogy’s development and continuing throughout its life (figure 1)[11, 12].
In the pre-development stage, a technology is not yet under development, and generally 
only limited evidence is available. In this stage, very early HTA can be informative for prod-
uct development decision-making. Evidence on current clinical practice allows for identify-
ing and monetarily valuing the potential improvement that a new technology might yield 
as compared to current practice (effectiveness-gap). Combining this with the technology’s 
expected downstream costs (headroom analysis) allows for determining the technology’s 
maximum ceiling price and for calculating the return on investment of the product. If the 
expected return on investment is sufficient to cover the costs of the new technology, fur-
ther development might be worth undertaking. On the other hand, if the costs exceed the 
maximum ceiling price of the product, one might rather channel investments towards more 
promising technologies[11-13]. 
Once a positive development decision has been made, a technology enters the develop-
ment stage. In this phase some evidence on costs and effectiveness becomes available, al-
lowing for early HTA, such as iterative decision modelling. These early evaluations are used 
for decision-making on the market access of the technology. 
At the post-market stage, a technology has been developed and brought to market. In 
this phase additional cost and effectiveness data become available from clinical studies. 
This allows for health economic evaluations to inform reimbursement decision-making by 
third-party payers, including whether and how to pay for a new intervention for different 
groups of patients that may benefit from the technology to varying degrees[14]. 
In practice however, HTA suffers from the problem that by the time the technology is as-
Figure 1. The iterative HTA process
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sessed, it is often already used in clinical practice, as decision-makers have to make timely 
decisions regarding development and coverage of new technologies, long before economic 
and effectiveness data become available[15]. This is also the case for NGS. Although only 
little cost-effectiveness evidence on NGS is available, TGP, WES, and WGS are increasingly 
being used[16]. Once technologies have diffused into clinical practice, it is difficult to dis-
card them, regardless the HTA results. In the case of NGS this can be illustrated by the fact 
that in the cost-effectiveness study in chapter 7, neurologists already seem to refrain from 
conventional genetic testing in the standard diagnostic pathway, as they believe in the value 
of WES. This delay in evaluation is likely to result in a suboptimal allocation of health care 
resources and consequently in suboptimal health care. 
Recommendations for the use of NGS in clinical practice
An important result of this thesis is the quantification of the real costs of three NGS appli-
cations: TGP, WES and WGS. We showed that TGP (€333) and WES (€792) are considerably 
lower-cost alternatives to WGS (€1,669). Decision-makers and clinicians should be aware of 
this. The decision on whether or not to use NGS, and which NGS approach to use should 
be based on a careful trade-off between costs, sequencing quality, the effectiveness of the 
test, and the consequences for the patient. The transparent and transferable per-sample 
costs provided in this thesis are adaptable to laboratory-specific conditions, and should be 
used as input of future cost-effectiveness analyses, and thereby contribute in making such 
trade-offs. 
NGS technologies are applied in numerous disease contexts and patient populations, e.g. 
gene panels for disorders with limited genetic heterogeneity such as cardiomyopathies or 
hereditary hearing loss, and WES/WGS in more extremely heterogeneous disorders asso-
ciated with more non-specific clinical symptoms, such as autism, intellectual disability or 
CPN[17, 18]. Being valuable in one context does not mean NGS is (equally) valuable in all its 
applications[19]. This is something that should be kept in mind before acquiring expensive 
equipment and implementing a technology into clinical practice, based on the cost-effec-
tiveness of one of a technology’s possible applications. As the initial acquisition investment 
for a technology is made at the hospital-level, a hospital wide HTA of the technology, taking 
into account all its possible applications, is valuable for deciding whether to implement the 
technology into clinical practice, and for which indications it should or should not be used.  
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Regarding the place in the diagnostic trajectory of CPN, this thesis showed that WES pro-
vides most value for money if not used as a last-resort test, but rather early in the diagnostic 
trajectory, and potentially as a first-tier test. Applying WES as an add-on test, when many 
conventional diagnostic testing has already been performed, resulted in an ICER of €8,950 
per additional diagnosis. On the contrary, performing WES as a first-tier test might result 
in cost savings. Paediatricians should be aware of the fact that WES is more likely to be 
cost-effective when applied earlier in the diagnostic trajectory. Also in hospitals without 
NGS services, physicians should consider WES as an alternative to sequential genetic testing 
for patients without clear symptoms. However, they should keep in mind that for patients 
with non-complex problems, for whom a diagnosis can be established with a minimum of 
conventional diagnostic testing, WES may be cost-increasing. This thesis showed that the 
application of WES as a first-tier test is only justifiable if at least 30% of all paediatric neurol-
ogy patients have complex disorders. In our tertiary clinic, this percentage is >80%, making 
WES worthwhile to implement. 
With regard to HRQoL, chapter 3 showed that, although parental SF-6D utility scores were 
normal, parental mental HRQoL was diminished as compared to the general Dutch popu-
lation. This study also demonstrated that 11% of the parents presented with pathological 
worry. Paediatricians should be aware of this, as parental mental health is known to influ-
ence the health of their children. Therefore, to prevent additional parent and patient HRQoL 
problems, it is important that parental health problems are detected timely, and that sup-
portive care is provided if needed.
Although this thesis focused on cost-effectiveness of NGS technologies, HTA has a broader 
perspective, including also social, legal and ethical aspects of the use of health technologies. 
In this light, a number of challenges around the implementation of NGS technologies into 
clinical practice should be mentioned. 
First, in clinical WES and WGS there is the potential of incidental findings (IFs), which are 
mutations that are not related to the indication for requesting the genome-wide test, but 
that may nonetheless be of (medical) value to the patient[20]. Regarding the report of such 
IFs, competing interests may arise. On the one hand there is the patient’s right not to know, 
i.e. the patient may decide for himself whether or not to receive genetic information on 
(the risk for) a disease, which is not the primary reason for which the sequencing was or-
dered[21]. On the other hand, there is the clinician who has the duty not to do intentional 
harm. What complicates it even more, is the fact that genetic testing does not only provide 
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information on the patient’s health, but potentially also on the health of family members. 
As NGS technologies are being increasingly used in clinical applications, the need for clear 
guidelines for reporting IFs increases. Recommendations of the American College of Medical 
Genetics and Genomics (ACMG) on this topic call for genetic laboratories to actively search 
for a delineated list of pathogenic variants for disorders for which preventive measures and/
or treatments are available, and disorders in which individuals with pathogenic mutations 
might be asymptomatic for long periods of time. They state that IFs in one of these variants 
should be reported, regardless the indication for which the sequencing was ordered, patient 
preferences or the age of the patient, and without informed consent[20]. Although this can 
be seen as a violation of the patient’s right not to know, the ACMG argues that a patient 
may still decide not to undergo sequencing at all, and stresses the importance of adequate 
pre- and post-test genetic counselling.  
Another issue in routine application of genomic diagnostics is genomic privacy. Roughly, 
there are two main threats in this field. First, there is the risk of loss of donor anonymity, 
which concerns the de-identification and aggregation of the genomic data. Recent research 
already showed that re-identification of DNA donors from a public database or publications 
is feasible[22]. Second, there is a risk of data leaks. Additionally,  the genomes of two related 
individuals are highly similar. Hence, the disclosure of a person’s genome can leak genom-
ic information about that person’s relatives[22]. Another key issue is how, how long, and 
where genomic data are stored, and who has access to it[23, 24]. 
Recommendations for future research
Regarding the timing of evaluation, in order to prevent suboptimal resource allocation, eval-
uation should preferably be performed in an earlier stage, before implementation into clin-
ical practice. The need for early HTA goes together with a need for development of better 
methods and tools for the early assessment of new technologies to improve decision-mak-
ing and thereby health care. 
With regard to the rapid technical and cost developments in the field of NGS, it has to be 
stressed that HTA should be an iterative process which continues also after clinical imple-
mentation. NGS has proven to be a valuable diagnostic tool already, and may become even 
more valuable as more knowledge on disease causing genetics becomes available over time. 
Moreover, sequencing costs have substantially decreased over the last years and might con-
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tinue to fall. Therefore, the cost-effectiveness of NGS might increase. It should be kept in 
mind that this complicates the comparison of cost-effectiveness analyses over time. There-
fore, additional research into the technical and cost developments of NGS technologies over 
time might be valuable to provide insight in potential future cost-effectiveness. 
Another important area for future research concerns the valuation of a technology. Health 
economic evaluations preferably measure the effectiveness of a technology in terms of clin-
ical utility expressed in QALYs. Unfortunately, our study design did not allow for a compari-
son of HRQoL between the conventional diagnostic pathway and WES. However, an interest-
ing topic for future research would be the valuation of the impact of a diagnosis on HRQoL 
by the completion of a generic HRQoL instrument (e.g. EQ-5D, SF-36 or HUI) both before 
and after a diagnosis is received. This would preferably be performed in a prospective study, 
including new patients who did not yet undergo a diagnostic Odyssey.
Besides medical value (i.e. HRQoL), which is derived from the medical treatment that fol-
lows the diagnostic result, diagnostics may have valuable non-health effects. Lee et al. iden-
tified two non-health dimensions of value for diagnostics, i.e. psychic, or wellbeing value, 
and planning value[25]. The wellbeing value captures the change of a patients’ sense of 
satisfaction as a result of diagnostics. Possible valuable results of a diagnosis that may posi-
tively influence a patients’ wellbeing are the provision of a label or prognostic information, 
reduction of uncertainty, accepting and coping with the disease, and access to social ser-
vices[26-28]. On the other hand, disclosure of a diagnosis may also result in loss of hope, 
and particularly in genetics, parental feelings of (self-)blame may play a role[27, 29]. In a 
different, but related part of our research project, the psychosocial effects of WES test re-
sults on parents of CPND patients was evaluated[27]. This study showed that a conclusive 
diagnosis indeed enabled parents to accept and cope with the disease. On the other hand, 
parents receiving negative WES results were found to alternate between accepting that they 
had to continue their lives with the etiologic uncertainty, and still longing for a continuation 
of clinical research towards a diagnosis[27].
Planning value includes patients’ choices on work, life-style and other life decisions as a 
consequence of a diagnostic result[25]. Particularly important in genetic testing, is family 
planning. Moreover, a conclusive WES diagnosis may help parents with attuning care facili-
ties and activities more closely to the needs of their child[27]. 
Additionally, some other aspects play a role in genetic testing. First, health economic evalu-
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ations typically measure the effect of a technology only for the affected individual. However, 
genetic diagnostic results provide information, not only for the affected individual, but also 
for family members. Therefore, spill over effects may play an important role in genetic test-
ing, and might be relevant to include in economic evaluation. Second is the value of innova-
tion. Innovation may be sped up by taking smaller incremental steps. Use of the intermedi-
ate technology, also if not cost-effective, makes it more likely that competitors will continue 
to progress on further improvements in health. For example, in the case of NGS, clinical 
use of WGS might currently not be cost-effective. However, the clinical use of WES might 
result in increased knowledge on the genetics behind diseases. Together with technological 
advances over time, this might increase the effectiveness of WGS and thereby also increase 
its cost-effectiveness. Additionally, WES is currently often performed in combination with an 
array, as some mutation that can be found with an array, are not detected by WES. In this 
case, WGS should be compared to the combination of WES and array. 
Third, in the case of NGS, besides being used as a diagnostic test, the technology also has 
a research application. The implementation of WGS in clinical practice would result in a 
furthering of our understanding of genetic diseases and may eventually contribute to the 
development of targeted (gene) therapies[30-32]. More research is however needed to de-
termine whether and how these non-health effects, spill over effects, and innovation and 
research value should be considered in a standard HTA. 
With regard to the choice of NGS application, as WGS is currently still more expensive than 
WES, research is needed to determine the added value of WGS in diagnostic applications 
compared to WES. Recent studies, comparing both strategies by sequencing the DNA of pa-
tients with both WES and WGS showed that both technologies perform well for the detec-
tion of SNVs and indels, but that WGS is more appropriate for detecting CNVs and mutations 
in GC-rich exons, due to technical limitations of WES[33-35]. The added value of WGS in CPN 
could be determined by resequencing the DNA of the 150 patients in our studies with WGS 
and comparing its diagnostic results with WES.
Concluding remarks
In conclusion, WES has proven to be a valuable diagnostic test in CPND in terms of diagnostic 
yield. However, in current clinical practice, when extensive diagnostics have already been 
performed, WES appeared also cost-increasing. Whether WES is deemed cost-effective, de-
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pends on the WTP for an additional diagnosis. 
The health economic evaluation of genomics, including WES, appeared not without chal-
lenges. Besides the valuation of intermediate outcomes and non-health effects, timing of 
evaluation is an issue. Ideally, evaluation should start very early, before an intervention is 
developed, to ensure resource allocation towards those interventions that provide most 
value for money. However, in a very early stage, generally little evidence is available. As 
a result, very early HTA appeared useful as a no-go decision-making tool, rather than for 
go-decision-making. Eventually, the evaluation of WES took place when it was already im-
plemented into clinical practice and clinical evidence became available. This is suboptimal 
as a technology that has been diffused into clinical practice is difficult to dismiss, regardless 
the HTA results.
Unlike WES, WGS is not yet routinely used in clinical practice. Therefore, research should 
now focus on the evaluation of WGS rather than WES, to provide a health economic evi-
dence to guide the decision-making on clinical implementation.
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Summary
About 3 - 4% of children in high-income countries suffer from neurodevelopmental condi-
tions. A considerable percentage of paediatric neurology patients seen in university hospi-
tals are referred for complex neurological disorders. These are disorders for which extensive 
diagnostic testing is required in order to find a definitive diagnosis as a result of 1) genetic 
heterozygosity; 2) complicated symptoms which may be caused by multiple genes; or 3) 
a changing clinical presentation over time. Ergo, these patients undergo lengthy and re-
source-intensive diagnostic trajectories, while definitive diagnoses are established for only 
for a minority of them.
A promising medical field that is rapidly evolving is the field of next-generation sequencing 
(NGS) technologies. These are genomic diagnostics which allow for massive and quick DNA 
sequencing. One of these technologies is whole exome sequencing (WES), which allows for 
sequencing a patient’s entire protein-coding region, i.e. all genes, simultaneously.
 As the majority of complex paediatric neurological disorders (CPND) are of a suspected 
genetic origin, the implementation of WES is expected to improve this diagnostic trajectory 
considerably by increasing diagnostic yield and lowering the time to diagnosis for these 
patients. However, it might also increase health care costs. This thesis focuses on the health 
technology assessment (HTA) of NGS technologies. This is illustrated by the case of whole 
exome sequencing in complex paediatric neurology (CPN). 
Part one
The first part of this thesis focused on the current diagnostic trajectory of CPN, with regard 
to diagnostic yield, health care resource use, and health-related quality of life (HRQoL). 
In chapter 2 the conventional diagnostic trajectory of CPN was assessed in terms of diagnos-
tic yield, healthcare resource use, and associated costs. Patients who were included were 
children (<18 years) presenting with complex neurological disorders of suspected genetic 
origin. Healthcare resource use was retrospectively collected from the first visit in the uni-
versity hospital. The average diagnostic trajectory took at least 40 months, with patients 
making 15.55 physician visits, and undergoing 7.73 genetic tests; 4.46 imaging tests; 2.48 
neurophysiologic tests; and 15.08 other diagnostic tests. On average, this trajectory cost 
€12,475 per patient, with €5,321 being for genetic testing. Six percent of the patients re-
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ceived a definitive diagnosis. Overall, chapter 2 shows that the current diagnostic trajectory 
in CPN is lengthy, resource-intensive and low yield. Implementing WES in this trajectory 
might result in cost-savings, assuming that the costs of WES are €3,600, and that it substi-
tutes conventional genetic testing.
In chapter 3, HRQoL of parents of CPN patients was measured using the SF-12, and con-
verted to utility scores with the SF-6D algorithm. Additional questionnaires were used to 
measure parental uncertainty (Visual Analogue Scale), worry phenomena (Penn State Wor-
ry Questionnaire) and patient HRQoL (SF-12 by proxy), and to obtain socio-demographic 
variables. Both fathers and mothers of CPN patients showed diminished mental HRQoL as 
compared to the general Dutch population. Additionally, fathers also showed diminished 
physical HRQoL; whereas in mothers, physical HRQoL was normal. The reduction in mental 
HRQoL is alarming, because children strongly rely on their parents for care. Also, parental 
mental health is known to influence children’s health. A linear mixed model with random ef-
fect showed that patient HRQoL (as scored by their parents) and parental worry phenomena 
were significantly correlated with parental mental HRQoL. To prevent exacerbation of the 
HRQoL problems of both the patients and their parents, clinicians should be alert on signs of 
mental problems and parental worry, so that supportive care can be provided timely. 
Part two
The second part of this thesis comprises the HTA of WES in CPN, including both an early 
(chapter 4), and a late health economic evaluation (chapter 7). 
In chapter 4 the feasibility and usefulness of the headroom method in the early evaluation 
of technologies that are unlikely to result in QALY gain were determined. This was illustrated 
by evaluating the room for improvement, and the potential of WES in the diagnostic trajec-
tory of CPN. In terms of diagnostic yield, this evaluation showed a large room for improve-
ment in current clinical practice. Assuming a diagnostic yield of 6% in current practice, and a 
willingness-to-pay value of €95 per percentage point additional diagnostic yield resulted in 
an effectiveness gap of €8,930. Under optimistic circumstances, in which WES substitutes all 
conventional genetic tests and 25% of all physician contacts, a total headroom of €15,028 
exists. This indicates that WES might be a cost-effective technology in the CPN diagnostic 
trajectory if its costs do not exceed €15,028. Chapter 4 shows that headroom analysis is a 
feasible and useful tool in early health economic evaluation of diagnostic technologies, even 
when no immediate QALY gain is expected. Effectiveness gap calculation is informative on 
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the room for improvement in a certain disease area and allows for selecting the most prom-
ising concepts from a larger pool of options, for decision-making regarding investments in 
research and further development, and for calculating a maximum ceiling price to still be-
cost effective. Note however, that such an evaluation does not guarantee future cost-effec-
tiveness or reimbursement of a technology, as the headroom method is based on optimis-
tic assumptions rather than real-world evidence. Overall, the headroom method might be 
most valuable as a rule-out tool to avoid investment in technologies that are unlikely to be 
able to meet even the most generous criteria for cost-effectiveness.
Chapter 5 comprises a cost analysis of three clinical applications of next-generation se-
quencing (NGS), including besides WES, targeted gene panels (TGP) and whole genome 
sequencing (WGS). Although commercial parties claim that they are able to sequence an 
entire human genome for less than $1,000, a complete, and transparent cost overview was 
still lacking. We showed that nowadays a human genome can be sequenced for €1,669. 
These are the total costs for running the diagnostic test, from DNA extraction to data in-
terpretation, report and storage. Only in a best-case scenario analysis, which assumes very 
efficient and long-term use of the equipment, and 50% reductions in both equipment and 
consumable costs, do the costs of WGS approach €1,000, which is nowadays approximately 
$1,100. TGP (€333) and WES (€792) appeared considerably less expensive alternatives to 
WGS. This does not imply that these should be preferred in clinical practice, since the choice 
of NGS approach depends not only on its per-sample costs but also on its diagnostic yield, 
which defines its effectiveness. However, decision-makers should be aware of this, and care-
fully weigh the extra costs with the added benefits before implementing WGS as a standard 
diagnostic test in clinical practice. 
Chapter 6 describes a clinical utility study on WES in CPN. In this chapter we retrospectively 
analysed the diagnostic yield and health care resource use of 150 patients in both diagnostic 
trajectories, of whom 50 patients (retrospective cohort studied in chapter 2) underwent 
WES as a last-resort test. The other 100 patients (prospective cohort studied in chapter 7) 
were a mixed cohort consisting of patients who were newly referred by either a general 
practitioner or medical specialist, and patients who had been referred to our centre previ-
ously. This chapter shows that WES improves the diagnostic trajectory of CPN significant-
ly, increasing diagnostic yield from 7.3% to 29.3%. On average, the costs for the standard 
diagnostic pathway were €10,723 per patient, of which the genetic tests were the major 
cost driver (€4,173). In comparison, the average costs for WES-based genetic testing in this 
cohort were €3,420 per patient. Consequently, the application of WES as a first tier genetic 
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tests would in this patient cohort have resulted in cost savings of €753 per patient, if no 
additional costs for genetic testing were made after a negative WES diagnosis. An explorato-
ry analysis suggested that in 36 of 44 patients in whom WES led to a conclusive diagnosis, 
no additional (confirmatory) diagnostic tests would have been performed. The remaining 
eight patients would still have received additional (confirmatory) diagnostic tests, ranging 
from a single cerebral imaging test or metabolic investigation to all diagnostic work-up as 
performed before. Taking this into account, the average costs, were WES used as a first tier 
diagnostic test in our patient cohort, would have amounted to €8,401  per patient. There-
fore, chapter 6 suggests a change in clinical paediatric neurology practice towards WES as 
a first tier test in the diagnostic trajectory of patients presenting with complex neurological 
disorders of presumed genetic origin.
In chapter 7 the cost-effectiveness of WES in current CPN clinical practice is empirically ex-
amined. Health care resource use associated with the conventional diagnostic trajectory 
of 100 patients was measured prospectively, from inclusion in this study until a diagnosis 
was reached, or when no diagnosis was reached, one year after inclusion. As all patients 
underwent both the conventional diagnostic pathway and WES, the real costs of the WES 
trajectory could not be determined and were assumed to equal the costs of two physician 
visits and a WES trio. The primary effectiveness outcome was diagnostic yield of both tra-
jectories. In addition, to explore whether it would indeed be cost-saving to perform WES 
as a first-tier test, a model-based cost-effectiveness analysis (CEA) was performed with the 
retrospectively collected cost data (from the first hospital visit in our university hospital until 
a diagnosis was reached, or in absence of a diagnosis, one year after inclusion) of these pa-
tients. Chapter 7 again shows that WES increases diagnostic yield substantially, from 8% to 
30% in this patient population. The average costs of the conventional diagnostic trajectory 
of these patients were €1,883; when retrospectively collected costs were included, these 
amounted to €9,337. With an average cost of €3,809 in the WES trajectory, an incremental 
cost-effectiveness ratio (ICER) of €9,016 per additional diagnosis was found, for WES as an 
add-on test. Whether this is deemed cost-effective depends on the willingness-to-pay for 
an additional diagnosis. Implementing WES as a first-tier test on the other hand, might sub-
stitute a substantial amount of conventional diagnostics, and thereby result in cost savings. 
The model-based CEA showed that the application of WES as a first-tier test seems only 
justifiable if at least 28% of all paediatric neurology patients are complex ones. 
In chapter 8 the main findings of this thesis are summarized and discussed. Additionally, 
some methodological issues are considered. First it is questioned whether our parallel de-
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sign was the best study design. Although it allowed for a direct comparison of the diagnostic 
yield of both trajectories, direct comparisons of the costs and HRQoL could not be made. 
For these outcomes a trial design would have been a better option. Another issue was the 
study population. Two cohorts (n = 50 and n = 100, respectively) of patients were included. 
The cohort of 100 patients was planned to consist only of patients who were newly referred 
from either a general practitioner or a peripheral hospital. However, this appeared difficult 
to accomplish in such a short time span, resulting in a mix of newly referred patients and 
patients who were already known in the university hospital. Although being more represen-
tative for clinical practice, this distorted the prospective cost-effectiveness analysis, as most 
patients already underwent multiple diagnostic tests before inclusion in this study. 
Furthermore, a number of recommendations in are given in chapter 8. Besides the recom-
mendations that are directly based on the study results, it is recommended to evaluate 
all possible applications of a technology before deciding on clinical implementation. Being 
valuable in one disease context does not automatically mean that it is (equally) valuable in 
all its applications. Also it is recommended to come up with guidelines around the use of 
NGS. Several issues that should be covered before NGS is routinely used in clinical practice 
are 1) the return of incidental findings (who decides which findings to report); 2) the right 
to know versus the right not to know (genetic testing provides information not only on the 
patient’s health, but potentially also on the health of his family members); and 3) genomic 
privacy (how and how long is genomic data stored, and who has access to it?). Regarding 
research, an important topic is the valuation of technologies. Health economic evaluations 
preferably consider effectiveness in terms of utilities, expressed in QALYs. However, for di-
agnostics, and particularly genomics, QALYs might not be a suitable effectiveness measure. 
Therefore, more research is needed on the valuation of non-health effects resulting from 
a technology. The same goes for the innovation value and research value of technologies. 
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Samenvatting
Naar schatting hebben zo’n 3 tot 4% van alle kinderen in hoge-inkomenslanden te kampen 
met een ontwikkelingsachterstand. Een groot percentage van alle kinderneurologische pa-
tiënten die gezien worden in academische ziekenhuizen, zijn daarheen verwezen in verband 
met een complexe aandoening. Hieronder vallen aandoeningen waarvoor uitgebreide diag-
nostiek vereist is om tot een definitieve diagnose komen, doordat 1) genetische heterogen-
iteit een rol speelt; 2) er sprake is van niet-specifieke symptomen die veroorzaakt kunnen 
worden door multipele gendefecten; of 3) een klinische presentatie die verandert over de 
tijd. Deze patiënten ondergaan doorgaans langdurige en dure diagnostische trajecten, en 
een definitieve diagnose wordt slechts voor de minderheid van hen vastgesteld.
Er vinden veelbelovende ontwikkelingen vinden plaats op het gebied van next-generation 
sequencing (NGS) technologieën. Dit zijn genomische technologieën die ons in staat stellen 
op grote schaal en met hoge snelheid DNA sequenties te bepalen. Eén van deze technolo-
gieën is whole exome sequencing (WES), een techniek die in één keer het volledige eiwitco-
derende deel (d.w.z. alle genen) van een individu in kaart brengt. 
Omdat de meerderheid van alle complexe kinderneurologische aandoeningen (CKA) een 
vermoedelijke genetische oorzaak heeft, bestaat de verwachting dat WES het diagnostisch 
traject van deze patiënten aanzienlijk zal verbeteren in termen van diagnostische opbrengt 
(aantal diagnoses) en de tijd tot het stellen van een diagnose. De focus van dit proefschrift 
ligt op de health technology assessment (HTA; de evaluatie van nieuwe interventies in de 
gezondheidszorg) van NGS technologieën. Dit wordt geïllustreerd aan de hand van WES in 
de klinische praktijk van CKA.
Deel 1
In het eerste deel van dit proefschrift ligt de focus op diagnostische opbrengt, zorggebruik 
en kwaliteit van leven in het huidige diagnostische traject in CKA. In hoofdstuk 2 zijn de 
diagnostische opbrengst, het zorggebruik en de bijbehorende kosten in dit traject gemeten. 
Geïncludeerde zijn kinderneurologische patiënten (<18 jaar) met complexe neurologische 
aandoeningen van vermoedelijk genetische oorsprong. Zorggebruik van deze patiënten 
werd retrospectief verzameld vanaf het eerste bezoek aan het Radboud universitair me-
dische centrum. Het gemiddelde diagnostische traject duurde tenminste 40 maanden, om-
vatte 15,55 polikliniek bezoeken; 7,73 genetische testen; 4,46 beeldvormende medische 
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onderzoeken; 2,48 neurofysiologische onderzoeken; and 15,08 andere diagnostisch testen. 
De gemiddelde kosten van dit traject waren €12.475 per patiënt, waarvan €5.321 voor ge-
netische testen was. Voor zes procent van deze patiënten werd een diagnose gesteld. Hoofd-
stuk 2 laat zien dat het huidige diagnostische traject in CKA langdurig is, veel zorggebruik 
kent, en een lage diagnostische opbrengst heeft. In de veronderstelling dat WES €3.600 kost 
en het de conventionele genetische diagnostiek vervangt, zou de klinische implementatie 
van WES in dit traject tot kostenbesparingen kunnen leiden.
In hoofdstuk 3 is de gezondheidseisgerelateerde kwaliteit van leven (KVL) van de ouders van 
CKA patiënten gemeten. Dit is gedaan met behulp van de SF-12 vragenlijst. Daarnaast heb-
ben ouders vragenlijsten ingevuld over gevoelens van onzekerheid (Visual Analogue Scale), 
hun neiging tot bezorgdheid (Penn State Worry Questionnaire), de kwaliteit van leven van 
hun kind (SF-12 proxy), en een aantal sociodemografische en socio-economische variabel-
en. Zowel bij vaders als bij moeders werd een verlaagde mentale KVL gevonden, in vergeli-
jking met de algemene Nederlandse bevolking. Daarnaast lieten vaders ook een verlaagde 
fysieke KVL zien; bij moeders bleek deze niet verlaagd. De gereduceerde mentale KVL is 
zorgwekkend, aangezien kinderen voor hun zorg afhankelijk zijn van hun ouders. Bovend-
ien is bekend dat de mentale gezondheid van de ouders de gezondheid van hun kinderen 
beïnvloedt. Een lineair mixed model met random effect liet zien dat de mentale KVL van de 
ouders negatief gecorreleerd was met hun neiging tot bezorgdheid en positief gecorreleerd 
met de KVL van hun kind (gescoord door de ouders zelf). Om verslechtering van de KVL van 
de patiënten en ouders te voorkomen, zouden artsen alert moeten zijn op signalen die kun-
nen wijzen op mentale problemen en bezorgdheid bij de ouders. Op die manier kan de juiste 
ondersteunende zorg in een vroeg stadium geboden worden.
Deel 2
Het tweede deel van dit proefschrift omvat de HTA van WES in CKA. In hoofdstuk 4 wordt 
onderzocht of de headroom methode een bruikbare tool is in de vroege evaluatie van tech-
nologieën die waarschijnlijk niet tot QALY winst zullen leiden. Ter illustratie zijn de ruimte 
voor verbetering en de potentiële waarde van WES in het diagnostische traject van CKA bep-
aald aan de hand van deze methode. Wat betreft diagnostische opbrengst werd een grote 
ruimte voor verbetering gevonden. Uitgaande van een diagnostische opbrengst van 6% in 
de huidige praktijk, en een bereidheid tot betalen van €95 per procentpunt toename in diag-
nostische opbrengst, werd een effectiveness gap van €8,930 gevonden. In het optimistische 
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scenario, waarin WES alle conventionele genetische diagnostiek plus 25% van de polikliniek 
bezoeken zou vervangen, resulteert dit in een totale headroom van €15.028. Dit impliceert 
dat WES in het diagnostische traject van CKA kosteneffectief zou kunnen zijn zo lang het 
niet duurder is dan €15.028. Hoofdstuk 4 laat zien dat de headroom methode bruikbaar en 
nuttig is als tool voor de vroege evaluatie van diagnostische technologieën, zelfs wanneer er 
geen sprake is van direct QALY winst. Het berekenen van de effectiveness gap geeft inzicht 
in de ruimte voor verbetering en kan nuttig zijn bij de selectie van de meest veelbeloven-
de concepten uit een grotere pool van ideeën, voor besluitvorming over investeringen in 
onderzoek en ontwikkeling van technologieën, en voor het berekenen van een plafondprijs 
waartegen een technologie nog kosteneffectief kan zijn. Aangezien de headroom methode 
gebaseerd is op optimistische aannames garandeert deze methode overigens geen toekom-
stige kosteneffectiviteit dan wel vergoeding van een technologie. De headroom methode is 
dan ook het meest waardevol als tool om no-go beslissingen te maken, om investeringen in 
technologieën die zelfs onder de meest gunstige omstandigheden niet kosteneffectief zullen 
zijn te voorkomen.
Hoofdstuk 5 omvat een kostenanalyse van drie klinische toepassingen van NGS, waaronder 
WES, targeted gene panels (TGP) en whole genome sequencing (WGS). Hoewel commer-
ciële partijen claimen een volledig humaan genoom te kunnen sequencen voor minder dan 
$1.000, is een compleet en transparant kostenoverzicht voor NGS technieken niet voor-
handen. Onze kostenanalyse laat zien dat het sequencen van een humaan genoom €1.669 
kost. Deze kostprijs omvat alle kosten voor de diagnostische test, van DNA extractie tot data 
interpretatie, -rapportage, en -opslag. Deze resultaten laten dus zien dat het felbegeerde 
$1.000 nog geen werkelijkheid is. Alleen in het meest gunstige scenario, waarin apparatuur 
langdurig en efficiënt gebruikt wordt, en waarin de kosten voor apparatuur en verbruiks-
goederen met 50% dalen, nadert de prijs voor WGS €1.000, wat overeenkomt met zo’n 
$1.100. TGP (€333) en WES (€792) bleken aanzienlijk goedkopere alternatieven voor WGS. 
Dit betekent niet dat hier in de kliniek de voorkeur naar uit moet gaan; de keuze voor welke 
NGS technologie wordt ingezet hangt immers niet alleen af van de kosten, maar ook van de 
opbrengsten van de technologie. Desalniettemin zullen besluitvormers zich bewust moeten 
zijn van deze prijsverschillen, en de extra kosten zorgvuldig moeten afwegen tegen de extra 
opbrengsten, alvorens WGS als standaard diagnosticum geïmplementeerd wordt. 
In hoofdstuk 6 wordt een studie naar de klinische bruikbaarheid van WES in CKA beschreven. 
In deze studie zijn de diagnostische opbrengst en het zorggebruik van 150 patiënten geme-
ten, in zowel het huidige diagnostische traject als met WES. Bij 50 patiënten werd WES als 
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“laatste redmiddel” ingezet (retrospectief cohort uit hoofdstuk 2). De andere 100 patiënten 
(prospectief cohort uit hoofdstuk 7) waren een gemixt cohort, bestaande uit patiënten die 
nieuw waren doorverwezen door een huisarts of vanuit een ander ziekenhuis, en patiënten 
die al in het Radboud universitair medisch centrum bekend waren. Deze studie laat zien 
dat de implementatie van WES de diagnostische opbrengst onder CKA patiënten aanzienlijk 
verhoogt, van 7,3% naar 29,3% De kosten in het huidige diagnostisch traject waren gemid-
deld €10.723 per patiënt. De grootste kostenpost werd gevormd door de genetische testen 
(€4.164). De kosten voor WES bedroegen gemiddeld €3.420 per patiënt. Zou WES in dit tra-
ject als eerste genetische test zijn ingezet, dan zou dit dus tot kostenbesparingen van €753 
per patiënt geleid kunnen hebben, aangenomen dat na een negatieve WES diagnose geen 
andere genetische testen meer zouden worden gedaan. Een exploratieve analyse sugger-
eerde dat 36 van de 44 patiënten met een positieve WES diagnose na WES geen diagnostiek 
meer zouden ondergaan. De andere acht patiënten zouden nog wel extra (bevestigende) di-
agnostische testen ondergaan, variërend van één cerebraal MRI-onderzoek of een metabool 
onderzoek tot het volledige traject zoals in de huidige praktijk. Dit meenemende zouden de 
gemiddelde kosten, zou WES als eerste diagnostische test zijn ingezet, €8,401  per patiënt 
hebben bedragen. Concluderend suggereert hoofdstuk 6 een verandering van de klinische 
praktijk, waarbij WES als eerste test wordt ingezet in het diagnostische traject van CKA pa-
tiënten bij wie een genetische oorzaak wordt vermoed. 
Hoofdstuk 7 behelst een empirische kosteneffectiviteitsanalyse van WES in de huidige klin-
ische CKA praktijk. Van 100 patiënten zijn zorggebruik en bijbehorende kosten prospectief 
gemeten, van het moment van inclusie in deze studie tot het moment dat een diagnose 
werd gesteld, of wanneer er geen diagnose werd gesteld, tot één jaar na inclusie. Alle pa-
tiënten hebben zowel het conventionele diagnostisch traject als WES ondergaan. Daarom 
konden de echte kosten van het WES traject niet bepaald worden. Deze zijn geschat overeen 
te komen met de kosten van 2 polikliniek bezoeken en een WES trio. De primaire effectivite-
itsmaat was de diagnostische opbrengt van beide trajecten. 
Om te bepalen of het gebruik van WES als eerste diagnostische test in deze patiëntenpop-
ulatie inderdaad kostenbesparend zou zijn, hebben we tevens een exploratieve kostenef-
fectiviteitsanalyse (model-based) uitgevoerd met behulp van retrospectief verzamelde 
kostendata van deze patiënten (van het eerste polikliniek bezoek in het Radboud universitair 
medisch centrum totdat een diagnose werd gesteld, of in afwezigheid van een diagnose, 
een jaar na inclusie). Hoofdstuk 7 laat wederom zien dat WES de diagnostische opbrengst 
in deze patiëntpopulatie aanzienlijk verhoogt (van 8% naar 30%). De kosten van het huidige 
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traject waren gemiddeld €1.883 per patiënt; wanneer de retrospectief verzamelde kosten 
ook werden meegenomen waren de kosten gemiddeld €9.337. Het WES traject daarente-
gen, kostte gemiddeld €3.809. Dit resulteert in een incrementele kosteneffectiviteitsratio 
(IKER) van €9.016 per additioneel gestelde diagnose, zou WES als add-on test worden toege-
past. Of dit als kosteneffectief wordt beschouwd is afhankelijk van de bereidheid tot betalen 
voor een additionele diagnose. 
Zou WES als eerste diagnostische test worden ingezet, dan zou deze een substantieel deel 
van de conventionele diagnostiek kunnen vervangen, en zodoende in kostenbesparingen 
resulteren. Onze exploratieve analyse laat zien dat dit alleen het geval is wanneer tenminste 
28% van alle kinderneurologische patiënten complexe neurologische aandoeningen heb-
ben.
In hoofdstuk 8 worden de belangrijkste resultaten uit dit proefschrift samengevat en be-
discussieerd. Daarnaast worden enkele methodologische kwesties besproken. Ten eerste 
de vraag of onze parallelle studieopzet de beste opzet voor deze studies was. Hoewel deze 
studieopzet ons in staat stelde de diagnostische opbrengst van beide trajecten direct te 
vergelijken, konden vergelijkingen van kosten en KVL niet worden gemaakt. Voor deze uit-
komsten was een trialopzet beter geweest. Een andere kwestie was de studiepopulatie. Er 
werden voor de studies in dit proefschrift twee cohorten (n=50 en n=100, respectievelijk) 
van patiënten geïncludeerd. De planning was dat het cohort van 100 patiënten volledig uit 
nieuw doorverwezen (vanuit de huisarts of een perifeer ziekenhuis) patiënten zou besta-
an. Echter, dit bleek niet haalbaar in het korte tijdsbestek dat we hadden voor inclusie. Als 
gevolg bestond het cohort uit een mix van nieuw verwezen patiënten en patiënten die al 
langer in ons ziekenhuis bekend waren. Hoewel dit wel representatiever is voor de klin-
ische praktijk, heeft dit tot vertekening geleid in de prospectieve kosteneffectiviteitsanalyse, 
aangezien de meeste patiënten al meerdere diagnostische testen had gehad voor inclusie 
in deze studie. 
Tot slot worden in hoofdstuk 8 een aantal aanbevelingen gedaan. Naast de aanbevelingen 
die direct gebaseerd zijn op onze studieresultaten, wordt aanbevolen dat bij de evaluatie van 
een technologie alle mogelijke toepassingen van deze technologie meegenomen worden. 
Het feit dat een technologie waardevol is in één context wil nog niet automatisch zeggen dat 
deze ook (evenzo) waardevol is in andere toepassingen. Ook wordt benadrukt dat er richt-
lijnen moeten worden opgesteld omtrent het gebruik van NGS technologieën. Een aantal 
issues die daarin in ieder geval naar voren moeten komen zijn 1) toevalsbevindingen (wie 
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bepaalt welke toevalsbevindingen aan de patiënt gerapporteerd worden?); 2) het recht om 
iets te weten versus het recht om iets niet te weten (genetische testen leveren niet alleen 
informatie op over de gezondheid van de patiënt, maar potentieel ook over de gezondheid 
van zijn familieleden); en 3) genomische privacy (hoe, en hoe lang wordt genomische data 
opgeslagen, en wie heeft daar dan toegang toe?).                    
Wat betreft wetenschappelijk onderzoek is de valuering van technologieën een belangrijk 
punt. Bij voorkeur wordt in gezondheidseconomische evaluaties de effectiviteit van een in-
terventie uitgedrukt in QALYs. Voor diagnostische, en met name genomische technologieën, 
zouden QALYs echter wel eens een ongeschikte uitkomstmaat kunnen zijn. Daarom is meer 
onderzoek nodig naar de waardering van de effecten, anders dan gezondheid, van technol-
ogieën. Dit behelst ook de waarde voor onderzoeksdoeleinden en innovatie. 
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Dankwoord
Zo, het zit er op! Dit was het dan, 3 jaar werk netjes bij elkaar tot één boekje gebundeld. En 
ik kan niet anders zeggen dan dat mijn periode als PhD’er een ontzettend mooie was! Ik heb 
genoten van de leuke collega’s, de sociale activiteiten, en wat heb ik in korte tijd veel geleerd 
zeg! Vijf minuten voor het sollicitatie gesprek nog even gegoogled wat het ook weer precies 
was dat HTA, en nu ligt er gewoon een afgerond proefschrift! Wow! Maar een proefschrift 
schrijven, dat doe je niet alleen. Ik wil dan ook iedereen die op welke wijze dan ook heeft 
bijgedragen aan dit proefschrift bedanken, en een aantal mensen in het bijzonder.
Promotieteam
Allereerst Janneke, ik had me geen betere begeleider kunnen wensen! Vanaf het begin van 
mijn promotietraject heb je me het volste vertrouwen gegeven dat dat boekje wel goed zou 
komen. Ik heb ontzettend veel van je geleerd, en kon altijd bij je terecht als ik vast zat of even 
snel wilde overleggen. Ik vond het een hele relaxte manier van samenwerken, en kan alleen 
maar hopen in mijn nieuwe werkomgeving meer mensen als jij tegen te komen! 
Lisenka, stiekem heb ik toch ook wel heel wat uurtjes op jouw kamer doorgebracht. En dat is 
maar goed ook, want jouw genetische kennis was onmisbaar voor het tot stand komen van 
dit proefschrift! Toen je gevraagd werd om deel uit te maken van het promotieteam was je 
direct enthousiast, en in de afrondende fase heb je me met de laatste dingetjes uit de brand 
geholpen. Super fijn!
Gert Jan, bedankt dat je mijn promotor wilde zijn. Na alles wat ik al van je geleerd heb de 
afgelopen jaren, zijn er nog 2 dingen waarin ik zo goed in hoop te worden als jij: 1) het 
schrappen van hele lappen tekst, zonder ook maar iets aan boodschap te verliezen; 2) het 
maken van de perfecte carbonara. Ik heb ‘m nooit geproefd, maar ik heb je horen zeggen 
dat je de beste maakt, en ik verre van, dus tja... dit lijkt mij een goede gelegenheid om dat 
recept te delen, toch? ;)
Michel, een kinderneuroloog kon natuurlijk ook niet ontbreken in de promotiecommissie. 
Als 2e promotor heb je, ondanks je drukke schema, in alle papers gecheckt of alles klinisch 
wel in orde was. Dank daarvoor!
Leden van de manuscriptcommissie, jullie wil ik graag bedanken voor al het werk dat jullie 
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steken in het lezen (en goedkeuren!) van dit proefschrift, en in de voorbereiding van de 
verdediging. Verder wil ik alle co-auteurs van de artikelen in dit proefschrift bedanken voor 
hun input.
Collega’s 
Eén van de belangrijkste dingen op werk is toch wel de sfeer. En het is geen geheim dat dat bij 
de afdeling HEV wel snor zit! Ik heb genoten van de koffiepauzes, lunchwandelingen, de ge-
zelligheid op de “derde”, en alle sociale activiteiten buiten werktijd: bowlen en wijnproeven 
met de SOA, bbq’s, PhD diners, RIP-etentjes, pubquizzen, fietsweekenden, promotiefeesten, 
en stapavondjes (al dan niet met de SOA pot  op zak, sorry nog daarvoor Hans! xD).
In die paar jaar op de afdeling heb ik verschillende kamergenoten gehad: Ik begon in kamer 
3.10, met Lotte die mij wegwijs maakte op de afdeling. Al snel degradeerde ik echter met 4 
niveaus naar de kelder. 
Gelukkig moest Ralph datzelfde lot ondergaan, en zijn tijd met mij op één kamer doorbren-
gen. Ralph, ik heb me de pleuris gelachen met je! We bleken dezelfde foute muzieksmaak 
te delen, evenals een ondermaats gevoel voor humor. Foute muziekuurtjes werden al gauw 
foute muziek-vrijdagmiddagen, the best of 9-gag werd ruimschoots gedeeld, en toen we op 
congres en vakantie gingen in de VS bleken we ook nog eens even erge vliegtuig-nerds, en 
besloten we op de terugweg niet direct, maar via Parijs te vliegen, omdat we dan met een 
A380 konden. 
Na 1,5(?) jaar verhuisde ik terug naar mijn oude kamer op de derde verdieping en werd ik 
kamergenoot van Tessel en Daniëlle, later Annemiek, Dagmar, Romy en Anouck. Ik wil jullie 
via deze weg allemaal bedanken voor de gezelligheid! Hoewel we het er al vaak over gehad 
hebben, was er toch echt een collega met een auto (nice Anouck!) voor nodig om eindelijk 
eens wat kamerversiering te regelen in de vorm van planten, die het deels wel en helaas ook 
deels niet overleefd hebben.  
Naast kamergenoten, zijn er nog een aantal collega’s die ik hier graag wil noemen. Richelle, 
wij begonnen in dezelfde week bij HEV, en konden dus in het begin een beetje bij elkaar 
afkijken wat er allemaal van ons verwacht werd. Je was een erg gezellige, en sociale collega, 
altijd in voor iets leuks! Ellen, wij zaten samen in de PhD council. Ik vond het ontzettend leuk 
om samen allerlei activiteiten, zoals workshops, maar ook de PhD retreat te organiseren. 
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René en Herbert, gewoon omdat jullie tijdens ISPOR zo vaak gezegd hebben dat jullie in 
mijn dankwoord wilden, nou bij deze dan…  ;) Ik heb trouwens nog gebakken eieren van 
jullie tegoed!
Vrienden en famile
Vrienden en familie, jullie hebben waarschijnlijk geen idee waar mijn onderzoek nu precies 
over ging (tot nu tenminste, want je leest natuurlijk dit hele boekwerk even door, en niet 
stiekem alleen het dankwoord hè...). 
Frank, jij had natuurlijk als eerste bedankt moeten worden, want toen ik het lesgeven meer 
dan zat was, was jij het die met de vacature voor deze baan kwam aanzetten. Zonder jou was 
dit proefschrift er dus echt nooit geweest, thanks man!
Jan-Willem, jij bent mijn beste maatje sinds we elkaar, 15 terug al weer, bij de TV-opnames 
van de Achmea Kennis Quiz leerden kennen. Jij staat altijd voor me klaar, met jou is het altijd 
meteen gezellig, zelfs als we elkaar weer veel te lang niet gezien hebben. Ik zou eigenlijk een 
hele bladzijde aan je kunnen spenderen, maar dat doe ik lekker niet :p 
Veerle, we waren ganggenoten op Hoogeveldt. Daar keken we al samen Wie is de Mol en 
Expeditie Robinson, en ik ben blij dat we dat nog altijd doen! Ik vind het ontzettend leuk dat 
jij vandaag mijn paranimf wil zijn!
Anouck, we zijn niet heel erg lang kamergenoten geweest, maar het klikte eigenlijk vanaf 
het begin. Ik ben blij dat jij mijn paranimf wilde zijn, en dat we nog maar veel leuke dingen 
gaan doen!
Pap, mam, ik lijk te veel op jullie beide! Hebben jullie je al eens gerealiseerd dat ik in mijn 
PhD-traject, maar ook in mijn huidige baan, een combinatie heb gevonden van jullie groot-
ste interesses? Mam, de medische wereld vanuit jouw kant, en pap, de economie vanuit 
jou! Grappig hoe dingen lopen! Jullie hebben me altijd gemotiveerd mezelf vooral naast het 
schoolsysteem te ontwikkelen; Met dat Italiaans is het helaas nooit wat geworden, maar die 
cursus Excel uit groep 8 werpt zijn vruchten nog altijd af! xD
Dagmar, PhDs klagen vaak over hun salaris, en ik denk dat dat niet helemaal terecht is, 
aangezien ik van mijn salaris ook jouw salaris betaalde. Dank voor het schone huis, ik ga je 
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missen wanneer je in de zomer afstudeert en een echte baan vindt!
Mathijs, je bent gewoon een relaxt broertje, op te trommelen als er weer eens iets in elkaar 
gezet moet worden, van meubels tot dat bakbeest van een computer, je kunt het allemaal! 
Hopelijk studeer jij snel af, vind je snel een baan, en hebben Annelieke en jij het samen leuk 
in jullie nieuwe huisje!
Felix, Lilian, Laurie, Steven, Kelly, wat fijn om het afronden van mijn promotieonderzoek ook 
met jullie te kunnen delen, een betere schoonfamilie kun je je gewoon niet wensen!
Sander
Lieve Sander, ik heb lang nagedacht of ik jou hier eigenlijk wel moest noemen. Want tja.. zelf 
heb je nog eens de moeite niet genomen om een dankwoord te schrijven. Daarnaast loop je 
me er al maanden aan te “herinneren” dat jij al gepromoveerd bent, en dus een vraag mag 
(lees zal) stellen tijdens mijn verdediging. En als geen ander weet jij waar de zwaktes in mijn 
onderzoek zitten, en waarover ik absoluut geen vragen hoop te krijgen. Not cool! 
Toch kan ik jou niet overslaan in dit dankwoord! Allereerst waren we natuurlijk ooit collega’s 
en hebben we elkaar bij HEV leren kennen. Daarnaast heb je alle mijlpalen (ja elke publicatie 
is gewoon een mijlpaal :p) gedurende, maar ook na mijn promotietijd met me gevierd. En ik 
vind het super dat je dat ook vandaag weer doet! Dat we nog maar veel te vieren hebben, 
cheers motherfucker!
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